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ABSTRACT 
The advent of massively-parallel next-generation sequencing (NGS) 
methods has provided researchers with a powerful tool with which to 
interrogate and characterise the molecular landscape of cancer genomes. 
Compared to existing methods of DNA sequencing, NGS platforms generate 
massive amounts of sequence data and, as a consequence, can reveal 
information not just on single nucleotide variations (SNVs), but also on 
copy-number aberrations, translocations and large insertions and deletions 
in a single experiment. Furthermore, targeted NGS provides the capability 
to focus on a small number of targets simultaneously, with high accuracy 
and sensitivity. The presence of specific molecular markers acts as 
predictors of disease outcome, survival rates and treatment response in 
individual patients. Screening for such markers has become routine 
practice in diagnostic laboratories using traditional methods of DNA 
analysis, are widely used in diagnostic laboratories around the world. 
Whilst these methods are proven and reliable, their limitations lie in the 
fact that they focus on only the most prevalent mutations in a particular 
cancer. The ability to investigate multiple gene targets within individual 
patients, to a high level of accuracy, and to monitor these changes over 
time will be a valuable tool in cancer diagnostics. As such, there is a 
potential use case for NGS techniques in routine diagnostics. Therefore, 
this thesis investigated the extent to which NGS platforms could be used in 
viii 
 
a clinical setting for the diagnosis and risk-stratification of both lymphoid 
and myeloid malignancies. 
A targeted next-generation sequencing panel was designed and validated 
against existing diagnostic methods. All mutations in the validation cohort 
were correctly identified. Both the specificity and sensitivity of the assay 
were determined and were considerably better than those of the current 
‘gold-standard’ techniques. This panel has been fully validated and 
implemented into the diagnostic service at the John Radcliffe Hospital. The 
research applications of this panel were also demonstrated through the 
sequencing of a cohort of del(5q) MDS patients. It was not only found that 
mutations in TP53 and ASXL1 may be key drivers in the progression of 
del(5q) MDS into AML but also that 40% of del(5q) patients harboured at 
least one mutation. A number of mutations were below the limit of 
detection for Sanger sequencing, and so this study expands our knowledge 
of the del(5q) mutational landscape. 
Whole genome sequencing of 42 CLL cases revealed a high level of 
molecular heterogeneity, with mutations in key CLL driver genes including 
TP53, SF3B1, NOTCH1 and ATM. Both clinically relevant CNAs and 
translocations were detected in the cohort. Four mutation signatures were 
detected across the CLL genomes and are both associated with, and vary in 
their prevalence according to, specific clinical characteristics, including age 
and chemo-refractoriness. Mutations introduced as part of the SHM 
process in B-cells are present throughout the genome, including in patients 
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with unmutated IgHV genes. Regions of localised hypermutation are 
present in CLL, with a number affecting genes associated with coding 
mutations in CLL, including ATM, KLHL6 and MEGF9. A number of mutation 
clusters are also identified in potentially regulatory regions of genes. 
In summary, this thesis demonstrates that both whole genome sequencing 
and targeted sequencing panels can be introduced into diagnostics to aid 
the clinical decision-making process and also reveal important new findings 
that increase our understanding of the pathogenesis of leukaemia. 
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 INTRODUCTION Chapter 1 
1.1 Chronic Lymphocytic Leukaemia 
Chronic lymphocytic leukaemia (CLL) is the most common form of adult 
leukaemia in the western world (Swerdlow et al 2008), accounting for one 
third of new leukaemia cases each year (Siegel et al 2012). CLL is a 
haematological malignancy originating in the bone marrow and affects the 
precursors of a specific type of white blood cell, the lymphocyte (Figure 
1.1). CLL cells replicate at a higher rate and are resistant to apoptosis, 
causing them to out-compete the normal cells. CLL is characterised by both 
clinical and biological heterogeneity. The majority of CLL patients display 
few symptoms at initial diagnosis, after which the disease can progress into 
either an aggressive, chemo-resistant form with poor prognosis, or a 
relatively indolent form, with a life expectancy similar to that seen in the 
normal population (Gaidano et al 2012, Gruber and Wu 2014, Pekarsky et 
al 2010, Quesada et al 2013, Zenz, et al 2010a). CLL cells are defined by the 
presence of both CD5 and CD19 cell surface markers, with a diagnosis of 
CLL made when a patient presents with at least 5x109/L lymphocytes 
(Hallek et al 2008). The median age of patients at diagnosis is 70 years, 
with more males affected than females by a ratio of 1.7:1 (Molica 2006, 
Watson et al 2008). 
 
 
 
 
Figure 1.1 Stages of B-cell differentiation and associated malignancies. 
Flowchart showing the different stages and environments involved in B-cell haematopoiesis. (a) Initial stages of development occur within the bone marrow, with 
haematopoietic stem cells (HSC) differentiating into immature B-cells. (b) Further development occurs within the spleen or lymph node. B-cell malignancies are associated with 
distinct stages of B-cell development. CLL originates in either mature B-cells, in the case of IgHVunmut, or in memory B-cells as IgHVmut CLL. Abbreviations: HSC, Haematopoietic 
stem cell; MPP, multipotent progenitor cell; CLP, common lymphoid progenitor cell; ALL, acute lymphoblastic leukaemia; IgHVunmut, immunoglobulin heavy chain variable 
unmutated chronic lymphocytic leukaemia; MCL, mantle cell lymphoma; FL, follicular lymphoma; DLBCL, diffuse large B-cell lymphoma; BL, Burkitt’s lymphoma; MM, multiple 
myeloma; IgHVmut, immunoglobulin heavy chain variable mutated chronic lymphocytic leukaemia; MALT, mucosa-associated lymphoid tissue lymphoma; SMZL, splenic 
marginal zone lymphoma. Adapted from (Rickert 2013). 
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1.1.1 Risk Stratification in CLL 
There are two classification methods for CLL, the Rai staging system (Rai et 
al 1975), used primarily in North America, and the Binet staging system 
(Binet et al 1977) which is used in Europe. Both methods use a simple 
blood test, in combination with a physical examination, to classify CLL cases 
into either one of five groups (Rai) or one of three stages; A, B or C (Binet), 
each of which can be used as a prediction of overall survival (OS) rates.  
 
1.1.1.1 Rai staging 
First described in 1975 (Rai et al 1975), the Rai staging system initially 
arranged CLL cases into one of five risk categories (stages 0-IV) (Table 1.1). 
Patients presenting with lymphocytosis, defined as more than 15,000 
lymphocytes per cubic millimetre (>15,000/mm3), are categorised as being 
low risk stage 0. Stages I and II are intermediate risk, both presenting with 
lymphocytosis alongside enlargement of the lymph nodes (stage I), liver or 
spleen (both stage II). By contrast, the high risk stages III and IV may or may 
not present with organomegaly, being confirmed primarily by the presence 
of both lymphocytosis and either anaemia (haemoglobin <11g/dL) or 
thrombocytopaenia (platelets <100,000/mm3) respectively. These 
groupings predict OS rates in new CLL cases (Table 1.1).  
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Table 1.1 Risk stratification in CLL according to Rai staging  
Rai Stage Biological Indicators Median Survival (months) 
0 Lymphocytosis >150 
I Lymphocytosis with enlarged lymph nodes 101 
II Lymphocytosis with enlarged liver and/or spleen 71 
III 
Lymphocytosis and anaemia without 
thrombocytopaenia. Possible 
enlargement of any of lymph nodes, 
liver or spleen 
19 
IV 
Lymphocytosis and 
thrombocytopaenia with or without 
anaemia 
19 
(Rai et al 1975). 
 
1.1.1.2 Binet staging 
The Binet staging system, first described in 1977 (Binet et al 1977), is based 
upon the Rai method, with a few alterations. Patients are allocated to one 
of five risk categories based on a blood test and a physical examination. 
Stage 0 cases are defined as those with lymphocytosis (>4000/mm3) 
without any lymph node enlargement or splenomegaly; stage I, both 
lymphocytosis and lymph node enlargement; stage II, lymphocytosis with 
splenomegaly; stage III, lymphocytosis and both enlarged spleen and lymph 
nodes; stage IV, lymphocytosis with either severe thrombocytopaenia 
(platelets <100,000/mm3) or severe anaemia (<10g/dL haemoglobin (Hb)). 
Later work by the same group refined this schema (Binet et al 1981), 
dropping from five stages to three (A, B and C) and using total number of 
 
 
5 
 
organ enlargements regardless of location (Table 1.2). Patients with 
lymphocytosis and fewer than three enlarged organs are classified as group 
A. Group B patients present with lymphocytosis and at least three enlarged 
organs, while group C patients have anaemia and/or thrombocytopaenia, 
regardless of the number of enlarged organs. The difference in survival 
rates for these groups is marked, ranging from 10 years in group A, to two 
years for group C (Binet et al 1981). 
 
Table 1.2 Binet staging criteria in CLL 
Binet  
Group 
Hb Level 
(g/dL) 
Platelet count 
(k/mm3) 
Enlarged 
Organs 
Median 
OS 
A >10 >100 < 3 > 10 years 
B >10 >100 >3 7 years 
C <10 <100 Any number 2 years 
(Binet et al 1981). 
 
1.1.2 Prognostic Markers in CLL 
1.1.2.1 IgHV Mutation Status 
Somatic hypermutation (SHM) is an important part of the adaptive immune 
response. Upon activation by a foreign antigen, a mature B-cell enters the 
germinal centre of a lymph node, where the intracellular enzyme 
activation-induced cytidine deaminase (AID) introduces point mutations at 
the immunoglobulin-variable gene loci. These mutations result in the 
generation of a large antibody repertoire.  
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In 1999, work by both the Hamblin and Damle groups showed that CLL 
patients with hypermutated IgHV (<98% homology to the germline), were 
predicted to have significantly increased OS rates compared to un-mutated 
patients (Damle et al 1999, Hamblin et al 1999). More recent work has 
shown that hypermutated patients with the IgHV 3-21 subtype are now 
known to have the same poor prognosis as those with un-mutated IgHV 
(Thorsélius et al 2006, Tobin et al 2002). 
 
1.1.2.2 Cytogenetics 
Recurrent copy number aberrations (CNAs) are common in CLL, and can 
have a significant impact on the prognosis of the disease. Indeed, the 
presence or absence of a particular CNA can be used for risk stratification 
in new CLL cases (Döhner et al 2000, Pflug et al 2014). One of the most 
commonly used method of detecting CNAs is fluorescent in-situ 
hybridisation (FISH). This method involves the hybridisation of 
fluorescently labelled probes complementary to a specific target region of 
the genome. Subsequent visualisation with a microscope reveals 
information regarding the presence, absence or abnormal copy-number of 
the region in question. More recently molecular methods, including array-
based assays, are gaining acceptance as alternatives to FISH. These arrays, 
by interrogating SNPs genome-wide, provide information on copy-number 
changes and loss of heterozygosity along the length of each chromosome. 
Furthermore, by comparing the genomic position of recurrent CNAs in a 
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cohort of patients, it is possible to identify which genes are critical to the 
pathogenesis of the disease.  
 
1.1.2.2.1 Del(11q) 
Full or partial deletions of the q-arm of chromosome 11 (del(11q)) are the 
second most frequent chromosomal aberration found in CLL, occurring in 
10-20% of patients (Döhner et al 1997, Edelmann et al 2012, Hernández et 
al 2015, Neilson et al 1997, Pflug et al 2014, Puente et al 2015). These 
deletions are associated with rapid disease progression (Döhner et al 1997, 
Doneda et al 2003) represented by significantly lower OS rates than in 
patients with a normal karyotype (Döhner et al 1997, 2000, Neilson et al 
1997) (Table 1.3). Despite del(11q) CLL being classified as a high-risk 
disease, recent data have shown that patients with del(11q) as sole 
cytogenetic abnormality respond well to monoclonal antibody based 
treatment regimes. For example, phase II and phase III trials of 
chemoimmunotherapy combining purine analogues with the anti-CD20 
monoclonal antibody Rituximab, showed partial remission rates of up to 
90% in del(11q) cases, with up to 40% achieving complete remission 
(Fischer et al 2011, 2012, Hallek et al 2010). Interestingly, recent data have 
shown that the percentage of del(11q) positive CLL cells present in a 
patient can affect the disease course. Patients with reduced numbers 
(<40%) of del(11q) containing cells show both longer time to first 
treatment (TTFT) (44 months vs 19 months) and OS (157 months vs 90 
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months) compared to those with higher (≥40%) levels of del(11q) cells 
(Hernández et al 2015). The chromosomal region most commonly deleted 
as a result of del(11q), known as the minimally deleted region (MDR) is a 
small section located at the q22.3 band of chromosome 11. Specifically, 
this is the location of the tumour suppressor gene ATM (Döhner et al 1997, 
Stilgenbauer et al 1996).  
 
1.1.2.2.2 Trisomy 12 
Gains of chromosome 12 (trisomy 12) are found in 10-17% of CLL cases 
(Döhner et al 2000, Edelmann et al 2012, Pflug et al 2014, Puente et al 
2015) and confers an intermediate risk, with progression free survival 
times similar to patients with a normal karyotype (Döhner et al 2000, Van 
Dyke et al 2016) (Table 1.3). However, other studies have linked the 
presence of trisomy 12 in CLL to disease progression, specifically the 
development of an aggressive secondary lymphoma known as Richters 
syndrome (RS). In one study, using high density SNP arrays, trisomy 12 was 
present as the sole cytogenetic abnormality in 28% of CLL cases who went 
on to develop RS (Chigrinova et al 2013). The presence of trisomy 12 in 
more than 60% of CLL cells has been shown to predict for reduced 
progression free survival (González-Gascón et al 2015). Mutations in the 
NOTCH1 gene have also been associated with trisomy 12 in CLL (Balatti et 
al 2012), leading to a significant reduction in OS rates compared to trisomy 
12 cases with un-mutated NOTCH1 (Del Giudice et al 2012). 
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1.1.2.2.3 Del(13q) 
Deletions of the q-arm of chromosome 13 are the most frequent 
chromosomal aberration in CLL, occurring in 30-55% of cases (Döhner et al 
2000, Van Dyke et al 2016, Edelmann et al 2012, Pflug et al 2014, Puente et 
al 2015). Del(13q) offers the best prognostic outlook with longer 
progression free and OS than patients with normal karyotypes (Döhner et 
al 2000, Van Dyke et al 2016) (Table 1.3). The minimally deleted region 
centres on the 13q14 region, which contains a number of genes, most 
notably the micro-RNAs (miRNA) mir-15a and mir-16-a (Mertens et al 
2009). These miRNAs negatively regulate the activity of tumour protein 53 
(TP53) by binding to the 3’UTR, targeting it for degradation. Patients with 
del(13q) exhibit reduced mir15a and mir16a expression levels (Mosca et al 
2010), which effectively decreases the level of TP53 down-regulation (Lin et 
al 2014). Furthermore, the proportion of del(13q) positive CLL cells within a 
patient is also linked to the prognosis. Cases with a higher del(13q) load 
show significantly shorter treatment free survival (TFS) and OS (Huang et al 
2016, Puiggros et al 2013).  
 
1.1.2.2.4 Del(17p) 
Deletions of the p-arm of chromosome 17 are found in 4-12% of CLL cases 
prior to frontline therapy and confer a poor prognosis, with rapidly 
progressing disease and reduced OS and TFS (Döhner et al 2000, Van Dyke 
et al 2016, Edelmann et al 2012, Pflug et al 2014, Puente et al 2015) (Table 
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1.3). These deletions focus on the 17p13 band, which also harbours the 
well-characterised tumour suppressor gene TP53. Patients with del(17p) 
demonstrate low response rates to many chemotherapy regimens (Byrd et 
al 2006), with combination therapies offering no significant improvement 
(Bosch et al 2008, 2009, Fischer et al 2011, Hallek et al 2010, Mauro et al 
2014). However, treatment of del(17p) CLL with the Brutons tyrosine 
kinase (BTK) inhibitor Ibrutinib does show positive results, with a 30 month 
progression free survival of 96% and OS of 97% (Byrd et al 2015, O’Brien et 
al 2014). 
Table 1.3 Overall and progression free survival rates associated with 
cytogenetic subgroups in CLL. 
 Median Overall Survival (%) 
Median Progression Free 
Survival (%) 
Genetic 
Abnormality 5 year 10 year 3 year 5 year 10 year 
Del(17p) 22 N/R 7 N/R N/R 
Del(11q) 68 16 27 15 N/R 
Gain(12) 77 30 50 36 13 
Normal 80 50 60 42 16 
Del(13q) 95 62 73 66 31 
Abbreviations: N/R, not reached. (Döhner et al 2000). 
 
1.1.2.3 ZAP70 
ZAP70 is a protein tyrosine kinase, located at the q11.2 band of 
chromosome 2, which plays a role in B-cell development. Overexpression 
of ZAP70 enhances the activity of the B-cell receptor (BCR) pathway, a key 
mechanism for the survival of CLL cells. Early studies found that ZAP70 
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expression levels may provide a useful surrogate marker for IgHV mutation 
status, as those cases where >20% CLL cells showed high ZAP70 expression 
were also IgHV un-mutated (Crespo et al 2003, Dürig et al 2003, Wiestner 
et al 2003). Additional work identified it as a strong independent predictor 
of the need for treatment (Rassenti et al 2004). More recent data propose 
that the more aggressive disease course presented by this subset of CLL 
may be due to ZAP70 expression enhancing the migration capacity of the 
CLL cells, driving them towards the advantageous microenvironment of the 
bone marrow (Calpe et al 2013, Stamatopoulos et al 2009). The EGFR 
inhibitor Gefitinib, usually used to treat lung cancer, has shown some 
promise as a treatment regime, preferentially inducing cell death in ZAP70 
positive cells (Dielschneider et al 2014). 
 
1.1.2.4 CD38 
CD38 is a transmembrane glycoprotein, encoded for by a gene located at 
4p15, which plays a role in the regulation of intracellular Ca2+. When 
expressed on the surface of >30% of CLL cells, CD38 is an independent 
predictor of shorter OS (Damle et al 1999). CD38 expression associates 
with unmutated IgHV genes and poor response to chemotherapy. Further 
studies found that patients with a lower threshold of 20% CD38+ cells also 
displayed shorter survival times and a more aggressive disease course 
(Ibrahim 2001). In a manner similar to ZAP70, CD38+ patients exhibited 
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enhanced migration of their CLL cells towards the bone marrow via CXCL12 
signalling (Deaglio et al 2007, Vaisitti et al 2010).  
 
1.1.2.5 CD49d 
CD49d, an α-integrin subunit that forms part of the α4β1 lymphocyte 
homing receptor, has been shown to be a robust predictor of outcome in 
CLL patients. The gene encoding this protein is located at the q31.3 band of 
chromosome 2. High expression of CD49d (CD19dhigh), defined as the 
presence of CD49d in ≥30% of CLL cells, is associated with both shorter OS 
and reduced time to treatment (Gattei et al 2008, Zucchetto et al 2006) 
compared to CD49dlow CLL. Further studies found that CD19dhigh CLL cells 
would also express both CD38 and ZAP70, suggesting that CD49d may be 
linked to the increased migration of CLL cells into preferential micro-
environments (Nückel et al 2009, Shanafelt et al 2008). CD38 and CD49d 
work in tandem at opposite ends of the same pathway to promote the 
survival of CLL cells via VCAM-1 (Zucchetto et al 2009). As an indicator of 
disease progression in CLL, the addition of CD49d expression to other 
prognostic markers can improve the power of the analysis (Majid et al 
2011). It can also be used to further subdivide the mutated IgHV subgroup, 
predicting a shorter time to first treatment for IgHVmut/CD49dhigh compared 
to IgHVmut/CD49dlow (Baumann et al 2016). 
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1.1.2.6 β2-Microglobulin 
β2-microglobulin (β2M) is a component of the major histocompatibility 
complex (MHC) class I protein, present on the surface of all nucleated cells. 
It is also found as a free molecule in the surrounding serum. Levels of 
serum β2M were found to be elevated in CLL patients compared to age-
matched controls, 5mg/L and 2mg/L respectively, and that levels >4mg/L 
inferred a much lower survival time over cases with <4mg/L (12 months 
and 43 months respectively) (Di Giovanni et al 1989). Increased β2M levels 
also indicate shorter time to first treatment, compounded by a lower 
probability of achieving complete remission with combination therapies 
such as Fludarabine-Cyclophosphamide-Rituximab (FCR) (Delgado et al 
2009, Keating et al 2005). More recent studies, with larger cohorts, have 
confirmed β2M serum levels as an independent marker of shorter PFS, OS 
and poor treatment response, and correlated β2M serum levels with other 
markers of poor prognosis, including unmutated IgHV and high CD38 levels 
(Oscier et al 2010, Pratt et al 2016). 
 
1.1.3 Recurrent Gene Mutations in CLL 
CLL is a highly heterogeneous disease, both clinically and biologically. 
Despite the prognostic value of both the common chromosomal 
abnormalities and cell surface markers, more than 50% of patients will go 
on to develop disease progression and chemo-refractoriness (Tam et al 
2014). This clinical heterogeneity is likely due to underlying molecular 
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differences between patients. A number of explorative genome-wide 
(Puente et al 2011, Schuh et al 2012) and exome-wide (Quesada et al 2012) 
sequencing efforts have identified a number of recurrently acquired 
mutations in the coding regions of genes. The presence of mutations in 
genes including TP53 (Zenz et al 2008, 2009, 2010b), SF3B1 (Quesada et al 
2012, Rossi et al 2011, Wang et al 2011) and NOTCH1 (Fabbri et al 2011, 
Rossi et al 2012, Rossi et al 2011) have been associated with chemo-
refractoriness, advanced disease and poor prognosis. 
1.1.3.1 NOTCH1 
The NOTCH signalling pathway is involved in a number of crucial cell 
functions, including proliferation, cell differentiation and apoptosis. 
NOTCH1 is a transmembrane protein that cleaves its intracellular domain 
(NOTCH1IC) upon activation by an extracellular ligand. NOTCH1IC 
translocates to the nucleus and forms a complex with CBF1, MAML and 
p300 to become a transcriptional activator for NOTCH target genes. 
NOTCH1 is both upregulated and constitutively activated in CLL cells 
compared to normal controls, and is associated with apoptosis resistance 
(Rosati et al 2009). A 2bp deletion in the NOTCH1 PEST domain 
(del7544_45) is found in 4-12% of CLL cases (Di Ianni et al 2009, Puente et 
al 2011, Rossi et al 2011, Sportoletti et al 2010) and results in early 
termination of the PEST domain required for protein degradation. As a 
result, NOTCH1IC accumulates in the nucleus leading to constitutive 
activation of NOTCH1 target genes (Figure 1.2). These NOTCH1 mutations 
 
 
15 
 
are an independent predictor for shorter OS (Rossi et al 2011), with a 10-
year survival of 21% compared to 56% with wild-type NOTCH1 (Puente et al 
2011). Additionally, NOTCH1 mutations are found in 24% of trisomy 12 CLL 
samples and confer a 2.4x increase in the risk of death and a shortening of 
OS in this subgroup compared to trisomy 12 alone (Del Giudice et al 2012). 
NOTCH1 mutations have also been associated with an increased risk of 
transformation of CLL into diffuse large B-cell lymphoma (DLBCL) (Villamor 
et al 2013).  
 
Figure 1.2 Constitutive activation of NOTCH1 in CLL. 
(a) Schematic representation of the NOTCH1 transcript. (b) Following target gene 
transcription, wild-type NOTCH1 is targeted for proteasomal degradation, (c) whilst 
NOTCH1 with a disrupted PEST domain (NOTCH1ICMUT) escapes degradation and 
accumulates in the nucleus. Abbreviations: NOTCH1EC, extracellular domain; NOTCH1IC, 
intracellular domain; EGF, epidermal growth factor like domain; LNR, Lin-Notch repeat 
domain; HD, heterodimerisation domain; RAM, RBPJ-associated molecule domain; ANK, 
ankyrin repeat domain; TAD, transactivation domain; PEST, Proline-Glutamate-Serine-
Threonine rich domain.  
 
16 
 
1.1.3.2 TP53 
TP53 is a tumour suppressor gene located at 17p13.1 in humans, 
composed of 11 exons, 10 of which are coding regions. The translated 
protein consists of an N-terminal transactivation domain (TAD), a highly 
conserved DNA-binding domain, and a C-terminal oligomerisation domain 
(Figure 1.3). TP53 expression is increased in response to stress signals or 
following DNA damage, resulting in TP53 mediated initiation of one of 
several key pathways in an attempt to save the cell; including activation of 
DNA repair proteins, arresting cell growth at the G1/S point, or the 
initiation of apoptosis as a last resort. Mutations in TP53 (TP53mut) are one 
of the most frequently seen genomic alterations in many human cancers. 
In CLL, TP53 mutations are typically found in 8-15% of cases and are a 
marker of poor prognosis, being associated with a reduction in both OS and 
TTFT (Dufour et al 2013, Landau et al 2013, el Rouby et al 1993, Zenz, 
Eichhorst, et al 2010). The impact of TP53mut on the disease course is the 
same as that inferred by del(17p) (Rossi et al 2009). A number of trials have 
linked the presence of TP53mut with resistance to chemotherapy, 
particularly with Fludarabine based regimes (Gonzalez et al 2011, Zenz, 
Eichhorst, et al 2010). This is reflected in the increased incidence of TP53mut 
in Fludarabine-refractory (FR) patient cohorts (Messina et al 2014, 
Schnaiter et al 2013). However, recent work indicates that TP53mut patients 
do respond to treatment with the monoclonal antibody Alemtuzumab and 
novel B-cell receptor inhibitors such as BTK (Ibrutinib, Acalabrutinib) or 
phosphoinositide 3-kinase (PI3K) inhibitors (Idelalisib) and BCL-2 inhibitors 
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such as Venetoclax (Pettitt et al 2012, Sciumè et al 2015). Studies of 
TP53mut CLL samples, using whole-exome sequencing techniques, have 
revealed that TP53mut CLL cells tend to be subclonal at diagnosis before 
becoming the dominant clone at relapse. This suggests that firstly, TP53 
mutations contribute towards disease progression rather than initiation 
and secondly, that the presence of these mutations at low level at 
diagnosis is a reliable indicator of the rapid development of chemo-
resistance (Landau et al 2013, Rossi et al 2014). 
 
1.1.3.3 SF3B1 
Splicing factor 3B subunit 1 (SF3B1) forms part of the U2 small nuclear 
ribonucleoprotein complex that plays a role in mRNA splicing. Mutations in 
SF3B1 are common in CLL, present in 10-20% of cases (Jeromin et al 2014, 
Landau et al 2013, Messina et al 2014, Quesada et al 2012, Rossi, 
Bruscaggin, et al 2011, Stilgenbauer et al 2014). These mutations are 
typically missense variants clustered in the highly conserved HEAT domain 
of SF3B1, with 42-50% of mutations affecting the lysine residue at position 
700 (Jeromin et al 2014, Rossi, Bruscaggin, et al 2011, Stilgenbauer et al 
2014, Wang et al 2011). This recurrently affected region is predicted to 
form the inner surface of the SF3B1 protein, and therefore may represent 
disruption of a binding site, leading to the altered splicing function seen in 
these samples (Lili Wang et al 2011). Mutations in SF3B1 tend to be sub-
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clonal that expand over time contributing to disease progression, 
particularly following chemotherapy (Landau et al 2013).  
 
 
 
  
 
 
 
 
 
Figure 1.3 Distribution of TP53 mutations in chronic lymphocytic leukaemia 
(a) Schematic representation of the TP53 gene on chromosome 17. (b) Distribution of coding mutations reported in CLL according to the COSMIC database 
(http://cancer.sanger.ac.uk/cosmic, Forbes et al 2015) (b). The majority of reported mutations (78%, 292/304) are located within the DNA binding domain, encoded for by exons 
four to eight. Abbreviations: TAD, transactivation domain; PRD, proline-rich domain; OD, oligomerisation domain; NEG, negative regulation domain. 
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1.1.3.4 BIRC3 
BIRC3 is a negative regulator of the NF-κB signalling pathway, a known pro-
survival mechanism in CLL. The BIRC3 protein, in combination with TRAF2 
and TRAF3, negatively regulates the MAP3K14, which stimulates NF-κB via 
the non-canonical pathway. Mutations in BIRC3 are enriched in 
Fludarabine-refractory CLL samples, occurring in 15-24% of cases (Messina 
et al 2014, Rossi et al 2012) and are predominantly frameshift variants that 
remove the c-terminal RING domain of the protein. This domain is required 
for the degradation of MAP3K14. These mutations lead to constitutive 
activation of the NF-κB pathway in CLL. Recent data indicate that BIRC3 
disruption predicts for lower complete remission rates following first line 
treatment with Chlorambucil and Rituximab (Foà et al 2014).  
 
1.1.4 Influence of Gene Mutations on Risk Stratification 
Given the number of recurrently mutated genes recently identified in CLL, 
and their demonstrable impact on disease course, it seems reasonable to 
examine whether integration of these new prognostic markers into existing 
algorithms could offer an improvement in patient risk stratification. A study 
by Rossi et al (2013) devised a prognostic scoring system that integrated 
cytogenetic information with mutation screening data in four frequently 
mutated CLL genes (TP53, BIRC3, NOTCH1 and SF3B1) in a cohort of newly 
diagnosed CLL cases. The authors generated a hierarchical model with four 
risk groups; high, intermediate, low and very low, with 10-year survival 
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rates of 37.7%, 48.5%, 70.7% and 84.2% respectively (Table 1.4). In 
addition, a recent study in relapsed/refractory CLL samples revealed that 
the presence of subclones with >1 mutation in a driver gene has an impact 
on the prognosis of the disease, being associated with poorer overall 
response to treatment (Guièze et al 2015). 
 
Table 1.4 Prognostic risk categories in CLL.  
Risk Group Mutated Genes Cytogenetics 10 Year Survival (%) 
High TP53 and/or BIRC3 del(17p) 37.7 
Intermediate NOTCH1 and/or SF3B1 del(11q) 48.5 
Low - gain(12) 70.7 
Very Low - del(13q) 84.2 
10-year survival rates are expressed in comparison to those seen in a matched general 
population (Rossi et al 2013). 
 
The inclusion of gene mutations was found to significantly improve survival 
prediction (Baliakas et al 2014), and highlights the need for mutation 
screening at the diagnosis stage. 
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1.2 Acute Myeloid Leukaemia 
Acute myeloid leukaemia (AML) is characterised by the accumulation of 
immature, undifferentiated myeloid blast cells in the bone marrow and 
peripheral blood. A diagnosis of AML is confirmed when the proportion of 
these blasts exceeds the 20% threshold in either peripheral blood or bone 
marrow. AML is the most common myeloid malignancy in Europe, with an 
overall incidence of 3.7 new cases per 100,000 per year. This number 
increases with age, and is slightly more prevalent in males than females by 
a ratio of 1.2:1 (Visser et al 2012). Risk stratification in AML is based on the 
presence of cytogenetic abnormalities (Grimwade 2012), despite ~40% of 
cases having a normal karyotype (Grimwade et al 2010). The discovery of 
recurrently mutated genes in AML has added to the already considerable 
heterogeneous picture of this disease.  
 
1.2.1 Clinical Classification 
A number of different algorithms have been adopted for the classification 
of AML, involving a combination of morphological, cytochemical and 
molecular information. The French-American-British (FAB) group first 
devised a classification system for AML in 1976. The system uses a 
combination of the originating cell type and the level of cell differentiation 
to classify AML cases into one of eight subgroups (M0-M7) (Bennett et al 
1976, 1985) (Table 1.5). The World Health Organisation (WHO) developed a 
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more comprehensive system that improves upon the FAB classification by 
integrating information regarding recurring chromosomal abnormalities 
and gene mutations into the FAB system. The WHO classification identifies 
seven AML subtypes (Vardiman et al 2002, 2009) (Table 1.6). The recurring 
genetic abnormality subgroup predominantly concerns the presence of 
translocations involving the RUNX1, RARA, MLL and CBFB transcription 
factors although point mutations in genes including NPM1 and CEBPα are 
being added with each revision. 
Table 1.5 FAB classification of AML.  
FAB Group Name 
M0 Undifferentiated acute myeloblastic leukaemia 
M1 Acute myeloblastic leukaemia with minimal maturation 
M2 Acute myeloblastic leukaemia with maturation 
M3 Acute promyelocytic leukaemia 
M4 Acute myelomonocytic leukaemia 
M4eos Acute myelomonocytic leukaemia with eosinophilia 
M5 Acute monocytic leukaemia 
M6 Acute erythroid leukaemia 
M7 Acute megakaryocytic leukaemia 
(Bennett et al 1976). 
1.2.2 Structural Variants in AML 
In addition to classifying the subtype of AML at diagnosis, the presence of 
translocations can also add value in the context of risk stratification and 
treatment response predication.  
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Core binding factor AML (CBF-AML) comprises 15% of adult AML cases 
(Solh et al 2014) and is characterised by the presence of either the t(8;21) 
or inv(16) chromosomal abnormalities.  The t(8;21) event fuses the RUNX1 
gene with RUNX1T1, whilst inv(16) joins the MYH11 gene to CBFB. Both 
RUNX1 and CBFB form part of the core binding factor complex, a regulator 
of haematopoiesis. These fusion proteins repress a number of genes 
involved in hematopoietic differentiation (Alcalay et al 2003, Kundu and Liu 
2001, Mandoli et al 2014). CBF-AML cases display improved OS rates, with 
up to 61% of cases surviving 10 years from diagnosis (Grimwade et al 1998, 
2010). Treatment of CBF-AML with high-dose Cytarabine (HiDAC) achieves 
a five year complete remission rate of 78% (Bloomfield et al 1998) and 
decreases the likelihood of relapse (Byrd et al 2004). Combination 
therapies can also significantly improve overall survival in this AML subtype 
(Borthakur et al 2008, Kaspers et al 2013). 
Acute promyelocytic leukaemia (APL) is characterised by the presence of 
t(15;17), in which the promyelocytic leukaemia (PML) and retinoic acid 
receptor alpha (RARA) genes are fused together. APL accounts for 13% of 
new AML cases and is considered as favourable risk, with a 10-year survival 
rate of 81% (Grimwade et al 2010). Treatment of APL with all-trans retinoic 
acid (ATRA), often in combination with anthracyclines (Sanz et al 2015), 
achieves complete remission in up to 69% of cases (Castaigne et al 1990, 
Tallman et al 1997), with 77% of patients surviving to 10 years (Adès et al 
2010). 
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AML with t(9;11) (MLLT3;MLL) is classified as intermediate risk, with 10 
year survival rates of 39% (Grimwade et al 2010). The mixed lineage 
leukaemia gene (MLL) acts as a regulator of HOX gene expression via the  
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Table 1.6 Classification of acute myeloid leukaemia and related 
neoplasms according to 2008 WHO guidelines.  
1. Acute myeloid leukaemia with recurrent genetic abnormalities 
  
 
AML with t(8;21) (q22;q22); RUNX1-RUNX1T1 
   AML inv(16) (p13.1q22) or t(16;16) (p13.1;q22); CBFB-MYH11 
  
 
APL with t(15;17)(q22;q12); PML-RARA 
   AML with t(9;11)(p22;q23); MLLT3-MLL 
  
 
AML with t(6;9)(p23;q34); DEK-NUP214 
   AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
  
 
AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 
   *AML with mutated NPM1 
  
 
*AML with mutated CEBPα 
2. Acute myeloid leukaemia with myelodysplasia-related changes 
3. Therapy-related myeloid neoplasms 
4. Acute myeloid leukaemia, not otherwise specified 
  
 
AML with minimal differentiation 
   AML without maturation 
  
 
AML with maturation 
   Acute myelomonocytic leukaemia 
  
 
Acute monoblastic/monocytic leukaemia 
   Acute erythroid leukaemia 
  
  
Pure erythroid leukaemia 
    Erythroleukaemia, erythroid/myeloid 
  
 
Acute megakaryoblastic leukaemia 
   Acute basophilic leukaemia 
  
 
Acute panmyelosis with myelofibrosis 
5. Myeloid sarcoma 
6. Myeloid proliferations related to Downs syndrome 
    Transient abnormal myelopoiesis 
  
 
Myeloid leukaemia associated with Down syndrome 
7. Blastic plasmacytoid dendritic cell neoplasm 
* Indicates provisional entity (Swerdlow et al 2008).
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modification of histones and promoter binding (Hess 2004). The presence 
of t(9;11) disrupts the normal function of MLL and upregulates the HOX 
gene targets. Patients with t(9;11) generally display longer complete 
remission (CR) and EFS duration, along with improved OS rates in 
comparison to AML with other 11q translocations (Mrózek et al 1997, 
Rubnitz et al 2002). Despite this, t(9;11) AML is associated with high rates 
of relapse following chemotherapy (Chandra et al 2010).  
AML with t(6;9) is also an intermediate risk disease, with a trend towards 
poorer outcome. Twenty seven percent of patients survive for 10 years 
after diagnosis (Grimwade et al 2010). This translocation fuses the 5’ region 
of DEK on chromosome 6 to the 3’ region of CAN on 9q34 (von Lindern et al 
1992, Soekarman, von Lindern, Daenen, et al 1992, Soekarman, von 
Lindern, van der Plas, et al 1992). The CAN gene encodes for NUP214, a 
member of the FG-repeat containing nucleoporin family, whilst DEK is a 
proto-oncogene. The fusion protein initiates leukaemogenesis in a small 
subset of the haematopoietic stem cell (HSC) population (Oancea et al 
2010). 
By contrast, AML with inv(3)(q21;q26.2) represents a particularly 
aggressive disease course with poor survival (Fonatsch et al 1994, 
Grimwade et al 2010, Reiter et al 2000). These events affect the EVI1 
oncogene at 3q26.2 and RPN1 at 3q21. 
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1.2.3 Recurrent Gene Mutations in AML 
Despite the utility of chromosomal alterations in AML diagnosis, there 
remain 41% of cases presenting with cytogenetically normal AML (cn-AML) 
(Grimwade et al 2010), which thus fall into an indiscriminate, intermediate 
risk category. Over the course of the last decade, the addition of molecular 
findings, in particular mutations in a number of key genes, has added 
prognostic value to this category. The 2008 update to the WHO 
classification of myeloid neoplasms and acute leukemia (Swerdlow et al 
2008) added both AML with NPM1 mutations and AML with CEBPα 
mutations as two distinct, provisional, categories, reflecting the prognostic 
relevance of these genes. The next update to the classification is due in 
September 2016, and will likely add further molecular markers to the 
system. 
1.2.3.1 NPM1 
Nucleophosmin is a chaperone protein that continuously shuttles between 
the cytoplasm and the nucleus. It is encoded for by the NPM1 gene on 
5q35.1 and is translated into a protein, 294 amino acids in length. NPM1 is 
induced in response to cellular stress, whereupon it protects TP53 activity 
by repressing HDM2 mediated TP53 degradation (Colombo et al 2002, 
Kurki et al 2004). Insertions of 4bp sequences, causing a Trp288fs*12 
frameshift, have been identified in 45-60% of cn-AML patients (Falini et al 
2005, Schlenk et al 2008, Schnittger et al 2005, Christian Thiede et al 2006). 
These insertions cause the final seven amino acids of the C-terminal 
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domain to be substituted with 11 new residues (Figure 1.4). The new 
sequence contains an additional nuclear export amino acid sequence (NES); 
L-xxx-V-xx-V-x-L (Bolli et al 2007, Falini et al 2006), which facilitates the 
translocation of the NPM1 protein into the cytoplasm. Whilst the location 
of the mutation in exon 12 remains constant, the inserted sequence can 
vary. The most common mutation is a TCTG insertion, accounting for 58% 
of NPM1 mutated patients (Falini et al 2005), followed by CATG (3%) and 
CCTG (3%) insertions. On a functional level, the substitution of the 
tryptophan residue at position 288 with a cysteine, as is the case with the 
most commonly seen NPM1 variants, induces increased sensitivity to 
chemotherapy in AML cells (M Huang et al 2013, Schneider et al 2009).  As 
a result, NPM1 mutations in cn-AML are associated with higher CR rates, 
longer PFS and longer OS in both adult and childhood cases, in the absence 
of concomitant FLT3 mutations (Döhner et al 2005, Hollink et al 2009, 
Schlenk et al 2008, Schnittger et al 2005, Thiede et al 2006). Furthermore, 
monitoring the level of mutated NPM1 in a post-treatment tumour cell 
population can indicate relapse in cn-AML patients (Krönke et al 2011, 
Shayegi et al 2013).  
 
1.2.3.2 CEBPα 
The gene encoding for CCAAT/enhancer binding protein alpha (CEBPα) 
consists of a single exon 2.6kb in length, located at 19q13.1, and is involved 
in the differentiation of myeloid cells. Two protein products are generated 
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from this gene, the full-length canonical p42 isoform, and a shorter p30 
isoform that is not expressed in wild-type cells. Mutations in CEBPα have 
been identified in 7-10% of AML cases (Fasan et al 2014, Hollink et al 2011, 
Leroy et al 2005, Pabst et al 2001, Schlenk et al 2009, Wouters et al 2009), 
and are distributed throughout the coding region, with distinct clusters in 
both the C- and N-termini. Mutations in the N-terminal domain are 
predominantly frameshift insertions or deletions resulting in the expression 
of a truncated 20kD protein (Pabst et al 2001), whereas C-terminal variants 
are generally in-frame insertions or deletions, disrupting the DNA binding 
domain (Fasan et al 2014). Three patterns of mutation have been identified 
in CEBPα: 1; a single mutation on one allele (CEBPαsm), 2; mutations in 
both alleles (bi-allelic mutations, CEBPαdm), and 3; homozygous mutations 
due to loss of heterozygosity (LOH) (Fasan et al 2014, Wouters et al 2009). 
In 75% of CEBPαdm cases, mutations are found in both the C- and N-
terminus domains (Fasan et al 2014).  Studies show that CEBPαdm is a 
favourable prognostic marker, with improved rates of OS, EFS and relapse 
risk compared to wild-type CEBPα (Ahn et al 2016, Wouters et al 2009). 
 
 
 
 
 
Figure 1.4 NPM1 mutations in AML.  
(a) Location and frequency of indel (red) and missense (blue) variants in NPM1 in AML as recorded in the COSMIC database. (b) Each of the three most common 
insertions in NPM1 (red) affects the tryptophan residue at position 288, extends the protein by four residues, and introduces an additional L-xxx-V-xx-V-x-L NES 
(underlined and bold residues). (c) Action of NPM1 protein under normal and stress conditions, with and without NPM1 mutations. Abbreviations: OD, 
oligomerisation domain; HBD, histone binding domain. 
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1.2.3.3 FLT3 
Fms-related tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase involved in the 
regulation of haematopoiesis. Mutations in FLT3 take one of two forms, variable 
length in-frame internal tandem duplications (FLT3-ITD) in the juxtamembrane 
domain, or a single amino acid substitution of residue Asp835 in the activation 
loop (FLT3-TKD) (Abu-Duhier et al 2001). The incidence of FLT3-ITD varies from 20-
34%, depending on clinical characteristics (Levis 2013), whilst FLT3-TKD  mutations 
occur in 7-10% of cases (Fröhling et al 2002, Kottaridis et al 2001, Meshinchi et al 
2006, Schlenk et al 2008, Christian Thiede et al 2002).  Both the ITD and D835 
mutations result in constitutive activation of FLT3 (Abu-Duhier et al 2001, 
Yamamoto et al 2001) leading to the induction of downstream targets involved in 
signal transduction, cell proliferation and the differentiation and function of 
haematopoietic cells, including the signal transducer and activator of transcription 
5 (STAT5) and mitogen activated protein kinase (MAPK) genes (Hayakawa et al 
2000, Mizuki et al 2000, 2003, Zhang et al 2000). Mutations of FLT3 are considered 
to be a marker of poor prognosis with significant reductions of both PFS and OS 
(Fröhling et al 2002, Kottaridis et al 2001, Meshinchi et al 2006, Schlenk et al 2008, 
Christian Thiede et al 2002). A number of randomised trials have shown good 
response and complete remission rates with a variety of combination therapies, 
although these are often of short duration with relapse quickly following (Fiedler 
et al 2015, Mrózek et al 2012, Ravandi et al 2010, Stone et al 2012). Although not 
included in the current WHO classification system (Swerdlow et al 2008), it has 
been recommended that screening for mutations in FLT3, alongside both NPM1 
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and CEBPα, should be carried out for cn-AML patients who are likely to receive 
treatment other than low-dose chemotherapy (Döhner et al 2010). 
 
1.2.3.4 DNMT3a 
DNA methylation is an epigenetic mechanism through which the expression of 
individual genes can be carefully controlled. The addition of a methyl group (CH3) 
to the fifth carbon atom of a cytosine residue results in the formation of 5-
methylcytosine. These alterations predominantly occur at CpG islands, which often 
coincide with the location of gene promoter sequences. Methylation at these 
locations is associated with reduced expression levels of nearby genes (Deaton 
and Bird 2011). Aberrant DNA methylation is evident in a number of cancer types, 
either reducing the expression of tumour suppressors or increasing the expression 
of oncogenes. The methylation of cytosine residues is a result of the activity of the 
DNA methyltransferase family of enzymes. One of these genes, DNA cytosine-5-
methyltransferase 3a (DNMT3a) is frequently mutated in AML, with mutations 
seen in 17-24% of cases (Gaidzik et al 2013, Hou et al 2012, LaRochelle et al 2011, 
Ley et al 2010, Luskin et al 2016, Shivarov et al 2013, Thol et al 2011, Yan et al 
2011). Point mutations in DNMT3a are overwhelmingly concentrated on a single 
residue, Arg882, with 60% of all variants occurring at this position (Ley et al 2010). 
Patients with DNMT3a mutations are shown to have a significant reduction in 
global methylation levels (Qu et al 2014, Russler-Germain et al 2014, Yan et al 
2011), leading to upregulation of downstream targets, including members of the 
34 
 
HOX gene family and IDH1 (Qu et al 2014, Yan et al 2011). The utility of DNMT3a 
mutations as a prognostic factor, in terms of OS and PFS is unclear. A number of 
studies and meta-analyses demonstrated that the presence of a DNMT3a 
mutation predicted for reduced OS, TTF and RFS (Hou et al 2012, Ley et al 2010, 
Renneville et al 2012, Shivarov et al 2013, Thol et al 2011, Yan et al 2011), whilst 
conflicting studies report no impact on either OS or RFS (Gaidzik et al 2013, 
Marková et al 2012). One reason for this apparent discrepancy may be the effect 
of the induction therapy given as part of some clinical trials. It has been shown 
that increasing the dosage of anthracycline, in particular Daunorubicin, improves 
the OS of DNMT3a mutated AML, with 4-year survival rates of 33% compared to 
just 13% for patients given the standard dose (Luskin et al 2016, Patel et al 2012, 
Sehgal et al 2015).  
 
1.2.3.5 WT1 
Wilms tumour 1 (WT1) is a transcription factor encoded for by a 10 exon gene on 
11p13. The expressed protein contains a four zinc-finger DNA binding region at the 
C-terminus, and a transactivation domain at the N-terminus. Wild-type WT1 
proteins bind to the Tet Methylcytosine Dioxygenase 2 (TET2) gene (Rampal et al 
2014) and recruit it to its downstream targets. TET2 acts as a tumour suppressor 
by inhibiting leukaemic cell proliferation and colony formation (Yiping Wang et al 
2015). Mutations in WT1 are present in 5-12% of AML cases, including those with 
cn-AML (Becker et al 2010, Gaidzik et al 2009, Hou et al 2010, Krauth et al 2015, 
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Paschka et al 2008, Renneville, Boissel, Zurawski, et al 2009, Summers et al 2007, 
Virappane et al 2008). They are present throughout the coding region of the gene, 
although the majority cluster in exons seven and 9, which form part of the DNA 
binding domain. The majority of mutations are frameshift, introducing early 
termination codons and subsequently the loss of the C-terminus (Summers et al 
2007, Virappane et al 2008). Truncated WT1 proteins are subject to nonsense-
mediated decay (NMD), suggesting that haploinsufficiency, rather than loss-of-
function is the mechanism at work (Abbas et al 2010), whereby a reduction in 
functional WT1 protein levels reduces the ability of TET2 to inhibit the 
proliferation of AML cells. Mutations in WT1 are regarded as a marker of poor 
prognosis, with mutated patients less likely to achieve CR after the first cycle of 
induction chemotherapy (Renneville, Boissel, Zurawski, et al 2009). It is 
unsurprising, therefore, that this leads to both higher relapse rates and shorter OS 
than in patients with wild-type WT1 (Becker et al 2010, Paschka et al 2008, 
Virappane et al 2008).  
 
1.3 Current Sequencing Methods in Diagnostics 
1.3.1 Sanger Sequencing 
In 1977, improving on earlier work (Sanger and Coulson 1975), the Sanger group 
developed a method for determining the nucleotide structure of a single stranded 
DNA molecule (Sanger et al 1977a). This method, commonly and hereafter 
referred to as ‘Sanger sequencing’, works in a similar manner to a standard 
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polymerase chain reaction (PCR), in which a DNA polymerase, an oligonucleotide 
‘primer’ and deoxynucleotidetriphosphates (dNTPs) are used to amplify a specific 
nucleotide sequence, using single stranded DNA as a template. The fundamental 
difference between this and Sanger sequencing, is the introduction of modified di-
deoxynucleotidetriphosphates (ddNTPs) to the reaction mix, which terminate DNA 
strand extension upon incorporation. Four ddNTPs are used, one each for adenine, 
cytosine, guanine and thymine (ddATP, ddCTP, ddGTP and ddTTP respectively), in 
combination with unmodified dNTPs, usually at a 100-fold lower concentration. 
This imbalance ensures that, at each round of amplification, a small proportion of 
DNA molecules are prevented from extending by the ddNTPs, whilst the 
remainder continue to be amplified. This generates a collection of DNA fragments, 
or amplicons, each of which differs in length by a single base pair. The pattern 
formed by these fragments, when separated on a polyacrylamide gel, represents 
the order of nucleotides in the original DNA template (Figure 1.5). In the original 
paper Sanger et al (1977a) performed four separate sequencing reactions, using 
the same template DNA and a different 32P radiolabelled ddNTP in each, and 
proceeded to successfully sequencing the genome of the phiX174 bacteriophage 
(Sanger et al 1977b), generating sequencing reads of between 150-200bp with an 
error rate of one every 50 bases, in the first real example of whole genome 
sequencing. This method of DNA sequencing facilitated new studies in a range of 
fields, with almost 1300 studies utilising it over the course of the next eight years. 
During this time, Sanger sequencing remained a costly and laborious process, 
relying as it did on four individual reactions and hand-cast polyacrylamide gels. An 
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improvement to the method, therefore, was the development of dye-terminator 
DNA sequencing (L M Smith et al 1986), alongside the first automated DNA 
sequencing platforms, in which each ddNTP is labelled with a different fluorescent 
dye rather than 32P. This allowed the sequencing reaction to take place in a single 
assay, with the fragments being passed through a system of capillaries and across 
a detector. Analysis software is then used to determine the nucleotide order 
based on the colour pattern of the fragments.  
Ultimately, this both greatly reduced the price and increased the throughput and 
caused the method to become widely established in laboratories around the world 
and is regarded as the ‘gold standard’ method for mutation detection.  
Improvements to the chemistry used for Sanger sequencing have also led to an 
increase in the read length, with 700-1000bp routinely obtainable, alongside a 
reduction in the inherent error rate.  However, the sensitivity of the standard 
method is only around 20%, that is, mutations present at a level below that are 
unlikely to be picked up. This is not an issue for constitutional genetics, where 
variants are expected to be present at either 50 or 100%, but a cause for concern 
in the study of cancer, where somatic driver mutations may be present at much 
lower levels.  
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Figure 1.5 Outline of the Sanger sequencing method using fluorescent dye 
terminator chemistry.   
(a) Template DNA is amplified in a cycle sequencing reaction using a combination of fluorescently 
labelled ddNTPS, unmodified dNTPs, Taq polymerase and a single sequencing primer. (b) The 
inclusion of modified ddNTPs in the reaction mix results in a collection of labelled PCR fragments of 
varying length. (c) These fragments are separated by capillary electrophoresis and passed between 
a laser and a detector, which determine the identity of each nucleotide in sequence based on the 
wavelength of light emitted by the ddNTP. 
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1.3.2 Pyrosequencing 
First described in 1996 (Ronaghi et al 1996), pyrosequencing is a method of 
sequencing DNA templates using the ‘sequencing-by-synthesis’ principle, in which 
each base is identified during incorporation into the complementary strand. The 
region of interest is first amplified using a pair of specific primers, one of which is 
biotinylated, in a standard PCR reaction. The resulting amplicons are isolated using 
streptavidin beads and incubated with a sequencing primer, DNA polymerase, ATP 
sulfurylase, luciferase and apyrase enzymes, as well as the luciferin and adenosine 
5’ phosphosulfate (APS) substrates.   
The assay works via the indirect detection of the DNA polymerase activity, during 
a sequencing reaction. When DNA polymerase incorporates a dNTP molecule, it 
also causes the release of pyrophosphate (PPI). During pyrosequencing, PPI is 
converted into adenosine triphosphate (ATP) by ATP sulfurylase in the presence of 
APS. Luciferase uses this ATP to oxidise the luciferin, producing oxyluciferin and 
releasing light (Figure 1.6). The light signal is detected using a charge-coupled 
device (CCD) camera, with the magnitude corresponding to the number of 
nucleotides incorporated during that sequencing cycle.  
To identify which of the four possible nucleotides has been incorporated into the 
template, they are added to, and removed from, the reaction sequentially. This 
was achieved initially by washing the reaction mix between each nucleotide 
addition step. Ensuring that all previous nucleotides have been removed is critical 
to the accuracy of the assay. The later addition of an apyrase to the enzyme mix 
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(Ronaghi 1998) removed the need for these intermediate washes and paved the 
way for automated pyrosequencing systems.  
The biggest advantage of this method is its ability to detect mutations at levels as 
low as 5% (Ogino et al 2005, Tsiatis et al 2010), compared to the 15-20% often 
quoted for Sanger sequencing. It is also able to generate accurate sequence data 
from the first base, unlike Sanger, which has a short 20-30bp interference window 
at the beginning of the read. There remain, however, a number of limitations to 
the method, not least of which is a restricted read length of around 100bp 
(Gharizadeh et al 2002). Additionally, the sensitivity of the CCD determines how 
well the system deals with homopolymer regions, as the strength of the light 
signal could overwhelm the detector. The quality of the sequence data often 
deteriorates downstream of these homopolymer regions.  
Whilst these restrictions render this method unsuitable for de-novo sequencing, it 
is highly suited to more targeted approaches, where the mutation to be 
interrogated has been well defined. For example, colorectal cancer patients are 
often treated with EGFR inhibitors, such as Cetuximab, Panitumumab or Erlotinib. 
However, mutations in the BRAF or KRAS genes render this therapy ineffective 
(Amado et al 2008, Karapetis et al 2008, Lièvre et al 2008). Pyrosequencing assays 
are commonly used in diagnostic laboratories to screen for these well 
characterised BRAF and KRAS mutations (Dufort et al 2009, Loupakis et al 2009, 
Ogino et al 2005, Packham et al 2009), with the information being used to help 
guide treatment decisions.  
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Figure 1.6 Outline of the pyrosequencing chemistry.  
(a) Incorporation of a dNTP by DNA polymerase causes the release of pyrophosphate (PPI), which is 
converted into ATP by ATP sulfurylase, in the presence of APS. (b) Luciferase uses the ATP to 
oxidise luciferin, producing oxyluciferin and generating a visible light signal, the intensity of which 
is proportional to the number of bases incorporated. A CCD captures the light signal and converts it 
to a peak in a pyrogram. 
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1.3.3 Amplification Refractory Mutation System 
Amplification Refractory Mutation System (ARMS) PCR is a robust and reliable 
method for the detection of single point mutations in DNA. The assay works on 
the principle that an oligonucleotide with a mismatched base at the 3’ end will not 
function as a primer in a PCR reaction. Therefore, a primer that is complementary 
to a specific point mutation will only generate a PCR product in the presence of 
that mutation (Newton et al 1989). 
Taking advantage of this, an ARMS-PCR assay will typically contain one common 
amplification primer, one primer whose 3’ end is specific to the wild-type 
sequence and a third primer with a 3’ modification specific to the targeted 
sequence. Generally, the PCR product generated by the wild-type/common primer 
pair will be significantly different in size than that produced by the 
mutant/common primer pair, in order to make visualisation of the products easier. 
In the presence of unmutated template DNA, the combination of these three 
primers will generate a single, wild-type PCR product. By contrast, in the presence 
of template DNA with a heterozygous mutation, the assay will generate both the 
wild-type amplicon and a shorter ‘mutant’ amplicon (Figure 1.7). The mutational 
status of the sample can therefore be determined by size-separating the PCR 
products using agarose gel electrophoresis. When fully optimised, these assays are 
able to detect the presence of mutated alleles present at levels as low as 0.5% 
(Huang et al 2013). 
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As reliable, sensitive and simple to use as these assays are, they rely on the 
investigator having prior knowledge of the mutation in question. As a result, they 
are widely used in cancer diagnostics where the variant has been well 
characterised and has prognostic value to the clinician; including KRAS mutations 
in colorectal cancer (Bolton et al 2015), EGFR Leu858Arg mutations in lung cancer 
(Morise et al 2014, Que et al 2016), BRAF Val600Glu mutations in melanoma and 
thyroid cancer (Huang et al 2013, Lu et al 2015), JAK2 Val617Phe mutations in 
myeloid neoplasms (Kui et al 2013) and NOTCH1 mutations in CLL (Bo et al 2014). 
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Figure 1.7 ARMS-PCR workflow.  
(a, b) An allele specific primer, used in conjunction with wild-type forward and reverse primers, are 
used to generate amplicons by polymerase chain reaction. (c) These products  can then be 
separated and visualised on an agarose gel. Abbreviations: FP, forward primer; RP, reverse primer; 
ASP, allele specific primer. 
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1.4 Development of ‘Next-Generation’ Sequencing 
The publishing of the first drafts of the human genome in 2001 (McPherson et al 
2001, Venter et al 2001) facilitated a greater understanding of our genetic profile. 
Three years later, the final draft was released (International Human Genome 
Sequencing Consortium, 2004), forming an important tool in molecular research 
and analysis to this day. This feat is all the more impressive considering the 
techniques available at the time. Both the International Human Genome 
Sequencing Consortium (2004) and the Venter group (2001) used dideoxy capillary 
sequencing methods, typically yielding 700-800 nucleotides of data per 
sequencing reaction. Putting that into context, the human genome is some three 
billion nucleotides in length.  
In the years since a number of next-generation sequencing (NGS) methods have 
been developed. These systems offer a much greater level of sensitivity and 
throughput compared with the capillary methods that preceded them. They 
enabled researchers to sequence millions of DNA fragments simultaneously, with 
great sensitivity and accuracy. 
 
1.4.1 Roche 454 Pyrosequencing 
In 2005, the Margulies group described a method of generating >25 million bases 
worth of good quality data that utilised a combination of emulsion PCR and 
pyrosequencing (Margulies et al 2005). In contrast to other sequencing library 
preparation methods, in which the fragments are amplified in a single pooled 
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reaction, the 454 protocol clonally amplifies each fragment on the surface of DNA 
capture beads in an emulsion PCR reaction. Single stranded DNA molecules are 
generated from the genomic DNA source by either nebulisation or sonication. 
Following an end-repair reaction, adaptor sequences are ligated to each end of the 
fragments. These adaptors are complementary to the sequences found on the 
capture beads. The fragments are then diluted to a single molecule level and then 
mixed with the DNA capture beads in a manner that ensures that each capture 
beads contains only a single library fragment. Emulsion PCR, whereby each bead is 
isolated in its own reaction compartment, results in the amplification of the bound 
library fragment, with the bead surface containing 1x106 clonal copies of the 
original fragment. The beads are then loaded onto a picotiter plate (PTP), the 
surface of which is covered with individual wells that are sufficiently small that 
only a single capture bead will fit into each one. The capture beads are packed into 
the wells alongside enzyme beads upon which the reaction enzymes (sulfurylase 
and luciferase) have been immobilised. The PTP functions as a flowcell, in that the 
four dNTPs are washed across it in sequence. Each nucleotide incorporation event 
is accompanied by the release of a chemi-luminescent light signal, which is 
detected and recorded by a CCD (Figure 1.8). On-instrument analysis software 
combines information regarding both the location and magnitude of the light 
signal, along with the identity of the dNTP distributed across the flowcell, to 
generate linear sequence data per well. Roche first marketed this technology in 
2005 as the GS20 instrument, which has since evolved into the GSFLX+, with the 
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capacity to generate 700 megabases (Mb) of sequence data, with read lengths of 
700bp, in just 23 hours. 
 
Figure 1.8 Roche 454 sequencing workflow. 
(a) 454-specific adaptors are ligated to both the 5’ and 3’ ends of fragmented genomic DNA. (b) 
Single fragments are then ligated to DNA capture beads. (c)  Emulsion PCR generates clonal copies 
of the bound fragment. (d) DNA capture beads are then loaded into individual wells of a PTP with 
(e) amplification beads covered in both sulfurylase (orange) and luciferase (green) enzymes, where 
the pyrosequencing reaction occurs. Adapted from Mardis et al (2008). 
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The increased read lengths afforded by the Roche chemistry, compared to the 
Illumina and Life Technologies platforms, make this method uniquely suited to 
certain applications, particularly de-novo sequencing projects in which no 
reference genome is available for post-sequencing mapping. However, this 
chemistry encounters some of the same issues as standard pyrosequencing assays. 
Sequencing errors are often introduced in regions containing large homopolymer 
domains, particularly those enriched for adenine and thymine bases (Luo et al 
2012), as the proportional relationship between the signal intensity and the 
number of nucleotides incorporated becomes less reliable (Margulies et al 2005).  
 
1.4.2 Illumina Sequencing-by-Synthesis 
Bentley et al (2008) reported a method of using reversible terminator chemistry to 
produce between one and two billion bases of sequence data, a process known as 
‘sequencing-by-synthesis’ (Figure 1.9). Template DNA is fragmented via sonication 
to produce a pool of fragments of between 350bp and 550bp in length. Following 
an end-repair step, Illumina specific adaptors, P5 and P7, are ligated to each end 
of the library fragments. 
These adaptors are complementary to a lawn of oligonucleotides on the surface of 
the flow cell. The library fragments are then bound to the flow cell surface via an 
active heating and cooling step. The generation of clonal clusters is achieved by a 
process known as bridge amplification, in contrast to the emulsion PCR method of 
454 sequencing. The immobilised library fragments are arched over and bound to 
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an adjacent complementary oligo. A series of amplification cycles generates up to 
1,000 identical copies of each fragment in close proximity to each other, resulting 
in up to 50x106 clonal clusters bound to the flow cell surface. Once loaded onto 
the sequencing instrument, these clusters are denatured and the fragments 
corresponding to the reverse strand are chemically cleaved away, leaving only the 
forward strand available for sequencing. Primers complementary to the P5 and P7 
adaptor sequences are used to initiate the sequencing chemistry. This process 
utilises four different fluorescently labelled, reversible dye terminators that are 
concurrently washed across the flow cell and bind to the template DNA. In a 
manner reminiscent of Sanger sequencing, the modifications to the dye 
terminators allow for only a single base to be incorporated into each template 
molecule during each sequencing cycle. Once the next dye terminator has been 
incorporated into the template sequence, and the excess reagents have been 
washed away, the entire flow cell is imaged and the fluorescence is recorded. The 
next sequencing cycle begins with a chemical wash to first unblock the 
incorporated dye terminator, which facilitates the addition of the next base in the 
sequence.  
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Figure 1.9 Illumina sequencing-by-synthesis workflow. 
(a) Illumina specific adaptors (blue and purple) are ligated to fragmented genomic DNA, along with 
sample specific barcode sequences (orange). (b) Fragments are then annealed to the surface of the 
sequencing flowcell, and (c, d) amplified via a bridge amplification process. (e) The resulting 
clusters are then denatured to produce single stranded sequencing template. (f) A sequencing 
primer then binds to the adaptor sequence. (g) Reversible dye terminators are then washed across 
the surface of the flowcell, with each incorporation event releasing a chemi-luminescent signal. (h) 
The incorporated base is unblocked and the process is repeated along the length of the template. 
(i) A CCD records each signal, and the sequence of each cluster is determined based on the colour 
of the signal.  
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This continues in sequence until the full length of the forward read has been 
recorded. Employing the bridge amplification method a second time, which 
generates the reverse strand, and cleavage of the forward strand, enables paired-
end sequencing. 
By using this sequencing-by-synthesis method, the Illumina HiSeq 2500 instrument 
is able to generate 1000 gigabases (Gb) in a single sequencing run in less than a 
week. A single human genome, covered to a depth of at least 30x, is achievable in 
just 27 hours. In contrast to the Roche 454 platform, the read lengths achievable 
with the Illumina HiSeq are restricted to a maximum of 250bp. The recent 
development of the HiSeq 3000 and 4000 systems offers significant gains in 
capacity and accuracy over the HiSeq 2500. The introduction of a patterned flow 
cell, the surface of which is covered in nanowells at fixed locations, allows for 
uniformity in both the distribution and size of the clusters. This increases the 
accuracy of the sequencing and, therefore, improves the data output of the 
sequencer by reducing the number of reads discarded due to cross-talk between 
clusters. As a consequence of this, the HiSeq 4000 is able to generate up to 
1500Gb of sequence data, and can sequence 12 human genomes in just four days.  
Many research groups around the world have taken advantage of the quantity and 
quality of sequencing data obtainable through the Illumina platforms, in an effort 
to further characterise a number of cancers. These include both whole genome 
(Chapman et al 2011, Dulak et al 2013, Ho et al 2013, Link et al 2011, Morin et al 
2013, Puente et al 2011, Rafnar et al 2011, Walter et al 2012, Wang et al 2014) 
and whole exome (Holmfeldt et al 2013, Landau et al 2013, Lawrence et al 2013, 
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Lohr et al 2012, 2014, Ojesina et al 2014) sequencing efforts that have helped to 
determine the complex molecular landscape of cancer by identifying new driver 
mutations, elucidating the impact of subclones on disease progression and 
discovering putative targets for future therapeutic regimens. 
 
1.4.3 Emergence of Bench-top Instruments  
Whilst the high-throughput capability of both the 454 FLX and HiSeq 2500 systems 
are well suited for exome and genome-wide explorative studies, for some 
particular applications there remains a need for a more focussed approach. For 
example, the use of targeted sequencing assays allows a researcher to isolate 
multiple specific regions of the genome for amplification and sequencing at once, 
returning only data that is relevant to the application in question. To address this 
need there has since been a push by Illumina, Roche and Life Technologies to 
produce smaller, more efficient and user-friendly ‘bench-top’ sequencers.  
Illumina’s solution is the MiSeq series of instruments. The MiSeq utilises the same 
sequencing-by-synthesis chemistry as the larger HiSeq packaged in a much more 
compact format. It is capable of generating up to 15Gb of sequence data from 
2x300bp paired-end sequencing runs. Similarly, Roche has released the 454-junior 
instrument, a more compact version of its FLX+ sequencer. The 454-junior can 
generate 35Mb of data in 10 hours, with read lengths up to 400bp. Life 
Technologies developed the Ion Torrent personal genome machine (PGM), 
representing the first ‘non-optical’ semi-conductor sequencing system (Rothberg 
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et al 2011). In addition to a smaller physical footprint and data output, these 
instruments have much more automated and streamlined data analysis pathways. 
Software packages that are either on-instrument, in the case of the 454-Junior and 
Ion Torrent, or cloud based (MiSeq), analyse the data in real-time, aligning the 
sequence reads to a chosen genome to highlight any variants. These bench-top 
sequencers are ideal for targeted mutation analysis, whereby a number of 
candidate genes or mutational hotspots are simultaneously sequenced and 
analysed. This method of performing targeted sequencing is likely to be the 
primary application of NGS in clinical cancer diagnostics.  
 
1.5 Third-Generation Sequencing Platforms 
Despite the recent emergence and widespread acceptance of NGS platforms, a 
new generation of sequencing technologies is slowly emerging; so-called ‘third-
generation’ sequencing. Exactly what distinguishes between a second and third-
generation sequencing method remains somewhat ambiguous, but third-
generation sequencing platforms are generally based upon the concept of single-
molecule sequencing (SMS) without the need for template amplification. This 
reduces the likelihood of introducing errors into the template prior to sequencing, 
which can lead to false positive mutations.  
In 2009, Pacific Biosciences described a sequencing method referred to as Single 
Molecule Real Time sequencing (SMRT) (Eid et al 2009). This chemistry utilises a 
flowcell covered in small reaction wells, referred to as zero-mode wave guides 
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(ZMWs), on the bottom of which a single DNA polymerase molecule has been 
immobilised. Each ZMW is illuminated from underneath, however the wavelength 
of the light is too large to pass fully through the ZMW, resulting in a detection 
volume of 20 zeptolitres (10-21 litres) at the bottom of the well. Incorporation of 
fluorescently labelled nucleotides releases a light signal, which is detected by a 
CCD and converted into a base call depending on the colour of the signal. The 
small reaction volume ensures that only incorporated nucleotides are detected, 
reducing the background noise level 1000-fold over other methods. This method 
has been utilised in a number of studies where long-range sequencing reads and 
high sensitivity have been crucial to the outcome, including in the detection of 
HIV-1 drug resistance mutations (Da Wei Huang et al 2016), non-invasive testing 
for colorectal cancer (CRC) (Russo et al 2015) and full-length MHC class I 
sequencing (Westbrook et al 2015).  
One alternative method, currently in development by Oxford Nanopore 
Technologies, directly detects a single DNA molecule as it passes through a 
specifically bio-engineered nanopore. Each nanopore is based around a modified 
α-haemolysin ion channel, with both an exonuclease and a cyclodextrin sensor 
attached. These pores are embedded in a synthetic lipid bi-layer, which enables a 
current to be passed across it by altering the salt concentration on either side. 
Double-stranded DNA molecules are unwound at the entrance of the pore, with 
one strand then fed through by the current. During the transition through the 
pore, individual nucleotides are cleaved from the strand by the exonuclease. 
These cleaved nucleotides produce a disruption in the ionic flow through the pore, 
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altering the current in a manner proportional to the size, and therefore the 
identity, of the nucleotide in question. In this manner, the specific sequence of the 
DNA molecule can be inferred. A hairpin adaptor attached to the template DNA 
allows for ‘paired-end’ sequencing if required. This chemistry is expected to 
facilitate rapid sequencing of long DNA templates, without the need for error 
prone amplification, and the ability to handle complex or repetitive regions of the 
genome more accurately than earlier sequencing methods. Despite the early 
promise of nanopore sequencing, it is apparent that nanopore sequencing is still in 
its infancy, with studies highlighting high error rates and low alignment rates 
(Goodwin et al 2015, Mikheyev and Tin 2014). Efforts are now focussing on 
correcting these errors downstream of the sequencing process to generate more 
accurate data (Goodwin et al 2015, Madoui et al 2015).  
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1.6 Aims of this Thesis 
The work presented in this thesis aims to demonstrate that next-generation 
sequencing platforms can play important roles, both diagnostically and on a 
research basis, in the context of haematological malignancies. These aims will be 
achieved by: 
 
1. Designing and validating a targeted sequencing panel to screen for 
clinically relevant gene mutations in patients with known or suspected 
myeloid malignancies. 
 
2. Demonstrating the clinical utility of the targeted sequencing panel by 
applying it to a cohort of clinical patient samples. 
 
3. Describing the molecular landscape of the del(5q) MDS subtype using the 
targeted sequencing panel. 
 
4. Performing whole genome sequencing of a cohort of CLL patients to fully 
characterise the molecular landscape, with particular reference to 
somatically acquired mutations, structural rearrangements and mutational 
signatures. 
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 MATERIALS AND METHODS Chapter 2 
 
This chapter describes the protocols used in this work. Additional protocols, 
including primer sequences used for specific projects, are detailed in the relevant 
chapters. 
2.1 Extraction of Genomic DNA 
2.1.1 Extraction from Buffy Coat Samples 
Manual extraction of genomic DNA from isolated Buffy coat samples was kindly 
performed by Maite Cabes of the Oxford Radcliffe Biobank, using phenol 
chloroform as follows: one millilitre of 2x lysis solution, comprising 0.77M NH4Cl 
(Sigma-Aldrich Corporation, St. Louis, MO, USA) and 0.046M KHCO3 (Sigma-Aldrich 
Corporation, St. Louis, MO, USA) was added to the Buffy coat sample tube. The 
sample was then inverted and rotated for 10 minutes on a rotary mixer to lyse the 
red blood cells. The lysed sample was centrifuged at 28,341g for five minutes. 
After discarding the supernatant, the cell pellet was re-suspended in 200μl lysing 
solution, comprising 100mM NaCl (Sigma-Aldrich Corporation, St. Louis, MO, USA) 
and 25mM EDTA pH 8.0 (Sigma-Aldrich Corporation, St. Louis, MO, USA) along 
with 30μl of 10% SDS (Promega Corporation, Madison, WI, USA) and 200μl of 
10mg/ml proteinase K (Qiagen N.V., Hilden, Germany), and mixed by pipetting. 
The sample was incubated at 37oC overnight. The addition of phenol to the 
reaction generates an emulsion that isolates the proteins in the mixture. The 
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phenol can then be separated via centrifugation and removed. 700μl of phenol 
(Sigma-Aldrich Corporation, St. Louis, MO, USA) was added to the solution, 
followed by centrifugation at 28,341g for five minutes. The aqueous upper layer 
was then transferred to a new 0.5ml Eppendorf tube (Sigma-Aldrich Corporation, 
St. Louis, MO, USA) also containing 700μl phenol and the centrifugation repeated. 
The two wash steps were repeated, replacing the phenol with 700μl of chloroform 
(Sigma-Aldrich Corporation, St. Louis, MO, USA). The DNA was extracted by adding 
the final upper aqueous layer to a new 0.5ml Eppendorf tube containing 800μl of 
chilled (4°C) 100% ethanol (VWR International, Radnor, PA, USA) and 1μl 7.5M 
ammonium acetate (Sigma-Aldrich Corporation, St. Louis, MO, USA). The mixture 
was centrifuged at 13,226g for five minutes to collect the pellet, and washed in 
500μl 70% ethanol. The pellet was then air dried and re-suspended in nuclease-
free water (ThermoFisher Scientific, Waltham, MA, USA). 
 
2.1.2 Extraction from Saliva Samples 
Extraction of germline DNA from saliva samples was kindly performed by Maite 
Cabes of the Oxford Radcliffe Biobank using the Oragene DNA kits (DNA Genotek 
Inc, Ottawa, ON, Canada) as follows: each saliva sample was inverted 10 times to 
ensure adequate mixing and then incubated at 50°C for one hour. The sample was 
transferred to a 15ml Falcon tube (Thermo Fisher Scientific, Waltham, MA, USA) 
containing a 1/25th volume of PT-L2P solution (DNA Genotek Inc, Ottawa, ON, 
Canada), mixed by vortexing for 10 seconds and incubated on ice for 10 minutes to 
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precipitate out impurities. The sample was then centrifuged at 3,500xg for 10 
minutes. The supernatant was transferred to a new 15ml Falcon tube (Thermo 
Fisher Scientific, Waltham, MA, USA) and the pellet discarded. To precipitate the 
DNA, a 1.2x volume of room temperature 100% ethanol (VWR International, 
Radnor, PA, USA) was added to the supernatant, followed by inverting 10 times to 
mix. The sample was then allowed to incubate at room temperature for 10 
minutes, before centrifuging at 3,500xg for a further 10 minutes. The supernatant 
was removed and discarded and the pellet washed by adding 1ml of 70% ethanol 
(VWR International, Radnor, PA, USA) and incubating at room temperature for one 
minute. The supernatant was removed, taking care not to disturb the pelletised 
DNA. The DNA was re-hydrated by adding 0.5ml of TE buffer (10mM Tris-HCL, 
1mM disodium EDTA, pH 8.0) (Sigma-Aldrich Corporation, St. Louis, MO, USA) 
followed by vortexing for 30 seconds. The DNA was then incubated at room 
temperature overnight, followed by a final 30 second vortex mix and then 
transferred to a labelled 1.5ml Eppendorf tube (Sigma-Aldrich Corporation, St. 
Louis, MO, USA).   
 
2.2 Extraction of Total RNA 
Total RNA was manually extracted from blood samples using the Qiagen RNeasy 
mini kit (Qiagen N.V. Hilden, Germany). The extraction procedure occurs in two 
parts, the first produces a guanidine-thiocyanate–containing (GTC) lysate, which 
can be stored at -80°C for up to six months. The second stage isolates the total 
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RNA. Whole blood was transferred to a 50ml Falcon tube (Thermo Fisher 
Scientific, Waltham, MA, USA), and the volume made up to 50ml with red blood 
cell (RBC) lysis buffer (Qiagen N.V. Hilden, Germany). Rotation of the tube for 10 
minutes on a rotary mixer ensured efficient lysis of the sample. The lysed sample 
was centrifuged at 1509g for 10 minutes. The pellet was re-suspended in 20ml of 
RBC lysis buffer (Qiagen N.V., Hilden, Germany), mixed by rotation and centrifuged 
as above. The resulting cell pellet was re-suspended in the appropriate volume of 
RBC lysis buffer (Qiagen N.V., Hilden, Germany) in order that 1ml contained no 
more than 1x107 cells. One millilitre of this suspension was transferred to a new 
tube and centrifuged at 13,226g for 2mins 30sec. The supernatant was removed 
and the pellet re-suspended in a solution containing 600μl RLT buffer (Qiagen 
N.V., Hilden, Germany) and 6μl β-mercaptoethanol/ml (Sigma-Aldrich Corporation, 
St. Louis, MO, USA). Buffer RLT enhances the binding of RNA to the membrane of 
the RNeasy spin column (Qiagen N.V., Hilden, Germany). The sample was 
homogenised by hand using a 20-gauge needle. The volume was doubled with 
70% ethanol (VWR International, Radnor, PA, USA), and then washed through the 
RNeasy spin column, by centrifuging at 13,226g for 15 seconds, in two lots of 
700μl. The sample was then washed first with 700μl of a stringent wash buffer 
(RW1) (Qiagen N.V., Hilden, Germany) and then twice with 500μl of a non-
stringent wash buffer (RPE) (Qiagen N.V., Hilden, Germany), spinning as before. 
Once the membrane of the RNeasy spin column had air-dried, 30μl of nuclease-
free water (ThermoFisher Scientific, Waltham, MA, USA) was spun through the 
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column to elute the RNA into a 1.5ml Eppendorf tube (Thermo Fisher Scientific, 
Waltham, MA, USA).  
 
2.3 Calculation of DNA Quality and Concentration 
2.3.1 Nanodrop Spectrophotometry 
The concentration and quality of DNA samples was determined using a Nanodrop 
2000 UV-vis spectrophotometer (ThermoFisher Scientific, Waltham, MA, USA). 
This instrument generates data about both the concentration and purity of DNA 
samples in 15 seconds using only 1μl of undiluted material. In addition, the 
material used for measurement is recoverable. With the measurement arm raised, 
1.5μl of test sample was pipetted onto the pedestal. Closing the measurement 
arm sandwiched the sample between the light source and the detector. The 
Nanodrop 2000 software package v1.6.19 ( ThermoFisher Scientific, Waltham, MA, 
USA) was used to take the measurement and record the results for each sample. 
To determine a baseline measurement, 1μl of the solution used to re-suspend the 
DNA sample was used as a blank sample prior to the first test sample. The sample 
pedestal was wiped clean with distilled water between each test sample. DNA 
samples with a 260/280 ratio of ≥1.8, and RNA samples with 260/280 ratios ≥2.0 
were considered pure enough for downstream analysis. 
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2.3.2 Qubit Fluorometric Quantitation 
The Qubit fluorometric quantitation method utilises a fluorescent dye to quantify 
DNA samples. This approach is more accurate than spectrophotometric based 
methods, as it is able to distinguish between DNA, RNA and other contaminates, 
which may affect spectrophotometric readings. A Qubit 2.0 Fluorometer (Thermo 
Fisher Scientific, Waltham, MA, USA) was used to determine the concentration of 
extracted DNA samples. A working dilution of Qubit solution was prepared by 
diluting the Qubit dsDNA reagent (Thermo Fisher Scientific, Waltham, MA, USA) by 
a factor of 1:200 in Qubit dsDNA buffer (Thermo Fisher Scientific, Waltham, MA, 
USA). For each of the two standards, 190μl of Qubit solution is required, along 
with 199μl for each test sample. Ten microliters of each standard was added to 
separate Eppendorf tubes (Thermo Fisher Scientific, Waltham, MA, USA) and 
mixed with 190μl of the Qubit working solution. For each test sample, 199μl of 
Qubit solution (Thermo Fisher Scientific, Waltham, MA, USA) was added to 1μl of 
DNA. All tubes were mixed by vortexing and allowed to stand at room 
temperature for two minutes. Measurements of the standards were taken first to 
establish a standard curve, followed by each sample in turn. 
 
2.4 Calculation of RNA Quality and Concentration 
2.4.1 Qubit RNA Quantitation 
An estimate of the concentration of an RNA sample can be made using a Qubit 
RNA assay kit and the Qubit fluorometer. This assay is highly selective for single-
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stranded RNA molecules over double-stranded DNA. Working dilutions of the RNA 
samples, standards and the Qubit reagent (Thermo Fisher Scientific, Waltham, 
MA, USA)were created as per the DNA assay (described in section 2.3.2). Ten 
microliters of each standard was added to separate tubes and mixed with 190μl of 
the Qubit working solution. For each test sample, 199μl of Qubit solution (Thermo 
Fisher Scientific, Waltham, MA, USA) was added to 1μl of RNA. All tubes were 
mixed by vortexing and allowed to stand at room temperature for two minutes. 
Measurements of the standards were taken first to establish a standard curve, 
followed by each sample in turn. 
 
2.4.2 Agilent Bioanalyzer 
The quality, or integrity, of an RNA sample is an important factor in many 
experiments, particularly in next-generation sequencing where one of the first 
steps of library preparation involves degrading the sample. The Agilent bioanalyzer 
(Agilent Technologies, Santa Clara, CA, USA) provides an accurate assessment of 
both the quality and quantity of an RNA sample prior to downstream processing. 
The integrity of the RNA is reflected in the RNA integrity number (RIN) assigned to 
each sample run, on a scale of one to ten. Lower RIN scores (<4) indicate a higher 
level of RNA degradation than higher ones (>8). For whole transcriptome 
sequencing, only samples with a RIN >7 were selected. For each sample, 1μl of 
RNA was loaded into a single well of an Agilent RNA 6000 Nano chip and 
processed using a 2100 Bioanalyzer instrument (Agilent Technologies, Santa Clara, 
64 
 
CA, USA) as per the manufacturer’s instructions (http://www.agilent.com/cs/ 
library/usermanuals/Public/G2938-90034_RNA6000Nano_KG.pdf). 
2.5 DNA Sequence Analysis 
2.5.1 Polymerase Chain Reaction 
A number of experiments in this study employed the polymerase chain reaction 
(PCR). Whilst the specific conditions were optimised based on the primer and 
target sequences of each assay, the reaction mix remained the same. Each 25μl 
reaction consisted of 100-250ng of genomic DNA, 12.5μl of 2x Qiagen Multiplex 
Mastermix (Qiagen N.V., Hilden, Germany), 10pmol each of forward and reverse 
primers, with the final volume made up to 25μl with nuclease-free water 
(ThermoFisher Scientific, Waltham, MA, USA). Where the target sequence was GC-
rich, 5x Q solution (Qiagen N.V., Hilden, Germany), was also included. All primers 
were designed, and melting temperatures (Tm) were calculated, using Primer3 
software (http://primer3.ut.ee). All primers were supplied by Sigma-Aldrich 
Corporation (St. Louis, MO, USA). PCR reactions were performed under mineral oil 
in either 0.5ml PCR tubes (Thermo Fisher Scientific, Waltham, MA, USA) or 0.2ml 
96-well PCR plates (Corning Inc, Corning, NY, USA) on a T3 Biometra thermocycler 
(Biometra GmbH, Göttingen, Germany). The standard cycling conditions were: 
 
 1 cycle of:  15 minutes at 97°C 
 30-40 cycles of 30 seconds at 92°C 
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    30 seconds at Tm°C 
    20 seconds at 72°C 
 1 cycle of:  10 minutes at 72°C  
 1 cycle of:  Hold at 4°C  
2.5.2 Agarose Gel Electrophoresis 
PCR products were separated according to size using agarose gel electrophoresis, 
which uses an electrical field to move the negatively charged DNA towards a 
positive electrode through an agarose gel matrix. Smaller DNA fragments are able 
to move through the matrix more efficiently than larger fragments, and so will 
migrate further. 3% (w/v) gels were made by dissolving 6g of agarose (Sigma-
Aldrich Corporation, St. Louis, MO, USA) in 200ml of 1x Tris-Borate-EDTA (TBE) 
(Geneflow Ltd, Lichfield, UK) with 0.5μg/ml ethidium bromide (Sigma-Aldrich 
Corporation, St. Louis, MO, USA). The PCR product was mixed with 1/5 volume of 
5x loading dye comprising 2.5% Ficoll (Sigma-Aldrich Corporation, St. Louis, MO, 
USA), 0.01% bromophenol blue (Sigma-Aldrich Corporation, St. Louis, MO, USA) 
and 0.01% xylene cyanole (Sigma-Aldrich Corporation, St. Louis, MO, USA) and run 
with the DNA marker appropriate for the fragment sizes in a 1x TBE running buffer 
(Geneflow Ltd, Lichfield, UK). A voltage of 120V was applied across the gel for 45 
to 60 minutes. The gels were placed on a Bio-Rad UV transilluminator (Bio-Rad, 
Hercules, CA, USA) to visualise the DNA under ultra-violet light (302nm 
wavelength) and the images printed using a Mitsubishi P93D thermal printer 
(Mitsubishi Electric Corporation, Tokyo, Japan). 
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2.5.3 Purification of PCR Product 
Following PCR amplification, 10μl of PCR product was mixed with 10μl of 
MicroClean reagent (Microzone Ltd, Haywards Heath, UK) and mixed by pipetting. 
The sample was then centrifuged at 28,341g for 40 minutes to collect the pellet, 
and then spun inverted for 10 seconds at a very low speed (1.6g) on a stack of 
paper towels to remove the supernatant. The pellet was re-suspended in 12μl of 
nuclease-free water (ThermoFisher Scientific, Waltham, MA, USA) and allowed to 
stand for 10 minutes to re-hydrate. 
 
2.5.4 Sanger Sequencing 
DNA sequencing was based on the chain termination method first described by 
Prof. Sanger and colleagues (Sanger, Nicklen, et al 1977). The sequencing reactions 
were performed on an Applied Biosystems 3130xl Genetic Analyser (Applied 
Biosystems, Foster City, CA, USA). PCR reactions were performed as described in 
section 2.5.1. 
 
2.5.4.1 Chain Terminator PCR 
Each 10μl Sanger sequencing PCR reaction contained 1μl of purified PCR product 
(as described in section 2.5.3) and 9μl of reaction mix consisting of: 2μl 2.5x 
BigDye Terminator 3.1 ready reaction premix (Applied Biosystems, Foster City, CA, 
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USA), 1μl 5x BigDye sequencing buffer (Applied Biosystems, Foster City, CA, USA), 
1μl of 3.2 microlmolar (μM) sequencing primer (Sigma-Aldrich Corporation, St. 
Louis, MO, USA) and 5μl of nuclease-free water (ThermoFisher Scientific, 
Waltham, MA, USA). Cycle sequencing reactions were performed in 0.2ml 96-well 
plates, under mineral oil, on a T3 Biometra thermocycler (Biometra GmbH, 
Göttingen, Germany). The cycling conditions were: 
 
 1 cycle of:  1 minutes at 96°C 
 25 cycles of  10 seconds at 96°C 
    5 seconds at 50°C 
    4 minutes at 60°C 
 1 cycle of:  Hold at 4°C  
 
2.5.4.2 Ethanol EDTA Precipitation 
5μl of 125mM EDTA pH 6.0 (Sigma-Aldrich Corporation, St. Louis, MO, USA) and 
60μl of cold 100% ethanol (VWR International, Radnor, PA, USA) was added to 
each cycle sequencing reaction. The sample was inverted 10 times by hand to mix 
and then incubated at room temperature for 15 minutes. The plate was 
centrifuged at 2296g for 30 minutes at 4°C. The plate was then inverted to remove 
the supernatant and washed again in 60μl of ice-cold 70% ethanol (VWR 
International, Radnor, PA, USA). The samples were centrifuged at 2054g for 15 
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minutes, the supernatant removed and the samples allowed to air-dry. The dried 
samples were re-suspended in 8.5μl of Hi-Di formamide (Applied Biosystems, 
Foster City, CA, USA) prior to sequencing.  
 
2.5.4.3 DNA Sequence Data Analysis 
Sequencing analysis software (v5.4, Applied Biosystems, Foster City, CA, USA) was 
used to analyse the raw sequencing data in the first instance. This software 
performs base calling and generates quality values for each base and sample file. 
The output files from this process include text files of the DNA sequence and 
analysed ABI files, either of which can be used for downstream analysis. The ABI 
file extension contains information on both the DNA sequence and the 
chromatogram for each sample. For the identification of variants in the DNA 
sample, Mutation Surveyor (SoftGenetics, State College, PA, USA) software was 
used. This software takes analysed ABI files and performs a direct base-to-base 
comparison against a FASTA sequence file of the wild-type sequence. A FASTA file 
is a simple text-based format for representing a specific nucleotide sequence. 
 
2.5.5 DNA Fragment Analysis 
The insertion or deletion of a short stretch of DNA can be detected effectively via 
a DNA fragment analysis assay. Primers are designed to amplify a region of DNA 
spanning the site of the suspected insertion or deletion. One of the two primers 
has a fluorescent dye, such as cyanine-5 (Cy5), conjugated to its 5’ end. When 
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excited by a laser, these dyes emit a light signal, allowing the PCR fragment to be 
compared to a size standard on an automated DNA sequencer. Samples containing 
a deletion or insertion will appear shorter or longer than the wild-type, 
respectively.  
 
2.5.5.1 Detection of 4bp Insertion in NPM1 
Exon 12 of the NPM1 gene was amplified using primers (forward: CY5-ACT CTC 
TGG TGG TAG AAT GAA, reverse: GGC ATT TTG GAC AAC ACA TTC) previously 
designed and published by Scholl and colleagues (Scholl et al 2007). The forward 
primer had Cy5 dye conjugated to its 5’ end. Extracted DNA, as described in 
section 2.1, was amplified using the following amplification conditions: 95°C for 15 
minutes, followed by 40 cycles of 30 seconds at 92°C, 30 seconds at 58°C and 20 
seconds at 72°C, with a final extension step of 10 minutes at 72°C. The resulting 
PCR product was diluted 1:10 in nuclease-free water (ThermoFisher Scientific, 
Waltham, MA, USA). 2μl of this dilution was mixed with 40μl sample loading 
solution (Beckman Coulter, Brea, CA, USA) and 0.5μl GenomeLab DNA size 
standard 600 (Beckman Coulter, Brea, CA, USA) and subjected to capillary 
electrophoresis on a CEQ8000 Genetic Analysis System (Beckman Coulter, Brea, 
CA, USA). Data analysis was performed using CEQ analysis software version 9.0.25 
(Beckman Coulter, Brea, CA, USA) using default settings. 
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2.5.5.2 Detection of Internal Tandem Duplications in FLT3 
The fragment analysis protocol (section 2.5.5) was also used to screen for internal 
tandem duplications (ITDs) in the FMS-like tyrosine kinase-3 (FLT3) gene. The 
primer sequences were modified from those described by Murphy et al (2003) by 
conjugating WellRED fluorescent dyes (Sigma-Aldrich Corporation, St. Louis, MO, 
USA ) to the 5’ ends. The primer sequences were; forward: D4-GCA ATT TAG GTA 
TGA AAG CCA GC, reverse: D3-CTT TCA GCA TTT TGA CGG CAA CC, where D4 and 
D3 are WellRED dye codes. The standard PCR reagent mix was used (see section 
2.5.1 above), with the following amplification conditions: 95°C for 15 minutes, 
followed by 35 cycles of 30 seconds at 95°C, one minute at 56°C and two minutes 
at 72°C, with a final extension step of 10 minutes at 72°C. The resulting PCR 
product was prepared and sequenced as per section 2.5.4. 
2.5.6 Pyrosequencing Assay for JAK2V617F Mutation 
Pyrosequencing is a sequencing-by-synthesis assay by which short DNA molecules 
can be interrogated for the presence of small indels or single nucleotide 
polymorphisms (Ronaghi et al 1996). This method was used to detect the presence 
of the common Val617Phe point mutation in myeloid leukaemia cases. The 
Pyromark Assay Design software tool (v2.0, Qiagen, Hilden, Germany) was used to 
design a number of potential primer sequences, with the following found to be the 
most efficient; forward: biotin-GAA GCA GCA AGT ATG ATG AGC A, reverse: TGC 
TCT GAG AAA GGC ATT AGA A and the sequencing primer: TCT CGT CTC CAC AGA. 
The standard PCR amplification mix was used, as described in section 2.5.1 above, 
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with the forward and reverse primers, and with the addition of 2.5μl 5x Q-solution 
(Qiagen N.V., Hilden, Germany). Cycling conditions were 97°C for 15 minutes, 
followed by 35 cycles of 30 seconds at 97°C, 90 seconds at 62°C and two minutes 
at 72°C, with a final extension step of 10 minutes at 72°C. The pyrosequencing 
assay was performed on a Pyromark Q24 instrument (Qiagen N.V., Hilden, 
Germany) as per the manufacturer’s protocol 
(https://www.qiagen.com/us/resources/resourcedetail?id=59f0275d-e60f-4517-
b786-b0e0ca13952e&lang=en) The assay design software defined the 
dispensation order for the assay. 
 
2.5.7 Real-time PCR Assay for JAK2V617F Mutation 
Real-time PCR is a method commonly used to quantitatively determine the 
proportion of single nucleotide polymorphisms in DNA samples through Taqman 
allelic discrimination (Livak 1999). In this assay, allele specific probes, labelled with 
5’ reporter and 3’ quencher dyes, for both the wild-type and variant alleles, are 
incorporated into an otherwise standard PCR reaction. Incorporation of the probes 
into the PCR amplicon results in the cleavage of both the reporter and quencher 
dyes. This removes the suppression of the reporter signal by the quencher, and 
enables the detection of the reporter signal. The strength of the signal is 
proportional to the copy number of the target sequence. The Ipsogen JAK2 
MutaQuant kit (Qiagen N.V., Hilden, Germany) was used to determine the level of 
V617F JAK2 mutations. PCR reactions were setup in a 100-well rotor by a CAS1200 
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liquid handling instrument (Qiagen N.V., Hilden, Germany). Each reaction mix 
contained 6.25μl 2x Taqman Universal PCR Master Mix (Applied Biosystems, Life 
Technologies, Carlsbad, CA), 0.5μl 25x primer/probe mix (Qiagen N.V., Hilden, 
Germany), 3.25μl nuclease-free water (ThermoFisher Scientific, Waltham, MA, 
USA) and 25ng of sample DNA. The samples were amplified on a Rotor-Gene 6000 
instrument (Qiagen N.V., Hilden, Germany) using the following PCR conditions: 
50°C for two minutes, 95°C for 10 minutes, followed by 50 cycles of 95°C for 15 
seconds and 62°C for one minute, with signal acquisition in the FAM channel 
during the 62°C step. Each sample was tested for both wild-type and mutant 
alleles. Analysis of the raw data was performed using the Rotor-Gene Q software 
package (Qiagen N.V., Hilden, Germany). The cycle threshold was set at 0.03 with 
the slope corrected, as per the manufacturer’s guidelines 
(https://www.qiagen.com/us/resources/resourcedetail?id=58d4a7d9-287f-4b01-
85c3-5cb83db2228b&lang=en).  
Raw data tables for both wild type and V617F assays were exported into Excel 
(Microsoft, Redmond, WA) to facilitate further analysis. The standard curves were 
plotted (y = mean ct, x = Log10 CN, where CN is gene copy number/5µl) for both 
the wild-type and V617F standard samples, and values for both the slope of the 
line (Y) and coefficient of determination (R2) were extracted. The copy number for 
JAK2V617F was calculated as:  
 
𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝐶𝐶𝑡𝑡𝐽𝐽𝐽𝐽𝐽𝐽2𝑉𝑉617𝐹𝐹 − 𝑠𝑠𝑡𝑡𝑚𝑚𝑚𝑚𝑠𝑠𝑚𝑚𝑠𝑠𝑠𝑠 𝑐𝑐𝑐𝑐𝑠𝑠𝑐𝑐𝑚𝑚 𝑖𝑖𝑚𝑚𝑡𝑡𝑚𝑚𝑠𝑠𝑐𝑐𝑚𝑚𝑖𝑖𝑡𝑡𝐽𝐽𝐽𝐽𝐽𝐽2𝑉𝑉617𝐹𝐹
𝑠𝑠𝑡𝑡𝑚𝑚𝑚𝑚𝑠𝑠𝑚𝑚𝑠𝑠𝑠𝑠 𝑐𝑐𝑐𝑐𝑠𝑠𝑐𝑐𝑚𝑚 𝑠𝑠𝑠𝑠𝑠𝑠𝑖𝑖𝑚𝑚𝐽𝐽𝐽𝐽𝐽𝐽2𝑉𝑉617𝐹𝐹
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JAK2 wild-type copy number was calculated as:  
 
𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑐𝑐𝑡𝑡𝐽𝐽𝐽𝐽𝐽𝐽2𝑊𝑊𝑊𝑊 − 𝑠𝑠𝑡𝑡𝑚𝑚𝑚𝑚𝑠𝑠𝑚𝑚𝑠𝑠𝑠𝑠 𝑐𝑐𝑐𝑐𝑠𝑠𝑐𝑐𝑚𝑚 𝑖𝑖𝑚𝑚𝑡𝑡𝑚𝑚𝑠𝑠𝑐𝑐𝑚𝑚𝑖𝑖𝑡𝑡𝐽𝐽𝐽𝐽𝐽𝐽2𝑊𝑊𝑊𝑊
𝑠𝑠𝑡𝑡𝑚𝑚𝑚𝑚𝑠𝑠𝑚𝑚𝑠𝑠𝑠𝑠 𝑐𝑐𝑐𝑐𝑠𝑠𝑐𝑐𝑚𝑚 𝑠𝑠𝑠𝑠𝑠𝑠𝑖𝑖𝑚𝑚𝐽𝐽𝐽𝐽𝐽𝐽2𝑊𝑊𝑊𝑊
 
 
Final results were determined as a percentage of JAK2V617F allele load, calculated 
by:  
𝑐𝑐𝑠𝑠𝑖𝑖𝑐𝑐 𝑚𝑚𝑐𝑐𝑚𝑚𝑛𝑛𝑚𝑚𝑠𝑠𝐽𝐽𝐽𝐽𝐽𝐽2𝑉𝑉617𝐹𝐹
𝑐𝑐𝑠𝑠𝑖𝑖𝑐𝑐 𝑚𝑚𝑐𝑐𝑚𝑚𝑛𝑛𝑚𝑚𝑠𝑠𝐽𝐽𝐽𝐽𝐽𝐽2𝑉𝑉617𝐹𝐹 + 𝑐𝑐𝑠𝑠𝑖𝑖𝑐𝑐 𝑚𝑚𝑐𝑐𝑚𝑚𝑛𝑛𝑚𝑚𝑠𝑠𝐽𝐽𝐽𝐽𝐽𝐽2𝑊𝑊𝑊𝑊
 
2.5.8 Targeted Next-Generation Sequencing 
Targeted next-generation sequencing provides a convenient method of screening 
for a number of mutations simultaneously in a time and cost effective manner, 
and is starting to contribute to the diagnosis and management in a range of 
diseases. The Illumina TruSeq Custom Amplicon assay (TSCA) (Illumina, San Diego, 
CA, USA) was used to amplify and sequence a large number of targets in multiple 
patients simultaneously (Figure 2.1). Dual-barcoded libraries were generated from 
250ng of input DNA as per the manufacturer’s protocol 
(https://support.illumina.com/content/dam/illumina-support/documents/docume
ntation/chemistry_documentation/samplepreps_truseq/truseqcustomamplicon/tr
useq-custom-amplicon-15-protocol-1000000005006-01.pdf). Up to 20 patient 
libraries were subjected to 2x150bp paired-end sequencing per sequencing run on 
an Illumina MiSeq instrument (Illumina, San Diego, CA, USA). The Stampy and Comment [a1]: Ref 
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Smith-Waterman (Smith and Waterman 1981) algorithms were used to align the 
sequence reads to the hg19 human genome build in parallel, with both Platypus 
and GATK used for variant calling (Figure 2.2). Additionally, Pindel was applied to 
the ISW-generated BAM files to screen for larger indel events. Annotation of each 
variant was carried out using VariantStudio software (Illumina, San Diego, CA, 
USA). The design of individual sequencing panels is discussed in depth in the 
relevant chapters.  
Comment [a2]: Ref 
Comment [a3]: Ref 
Comment [a4]: Ref 
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Figure 2.1 TruSeq Custom Amplicon Assay Workflow 
(a, b) A series of probes, which are complementary to the DNA sequence immediately upstream 
and downstream of the target locus are designed and pooled together. (c) Genomic DNA is heat 
denatured and slowly cooled, allowing the probe pool to bind the specific targets. This is followed 
by an elongation and ligation process, to generate double-stranded target regions. (d) A 
polymerase chain reaction, using primers containing both sample-specific index sequences and the 
P5 and P7 sequences required for cluster generation, amplifies the target regions. (e, f) The 
resulting amplicon pool is then quantified and diluted, before loading onto a MiSeq instrument. 
DNA sequencing is then performed, as described in section 1.4.2. Abbreviations: gDNA, genomic 
DNA. 
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Figure 2.2 Analysis workflow for TruSeq custom amplicon sequencing data. 
FASTQ files from the MiSeq instrument are aligned to the hg19 build of the human genome using 
both ISW and Stampy, simultaneously. The resulting BAM files are then passed to GATK and 
Platypus, respectively for calling of SNVs and small indels. Additionally, BAM files generated by ISW 
are used as input for Pindel, which detects larger indels than either Platypus or GATK. The VCF 
output from Platypus and Stampy are annotated using VariantStudio. Abbreviations; ISW, Illumina 
Smith-Waterman aligner; BAM, binary alignment/map file; VCF, variant call file; GATK, genome 
analysis toolkit. 
 
2.5.9 Whole Genome Sequencing 
Whole genome sequencing of the 42 CLL patients in chapter four was provided by 
Illumina Inc. (Little Chesterford, UK). Library preparation, DNA sequencing, data 
alignment and variant calling were performed by Illumina Inc. The resulting VCF 
and BAM files were returned to Oxford, whereupon I performed additional data 
analysis and annotation. Matched germline and tumour sequencing libraries were 
prepared from 2μg of input DNA for paired-end sequencing. DNA fragments were 
generated by random shearing using a Covaris M220 instrument (Covaris Inc, 
Woburn, MA, USA). Each library was prepared using the TruSeq DNA PCR Free 
Comment [a5]: Refs 
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Library Preparation kit (Illumina, San Diego, CA, USA) as per manufacturer’s 
protocol (https://support.illumina.com/content/dam/illumina-support/documents 
/documentation/chemistry_documentation/samplepreps_truseq/truseqdnapcrfre
e/truseq-dna-pcr-free-library-prep-protocol-guide-15075699-a.pdf). Flowcell 
clusters were generated using a cBot instrument (Illumina, San Diego, CA, USA) 
with the Illumina V3 Cluster Generation kit (Illumina, San Diego, CA, USA). The 
libraries were subjected to 2x35bp paired-end sequencing on a HiSeq 2000 
instrument (Illumina, San Diego, CA, USA). Alignment of the sequencing reads to 
the hg19 human genome build was performed using iSAAC v01.13.04.04 (Raczy et 
al 2013). Single nucleotide variants (SNVs) and indels were called using Starling 
v2.0.3 and Strelka v2.0.10 (Saunders et al 2012) for germline and tumour reads 
respectively. All germline mutations were subtracted from the matched tumour, 
and the results were exported as both variant call files (VCF) and binary alignment 
map files (BAM). VCF files contain a list of all mutations detected in a particular 
sample, while BAM files contain information about the sequence alignment, which 
can be easily visualised using software such as the integrated genomics viewer 
(Broad Institute, Cambridge, MA, USA). Annotation of the variants was performed 
with VariantStudio v2.2 (Illumina, San Diego, CA, USA) (Figure 2.3). Variants were 
further filtered to omit any with a read depth <10x, or a quality score <30, from 
further analysis. Translocations were identified using the Delly program (Rausch et 
al 2012), with tumour and germline BAM files used as input. Copy number 
aberration analysis was performed using the Nexus 7 software (BioDiscovery Inc, 
El Segundo, CA, USA). 
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Figure 2.3 Analysis workflow for whole genome sequencing data. 
FASTQ output files from the HiSeq 2500 are first aligned to the hg19 build of the human reference 
genome using the iSAAC aligner, followed by SNV and small indel detection using Starling and 
Strelka for germline and tumour samples, respectively. The resulting VCFs were then annotated 
using VariantStudio. The iSAAC aligner also generates BAM files, which were used as input for both 
DELLY and Nexus, to screen for translocations and copy-number aberrations, respectively. 
Subtraction of all variants present in germline DNA from the tumour DNA results in a final list of 
somatically acquired, tumour specific mutations and structural alterations. Abbreviations: GL, 
germline; T, tumour; VCF, variant call file; BAM, binary alignment/map file. 
 
2.6 RNA Sequence Analysis 
2.6.1 Whole Transcriptome Sequencing 
Dr Basile Stamatopoulos kindly performed whole transcriptome sequencing on 32 
CLL patients in chapter four. For the whole transcriptome sequencing of CLL 
patients, sequencing libraries were prepared using the TruSeq Stranded Total RNA 
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Sample Preparation kit (Illumina, San Diego, CA, USA) according to the 
manufacturer’s protocol (https://support.illumina.com/content/dam/illumina-
support/documents/documentation/chemistry_documentation/samplepreps_trus
eq/truseqstrandedtotalrna/truseq-stranded-total-rna-sample-prep-guide-
15031048-e.pdf). Libraries were pooled and subjected to 2x76bp paired-end 
sequencing on a HiSeq 2500 instrument (Illumina, San Diego, CA, USA) using the 
FASTQ only mode. Running the instrument in this mode means that no data 
analysis (either alignment to a reference genome or variant calling) is performed, 
rather, the output is a FASTQ formatted file containing raw DNA sequence. 
Sequence data was aligned to the hg19 build of the human genome using the 
TopHat algorithm (Trapnell et al 2009). 
 
2.7 Statistical Analysis and Data Visualisation 
Statistical analyses were performed using SPSS version 22 (IBM Corporation, Armonk, NY, 
USA) and Prism version 5 (GraphPad Software Inc, La Jolla, CA, USA). Categorical variables 
were compared using either the X2-test or Fishers exact test as appropriate. P values were 
considered significant at the 0.05 level. Circos plots were generated using the Circos 
software platform version 0.69 (Krzywinski et al 2009). 
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 DESIGN AND VALIDATION OF A Chapter 3 
TARGETED NEXT-GENERATION SEQUENCING 
PANEL FOR MYELOID MALIGNANCIES 
3.1 Introduction 
Acute myeloid leukaemia is a biologically complex disease, with treatment choices 
heavily influenced by both molecular and cytogenetic factors. In the first instance, 
AML cases can be classified into one of three risk groups on the basis of 
chromosomal abnormalities, as described in section 1.2.1. Despite the clear 
clinical utility of cytogenetic information in risk stratification in AML, around 40% 
of patients present with a normal karyotype (Grimwade et al 2010) and thus fall 
into a heterogeneous intermediate risk category. 
A number of molecular abnormalities have been shown to have prognostic 
importance in AML, as described in section 1.2.3. In particular, the presence of an 
internal tandem duplication in the FLT3 gene (FLT3-ITD) confers a poor prognosis 
(Fröhling et al 2002, Kottaridis et al 2001, Christian Thiede et al 2002, Whitman et 
al 2001), and can shift a patient with otherwise normal cytogenetics from the 
intermediate to the high risk group. Mutations in NPM1, on the other hand, confer 
a better prognosis, with increased OS and response to therapy in the absence of 
FLT3-ITDs (Döhner et al 2005, Hollink et al 2009, Schlenk et al 2008, Schnittger et 
al 2005, Thiede et al 2006). Other recurrently mutated genes identified in AML 
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include ASXL1, CEBPα, DNMT3a, IDH1 and IDH2, although the full prognostic value 
of these remains to be fully determined (Table 3.1). 
Traditional methods of screening for these mutations, including Sanger 
sequencing, pyrosequencing and allele-specific PCR (see section 1.3), are widely 
used in diagnosis, treatment selection, response monitoring and relapse 
prediction in laboratories around the world. Whilst all these methods are proven 
and reliable, their limitations lie in the fact that they are targeted at only the most 
prevalent mutations in a particular cancer. The ability to investigate as many 
candidate genes involved as possible in a particular patient’s cancer, to a high level 
of accuracy, and to monitor these changes over time, will be a valuable tool in 
cancer diagnostics.  
 
 
 
 
 
Table 3.1 Prevalence and prognostic impact of recurrently mutated genes in AML 
Gene Mutation Prevalence Prognostic Value Reference 
FLT3 Variable length ITD 20-30% Shorter overall and disease free survival 
(Fröhling et al 2002, 
Kottaridis et al 2001, 
Christian Thiede et al 2002, 
Whitman et al 2001) 
NPM1 4bp insertion in exon 12 
48-64% in normal karyotype, 8% 
with additional cytogenetic 
abnormalities 
Increased overall survival and 
reduced relapse risk in absence 
of FLT3-ITD 
(K Döhner et al 2005, Gale et 
al 2008, Schnittger et al 2005, 
Christian Thiede et al 2006, 
Verhaak et al 2005) 
ASXL1 Frameshift or nonsense variants in exon 12 17% 
Shorter event-free survival and 
shorter overall survival (Schnittger et al 2013) 
CEBPα Frameshift or nonsense variants in exon 1 7-9% 
Longer relapse free survival 
and overall survival in absence 
of FLT3-ITD 
(Dufour et al 2010, Helbig et 
al 2014, Pabst et al 2001, 
Renneville et al 2009, 
Snaddon et al 2003) 
DNMT3a Missense mutations affecting arginine 882 18-30% 
Shorter overall survival and 
increased risk of relapse 
(Hou et al 2012, Ley et al 
2010, Marková et al 2012, 
Thol et al 2011) 
IDH1 Missense mutations affecting arginine 132 5-6% Unknown 
(Chou et al 2010, Schnittger 
et al 2010) 
IDH2 
Missense mutations 
affecting arginine residues 
140 and 172 
12% Unknown (Thol et al 2010) 
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3.2 Aims and Objectives 
The aim of this work is to design and validate a multi-gene next-generation 
sequencing panel to be used in the diagnostic screening of patients with 
known or suspected acute myeloid leukemia, myelodysplastic syndromes 
or myeloproliferative neoplasm.  
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3.3 Materials and Methods 
3.3.1 TruSeq Custom Amplicon Panel Design 
A TruSeq Custom Amplicon (TSCA) sequencing panel (Illumina, San Diego, 
CA, USA) was designed to target the exons of 25 genes (Figure 3.1, Table 
3.2). The panel was defined using the online DesignStudio pipeline 
(http://designstudio.illumina.com). In genes with well-defined mutational 
hotspots, only these regions were targeted; otherwise the entire coding 
sequence of the gene was sequenced. Each target region was designed to 
cover both the exon in question, and included a 10bp margin on either 
side. This was designed to detect any mutations affecting splice sites within 
genes. It was also designed to avoid regions containing known 
polymorphisms, the presence of which can affect the ability of the probes 
to bind to the target sequence. The final design of the assay covered 
46,604bp of genomic sequence (96% of the desired region), spread across 
322 amplicons. The missing regions included exon three of NRAS, exons 
nine and 10 of EZH2 and exon 31 of ATRX, a total of 1,844bp. Subsequent 
updates of this panel, with improved chemistry and synthesis methods, 
now include all of these regions.  
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Figure 3.1 Overview of the genes targeted by the TSCA panel. 
The genes targeted by the panel play roles in one of four biological processes; signalling 
pathways (JAK2, FLT3, KIT), metabolic pathways (IDH1, IDH2), DNA modification (ASXL1, 
DNMT3A) or gene expression (NPM1). Target genes were selected based on their 
presence in the literature as being prognostic markers, or as having implications in the 
therapy selection in AML, MDS or MPD. 
 
 
 
 
Table 3.2 Details of genomic regions targeted by the myeloid TSCA panel.  
Gene Location Chromosomal Coordinates (hg19) Targeted Exons 
Malignancy                  
(% recurrence) References 
ASXL1 20q11.21 30,946,147-31,027,122 12 MDS (11-21%) AML (10%) 
(Abdel-Wahab et al 2011, 
Boultwood et al 2010, Gelsi-
Boyer et al 2009, Metzeler et al 
2011) 
ATRX Xq21.1 76,760,356-77,041,719 8 to 10 and 17 to 31 ATMDS 
(Gibbons et al 2008, Herbaux et 
al 2015, Steensma et al 2004) 
CBL 11q23.3 119,076,986-119,178,859 8 and 9 MDS (5%) (Grand et al 2009) 
CBLB 3q13.11 105,377,109-105,587,887 9 and 10 MDS (1%) (Aranaz et al 2012) 
CBLC 19q13.32 45,281,126-45,303,903 9 and 10 MDS (1%) (Aranaz et al 2012) 
DNMT3A 2p23.3 25,455,830-25,564,784 23 MDS (8%) AML (4-20%) 
(Ley et al 2010, M J Walter et al 
2011, Yamashita et al 2010) 
ETV6 12p13.2 11,802,788-12,048,325 All eight exons     
EZH2 7q36.1 148,504,464-148,581,441 2 to 20 MDS (7-12%) (Abdel-Wahab et al 2011, Ernst et al 2010) 
FLT3 13q12.2 28,577,411-28,674,729 14, 15 and 20 AML (25-37%) (Patel et al 2012, Stirewalt and Radich 2003) 
IDH1 2q34 209,100,953-209,119,806 4 AML (8%) (Mardis et al 2009, Patel et al 2012) 
IDH2 15q26.1 90,627,212-90,645,708 4 AML (8%) (Patel et al 2012) 
JAK2 9p24.1 4,985,245-5,128,183 12 and 14 MPN (48-80%) 
(Baxter et al 2005, James et al 
2005, Kralovics et al 2005, Levine 
et al 2005) 
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KIT 4q12 55,524,095-55,606,881 2, 8-11, 13, 17 AML (24%) (Klein et al 2015) 
MPL 1p34.2 43,803,475-43,820,135 10 MPN (8.5%) (Beer et al 2008) 
NPM1 5q35.1 170,814,708-170,837,888 12 AML (24-29%) (Mardis et al 2009, Patel et al 2012) 
NRAS 1p13.2 115,247,085-115,259,515 2 and 3 AML (9%) (Mardis et al 2009) 
PDGFRA 4q12 55,095,264-55,164,412 12, 14 and 18     
RUNX1 21q22.12 36,193,574-36,260,987 3 to8 MDS (20%) (Harada and Harada 2009) 
SF3B1  2q33.1 198,256,698-19,8299,771 15 and 16 MDS (13-20%) (Papaemmanuil et al 2011, Yoshida et al 2011) 
SRSF2 17q25.1 74,730,197-74,733,493 1 MDS (10%) (Yoshida et al 2011) 
TET2 4q24 106,067,842-106,200,960 3 to 11 MDS (19-26%) (Delhommeau et al 2009, Langemeijer et al 2009) 
TP53 17p13.1 7,571,720-7,590,868 4 to 9 MDS (5-10%) (Pellagatti and Boultwood 2015) 
U2AF1 21q22.3 44,513,066-44,527,688 2 and 6 MDS (9%) (Graubert et al 2011) 
WT1 11p13 32,409,322-32,457,081 7 and 9  AML (11%) (Paschka et al 2008) 
ZRSR2 Xp22.2 15,808,574-15,841,382 All 11 exons MDS (4%) (Yoshida et al 2011) 
Most target genes contained well-defined mutational hotspots, and so only these regions were targeted by the panel. In contrast, for genes such 
as ETV6 and ZRSR2 in which there are no common mutation hotspots, the complete coding sequence was sequenced. All co-ordinates refer to 
hg19 genome build. 
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3.3.2 Patient Samples 
3.3.2.1 Validation Cohort 
DNA samples from nine patients with confirmed MDS were selected for the 
validation cohort. All samples had been previously screened for common 
MDS mutations at diagnosis by the Oxford University Hospitals Trust 
Molecular Diagnostics unit using either Sanger sequencing (as described in 
section 2.5.4, pyrosequencing as described in section 2.5.6 or DNA 
fragment analysis as described in section 2.5.5. The nine samples 
harboured a total of 17 variants across 11 genes (ASXL1, DNMT3a, EZH2, 
FLT3, IDH1, IDH2, KIT, NPM1, NRAS, RUNX1 and TP53) and included 
missense (n=5), nonsense (n=3) and insertion/deletions (n=9). 
 
3.3.2.2 Test Cohort 
DNA samples from 43 untreated MDS cases, each harbouring a 5q deletion, 
were selected for mutational screening from collaborating institutes (St 
Johannes Hospital, Duisburg, Germany; Heinrich Heine University, 
Düsseldorf, Germany; University of Navarra, Pamplona, Spain; and Royal 
Bournemouth Hospital, UK). The ethics committees of all institutes 
involved approved the work, and informed consent was obtained from all 
patients, in line with the declaration of Helsinki. These included 22 patients 
classified as 5q- syndromes, nine with refractory anaemia (RA) and 12 with 
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advanced MDS (defined as having bone marrow with >5% blast cell 
content).  
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3.4 Results 
3.4.1 Targeted Sequencing Panel Performance 
3.4.1.1 Mutations Identified in the Validation Cohort 
Dual-barcoded sequencing libraries were generated, sequenced and 
analysed according to section 2.5.8. Five missense, three nonsense and 
seven frameshift mutations were identified in the validation cohort (15 out 
of 17, 88.2%). Of note, the short frameshift mutations in both ASXL1 and 
NPM1 (1bp and 5bp respectively) were correctly detected (Table 3.3). All 
mutations were identified by GATK through the BaseSpace pipeline, with 
the exception of the TP53 deletion in Test009, which was generated by 
Platypus, and the FLT3-ITDs, which were detected by Pindel. 
Analysis of the aligned sequencing reads using the Integrated Genomic 
Viewer (IGV, Broad Institute) for one of the validation samples (Test009) 
revealed a dramatically reduced read depth of 30x across TP53, compared 
to >1000x within this sample at other positions and across the other 
samples. This suggested an inability to align the TP53 sequence reads to 
the reference genome, which can be indicative of a deletion in the region. 
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Table 3.3 Summary of mutations present in TSCA panel validation 
samples.  
Sample 
ID Gene Mutation Coding change 
Sequencing 
Depth VAF 
TEST001 ASXL1 c.1925het_insA p.Gly643ArgfsX13 239 0.6 
TEST001 EZH2 c.290dup p.Leu98IlefsX28 895 0.32 
TEST001 EZH2 c.748C>CT p.Gln250X 437 0.42 
TEST001 NRAS c.35G>GA p.Gly12Asp 955 0.32 
TEST001 RUNX1 c.422C>CA p.Ser141X 361 0.31 
TEST002 ASXL1 c.1748G>GA p.Trp583X 159 0.28 
TEST003 IDH2 c.13775G>GA p.Arg140Gln 1382 0.51 
TEST003 NPM1 c.860_863dup p.Trp288CysfsX12 836 0.23 
TEST003 FLT3 79bp insertion  - 756 0.42 
TEST004 NPM1 c.860_863dup p.Trp288CysfsX12 734 0.25 
TEST004 FLT3 64bp insertion  - 1294 0.12 
TEST005 NPM1 c.860_863dup p.Trp288CysfsX12 527 0.15 
TEST006 DNMT3a c.2844G>GA p.Arg882Val 250 0.44 
TEST007 KIT c.2447A>AG p.Asp816Val 248 0.39 
TEST008 NPM1 c.860_863dup p.Trp288CysfsX12 875 0.2 
TEST008 IDH1 c.6694C>CT p.Arg132Cys 1390 0.48 
TEST009 TP53 c.489_471del p.Lys164AlafsX12 731 0.95 
Sequencing depth = number of sequencing reads covering the mutation. VAF = variant allele frequency 
 
The sequence data for Test009 was subsequently submitted to the Stampy 
(Lunter and Goodson 2011) and Platypus (Rimmer et al 2014) analysis 
pipeline, which revealed a 19bp deletion in exon five of TP53. The initial 
read alignment and variant calling failed to align any reads containing 
deletions to the reference genome, resulting in a much lower read depth 
across this locus (~30x). By comparison, re-analysis of the same data using 
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the Stampy and Platypus pipeline resulted in a greater number of aligned 
reads, giving a higher read depth (>700x) and successful identification of 
the 19bp deletion (Figure 3.2). 
The initial data analysis also missed the two internal tandem duplications in 
FLT3 in samples Test003 and Test004, again likely due to the alignment 
algorithms inability to successfully map the reads containing the additional 
sequence. Another alignment and variant calling algorithm, Pindel (Ye et al 
2009), was used to detect these insertions. 
In addition to the known control mutations, six mutations affecting five 
genes in five samples were found (Table 3.4). One of the mutations, a TET2 
Cys1464X nonsense variant in Test001, was visible in earlier Sanger 
sequencing traces; however at the time, the variant had not been picked 
up by the analysis software due to the high level of background noise. The 
Cys1464X variant was detected and called from the MiSeq data with a VAF 
of 0.47 (200/423 reads). The variant can be seen in the Sanger sequencing 
trace (Figure 3.3), but was not identified by the Mutation Surveyor 
software (SoftGenetics, State College, PA, USA). All remaining additional 
mutations were confirmed by Sanger sequencing and fragment analysis. 
 
 
 
 
Figure 3.2 Comparison of NGS read alignments covering across the 19bp TP53 deletion in Test009 
(a) The inability of the BWA aligner to map reads containing the deletion is represented by a lower read depth, (b) compared to the Stampy and 
Platypus pipeline results (b). Individual sequencing reads are represented by single horizontal grey bars, with the total read depth represented by 
vertical grey bars above each base. 
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Table 3.4 Summary of the additional mutations detected in the validation cohort 
Sample 
ID Gene Mutation Coding change 
Sequencing 
depth VAF 
TEST001 TET2 c.4412C>CA p.Cys1464X 423 0.47 
TEST005 TET2 c.3767_3771dup p.Leu1258AlafsX10 2968 0.25 
TEST006 NPM1 c.860_863dup p.Trp288CysfsX12 999 0.18 
TEST007 RUNX1 c.291delC p.Leu71SerfsX24 395 0.51 
TEST007 SF3B1 c.2098T>TC p.Lys700Glu 2053 0.45 
TEST008 FLT3 c.2508_2510del p.Ile836del 2271 0.48 
Sequencing depth = number of sequencing reads covering the mutation. VAF = variant allele frequency. 
 
3.4.1.2 Assay Limit of Detection 
To determine the limits of detection of the assay, the variant allele 
frequencies (VAF) for mutations in JAK2 from the targeted sequencing 
panel were compared with those obtained from a quantitative real-time 
PCR assay. For the test cohort, seven samples harbouring a previously 
identified JAK2 Val617Phe (JAK2V617F) mutation were selected, with a VAF 
ranging from one to 24%.  
Real-time PCR assays were performed using the commercially available 
JAK2 MutaQuantTM kit (Qiagen N.V., Hilden, Germany), which distinguishes 
between JAK2 wild type and the JAK2V617F alleles through Taqman allelic 
discrimination. Allele specific probes, labelled with 5’ reporter and 3’ 
quencher dyes, for both wild-type and JAK2V617F alleles are used to amplify 
the region of interest. The JAK2V617F VAF can be calculated from the 
fluorescent levels of each assay. 
 
 
 
Figure 3.3 Detection of the TET2 Cys1464X mutation in sample Test001 by both Sanger and NGS.  
The mutated C>A nucleotide can be seen in the MiSeq sequencing traces (top pane) and at a low level in the Sanger sequencing trace (green peak at 
the indicated position, bottom pane). This mutation was missed during analysis of the Sanger data due to the high background noise level. 
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Table 3.5 JAK2 V617F variant allele frequencies in RT-PCR and MiSeq data 
 
RT-PCR MiSeq 
Sample ID JAK2 WT Copy Number 
V617F Copy 
Number VAF Total Depth 
Reference 
Depth 
Variant 
Depth VAF 
JAK2_A 60035 1865 0.03 8205 7564 628 0.08 
JAK2_B 51617 5929 0.10 7924 6540 1366 0.17 
JAK2_C 58408 9834 0.14 7883 5859 2015 0.26 
JAK2_D 52331 7917 0.13 7828 6342 1472 0.19 
JAK2_E 59013 852 0.01 7411 7219 177 0.02 
JAK2_F 50564 10411 0.17 8139 6390 1719 0.21 
JAK2_G 36490 11804 0.24 7637 5290 2333 0.31 
 
The variant allele frequency of the JAK2V617F positive samples, as determined by the real-time PCR assay, ranged from 1-24%. All 
mutations with a VAF >3% (6/7, 86%) were successfully aligned and called in the MiSeq data. The remaining mutation (1% VAF) 
was present in the sequencing reads, but was below the detection limit of the variant calling software. 
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3.4.1.3 Calculation of Assay Background Interference 
The background noise level of the assay was calculated by investigating the 
sequencing read composition at 31 SNP loci over 14 chromosomes in 15 
samples (Table 3.6). The SNPs were all initially identified by the data 
analysis pipeline, are bi-allelic and are all recorded in dbSNP135 as being 
non-pathogenic. At each locus (n=465), the level of background noise was 
determined by expressing the number of sequencing reads containing any 
of the alternate nucleotides (3 in the case of homozygous SNPs, two in the 
case of heterozygous SNPs) as a percentage of the total number of calls at 
that position. 
The mean level of background noise in the assay was thus determined as 
0.31% (range 0.0-0.8%) across all SNP loci in all samples, and was 
consistently low, both between the SNPs (mean 0.31%, range 0.1-0.8%), 
and between the samples (mean 0.33%, range 0.25-0.55%) (Figure 3.4). 
Interestingly, the background level at heterozygous loci was lower than 
that at homozygous loci (0.2% and 0.4% respectively). The data for the 
highest background measurements (2.4 and 4.0%, in different samples and 
at different loci) are likely skewed due to low sequence coverage (80 and 
24 reads respectively).  
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Table 3.6 Details of 31 SNPs used for assay background noise analysis. 
Chromosome 
Genomic  
Co-ordinates 
(hg19) 
dbSNP ID Alleles 
1 115,256,669 rs969273 C/T 
2 198,266,943 rs788019 C/T 
3 105,439,026 rs2305035 C/T 
3 105,438,957 rs2305036 A/C 
3 105,453,034 rs6768096 A/G 
3 105,438,806 rs7624400 A/G 
4 55,141,055 rs1873778 C/T 
4 106,196,951 rs2454206 A/G 
4 55,593,464 rs3822214 A/C 
5 112,228,667 rs430665 C/T 
7 148,508,833 rs2072407 C/T 
7 148,506,064 rs740949 A/G 
9 5,073,770 rs77375493 G/T 
12 11,803,228 rs2541135 C/T 
12 11,803,220 rs2856305 A/C 
13 28,607,916 rs2491222 A/T 
13 28,607,989 rs2491223 G/T 
17 7,579,472 rs1042522 C/G 
17 7,578,115 rs1625895 C/T 
17 74,733,099 rs237057 C/T 
19 7,806,868 rs1544767 A/T 
20 31,025,231 rs2295763 A/G 
20 31,025,163 rs2295764 C/T 
20 31,024,274 rs4911231 C/T 
20 31,022,959 rs6058694 C/T 
21 36,206,932 rs11702841 A/G 
X 15,838,366 rs2301724 C/T 
X 76,937,963 rs3088074 C/G 
X 76,940,534 rs35268552 A/G 
X 15,808,795 rs4830994 C/T 
X 133,511,988 rs5978001 A/G 
All co-ordinates refer to hg19 genome build. 
Taken together, the sensitivity of the panel is calculated at 1-3%, 
depending on both the particular locus examined and the variant caller 
software used for analysis. 
 
 
 
Figure 3.4 Comparison of background sequencing calls in NGS data.  
Each boxplot represents the distribution of background sequencing calls at 31 SNP loci in 15 AML samples, represented as a percentage of total sequencing reads. The 
x-axis represents each of the 31 loci analysed. The y-axis shows the percentage of sequencing reads containing alternate base calls.  
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3.5 The Mutational Landscape of del(5q) MDS 
The first application of this panel was the characterisation of the 
mutational landscape of a cohort of 43 early or advanced del(5q) 
myelodysplastic syndrome cases (Fernandez-Mercado et al 2013). DNA for 
the sample cohort, comprising 22 patients diagnosed with 5q- syndrome, 
nine with refractory anaemia and 12 with advanced MDS, was kindly 
provided by Dr Marta Fernandez-Mercado of the LLR Molecular 
Haematology Unit at the University of Oxford. I was responsible for 
sequencing the cohort using the myeloid panel, along with the initial data 
analysis, including alignment of the data to the hg19 reference genome, 
generation of a list of variants and filtering based on the quality of the calls. 
Dr Fernandez-Mercado provided further analysis in the context of the 
mutational landscape of del(5q) MDS.  
A total of 29 mutations were detected in the cohort (Appendix A). Overall, 
45% of early and 66.7% of advanced cases presented at least one mutation 
(Figure 3.5). Genes with the highest mutation frequency among the 
advanced cases were TP53 and ASXL1 (mutations present in 25% of cases 
each). Mutations in these genes occurred at a much lower frequency in the 
5q- cases (4.5% and 13.6% respectively), suggesting a potential role for 
these genes as drivers of AML progression in del(5q) MDS.  
The 5q- syndrome is widely considered to be relatively genetically stable 
compared to other MDS subtypes, a fact that is reflected in its relatively 
good prognosis. Previous studies have described mutations in a limited 
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number of genes, including TP53 (Sebaa et al 2012), JAK2 (Ingram et al 
2006) and ASXL1 in del(5q) MDS. In this study, we determined that over 
40% of 5q- syndrome patients harbour a mutation in genes including TET2, 
SF3B1, RUNX1, WT1 and ASXL1. 
Table 3.7 List of mutations detected in 43 MDS cases 
Sample 
ID Gene 
Genomic 
coordinates 
(hg19) 
DNA 
change 
Amino acid 
change 
Variant 
Reads 
Total 
Reads VAF 
MDS16 RUNX1 chr21:36,259,324 A>AG Leu29Ser 23 72 0.32 
MDS15 SF3B1 chr2:198,266,834 T>TC Lys700Glu 170 1496 0.11 
MDS07 DNMT3A chr2:25,457,242 C>CA Arg882Leu 92 1176 0.08 
MDS08 ASXL1 chr20:31,022,449 insG Gly646TrpfsX12 174 389 0.45 
MDS08 WT1 chr11:32,413,565 C>CT Arg462Gln 174 355 0.49 
MDS14 TET2 chr4:106,193,748 C>CT Gly646TrpfsX12 309 685 0.45 
MDS12 ASXL1 chr20:31,022,449 insG Gly646TrpfsX12 37 351 0.11 
MDS12 SF3B1 chr2:198,266,834 T>TC Lys700Glu 620 1549 0.40 
MDS12 TET2 chr4:106,164,896 insA Tyr1255X 41 771 0.05 
MDS06 TET2 chr4:106,197,552 C>CT Pro1962Leu 303 602 0.50 
MDS11 ASXL1 chr20:31,022,902 G>GA Trp796X 144 402 0.36 
MDS10 TP53 chr17:7,578,413 C>CG Val173Leu 109 265 0.41 
MDS29 JAK2 chr9:5,073,770 G>GT Val617Phe - - - 
MDS34 JAK2 chr9:5,073,770 G>GT Val617Phe - - - 
MDS29 DNMT3A chr2:25,457,176 G>GA Pro904Leu 198 450 0.44 
MDS28 U2AF1 chr21:44,514,777 T>TC Gln157Arg 242 632 0.38 
MDS30 CBL chr11:119,149,332 C>CT Ala447Val 99 227 0.44 
MDS26 TP53 chr17:7,577,553 A>AG Met243Thr 327 1166 0.28 
MDS37 TP53 chr17:7,577,120 C>CT Arg273His 620 754 0.82 
MDS42 ASXL1 chr20:31,023,821 G>GT Glu1102Asp 366 806 0.45 
MDS42 CBL chr11:119,149,004 G>GT Trp408Cys 267 278 0.96 
MDS36 ASXL1 chr20:31,024,704 G>GA Gly1397Ser 875 1755 0.50 
MDS33 TET2 chr4:106,196,850 insCATG Glu1728Aspfs*13 121 713 0.17 
MDS43 TET2 chr4:106,164,880 G>GT Glu1250X 313 1145 0.27 
MDS43 ASXL1 chr20:31,022,449 insG Glu646TrpfsX12 470 1097 0.43 
MDS39 TP53 chr17:7,578,190 T>TC Typ220Cys 48 124 0.39 
MDS39 TP53 chr17:7,578,275 G>GA Gln192X 99 201 0.49 
MDS38 TP53 chr17:7,577,538 C>CA Arg248Leu 1168 2648 0.44 
MDS38 TP53 chr17:7,577,568 C>CT Cys238Tyr 998 2664 0.37 
Total reads indicates the number of sequencing reads covering each locus, and includes both reference 
and variant calls. VAF is shown as a fraction of variant reads to reference reads. Abbreviations: VAF, 
variant allele frequency. All co-ordinates refer to hg19 genome build. 
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Six of the mutations detected are present at levels below the detection level of 
Sanger sequencing (15-20%). Sanger sequencing has been the gold standard of 
DNA sequencing for many years, and the vast majority of sequencing studies 
published to date have used this technology. It is likely, therefore, that previous 
studies have underestimated the prevalence of mutations in MDS. 
 
 
 
Figure 3.5 Mutations, deletions and loss of heterozygosity in 25 genes analysed in 43 del(5q) MDS samples.  
Each column represents an individual sample with each row representing one gene in the sequencing panel. Grey boxes indicate mutated cases. Black boxes mark 
samples for which SNP-array data were available. Δ: gene encompassed within a region of cytogenetic loss. Θ: gene encompassed within a region of uniparental 
disomy (UPD) (Fernandez-Mercado et al 2013). X: two mutations in one gene in a single patient. Abbreviations: RA, refractory anaemia. 
104 
 
 
105 
 
3.6 Diagnostic Application of the Myeloid 
Sequencing Panel 
In addition to the explorative study into the molecular landscape of del(5q) 
MDS, the clinical utility of the panel has been demonstrated by applying it 
to a cohort of patients with confirmed or suspected myeloid disorders. 
Decisions regarding patients for whom the additional mutation data either 
altered or confirmed a diagnosis, impacted upon the treatment choice or 
determined prognosis, were made during weekly multi-disciplinary team 
(MDT) meetings involving relevant clinicians and clinical scientists.  
In order to ensure that only clinically relevant mutations are returned to 
the clinicians, a reporting algorithm was designed, in consultation with 
both clinicians and clinical scientists, which would filter the mutation data 
for each patient. Only those variants with a VAF greater than 10%, a read 
depth of 50x and that are described as acquired in publically available 
databases were reported. Additionally, novel mutations predicted to 
produce a truncated protein were also reported. 
The clinical utility of the assay was determined by considering changes in 
diagnosis, treatment or follow-up in response to the mutation data and the 
implications for prognosis as suggested by published disease-specific 
prognostic algorithms for AML (Patel et al 2012), MDS (Bejar et al 2011), 
myelofibrosis (Vannucchi et al 2013) and CMML (Itzykson et al 2013). In the 
year from April 2015, 270 clinical cases were submitted for sequencing 
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with the myeloid sequencing panel, comprising 66 AML cases, 74 MDS 
cases, 40 MPN cases and 90 with other pre-leukaemic malignancies, 
including primary myelofibrosis, pancytopenia and neutropenia. Mutations 
were identified in 60% of patients (n=164) of which 55% (n=91) were 
classified as clinically relevant (Figure 3.6, Appendix B).  
 
Figure 3.6 Clinical utility of the myeloid sequencing panel 
Summary of the clinical implications of mutations detected in MDS, MPN, AML or other 
pre-leukaemic patients using the myeloid sequencing panel. Abbreviations: MDS, 
myelodysplastic syndrome; MPN, myeloproliferative neoplasm; AML, acute myeloid 
leukaemia; MRD, minimal residual disease. 
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Twenty-seven cases harboured mutations targetable by currently available 
treatments. Forty-three (61%) of the clinically important mutations 
indicated poor risk disease, with a further eight (9%) indicating good risk. 
Five AML patients (7%) harboured insertions in NPM1, which can be used 
to monitor minimal residual disease (MRD) (Ivey et al 2016). The final eight 
mutations (9%) confirmed a suspected diagnosis, including one case in 
which the presence of both RUNX1 and TET2 mutations confirmed a CMML 
diagnosis without the need for a bone marrow extraction. Furthermore, 
one case was found to have no mutations in any of the targeted genes, 
lending weight to the patient having something other than a myeloid 
malignancy. 
 
3.7 Discussion 
This study demonstrates the efficacy of a targeted next-generation 
sequencing panel for use in routine diagnostics. All 17 mutations present in 
the validation cohort were all ultimately identified in the MiSeq data, 
demonstrating both the robustness of the NGS chemistry, and concordance 
with the current gold-standard methods of mutation detection.  
After single base substitutions, indels are the second most frequent form of 
variation found in the human genome, and are often linked to the 
pathogenesis of a disease where they alter the amino acid sequence of a 
coding gene. The majority of indels are between two and 16bp in size 
(Mullaney et al 2010), but there still remains a significant number of events 
108 
 
ranging up to 1,000bp (Mills et al 2011). These larger indels are difficult to 
detect in NGS data, due to the possibility of them being larger than the 
sequencing read length. A number of tools are available for indel detection, 
which vary in their methodologies. A recent comparison of different 
aligners demonstrated the strengths and weaknesses of each, with Pindel 
being able to detect indels up to 2,000bp in whole exome data, whilst 
GATK is better suited to 10-100bp indels (Ghoneim et al 2014). This study 
reinforces the importance of using the appropriate tools, in combination, 
for variant calling. In particular, the standard BWA/GATK pipeline was only 
able to correctly identify the single base substitutions and smaller indels, 
with Pindel and Platypus identifying both FLT3-ITDs and the TP53 deletion. 
The high sensitivity and low background noise level of the assay enabled 
the detection of mutations as low as 3% VAF. Recent studies have shown 
that low level, sub-clonal, mutations present at levels below the detection 
limit of Sanger sequencing, have the same impact on disease progression 
as high frequency clonal mutations. CLL patients with sub-clonal coding 
mutations in TP53, for example, demonstrate the same reduction in 5-year 
overall survival rates as those with clonal mutations (Nadeu et al 2016). 
Similarly, both clonal and sub-clonal NOTCH1 mutations show a significant 
reduction in time to treatment (Nadeu et al 2016). A recent study in 
juvenile myelomonocytic leukaemia (JMML), showed that sub-clonal 
mutations in SETBP1 confer reduced event free survival rates compared to 
wild-type SETBP1 (Stieglitz et al 2015).   
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The finding that mutations were only detected in 10 of the 25 genes (40%) 
is not unsurprising. Whilst the genes selected for inclusion on the panel are 
recurrently mutated in myeloid disorders and, in some cases, have 
prognostic value, the recurrence of each varies between disease types.  
Genome-wide studies of AML have shown that despite a relatively low 
overall coding mutation count compared to other cancer genomes 
(Alexandrov et al 2013, Cancer Genome Atlas Research Network 2013), 
these mutations tend to be found in a small subset of genes, in particular 
FLT3 (mutated in 20-30% of AML cases) (Fröhling et al 2002, Kottaridis et al 
2001, Christian Thiede et al 2006, Whitman et al 2001), NPM1 (48-64% 
AML cases) (Döhner et al 2005, Schnittger et al 2005, Thiede et al 2006), 
ASXL1 (17% AML cases) (Schnittger et al 2013) and DNMT3α (18-30% AML 
cases) (Dufour et al 2010, Helbig et al 2014, Pabst et al 2001, Renneville et 
al 2009). By contrast, the same genes are mutated at a much lower 
frequencies in MDS, representative of its status as a pre-leukaemic 
condition. Furthermore, the del(5q) MDS subtype is considered to be 
relatively genetically stable, with very few somatic mutations (Scharenberg 
et al 2016) or chromosomal abnormalities (Wang et al 2008), a fact 
reflected in its generally good prognosis.  These factors, along with the 
small cohort size in this study, and given that the panel was designed to be 
applicable to a wide range of myeloid malignancies, offer an explanation 
for the unmutated genes.  
This panel has since been adopted as a routine test in the molecular 
haematology laboratory at the John Radcliffe Hospital, Oxford. In the year 
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since going live with the test, in April 2015, 270 cases have been screened 
using this test, with the results being fed back to clinicians to aid in the on-
going diagnosis and treatment of AML and MPDs. 
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 WHOLE GENOME SEQUENCING Chapter 4 
OF 42 CHRONIC LYMPHOCYTIC LEUKAEMIA 
PATIENTS 
4.1 Introduction 
Chronic lymphocytic leukaemia (CLL) is the most common form of adult 
leukaemia in the western world (Swerdlow et al 2008), accounting for one 
third of new leukaemia cases each year (Siegel et al 2012). CLL is 
characterised by significant clinical heterogeneity. While one third of 
patients never require any treatment, the others invariably develop disease 
progression and, ultimately, resistance to chemotherapy. This clinical 
heterogeneity is reflected, at least in part, by characteristic biological 
features. Amongst the most frequent genomic aberrations are 
chromosomal deletions and amplifications (Döhner et al 2000), which have 
been associated with diverse phenotypes and contrasting clinical 
behaviours (Seiler et al 2006).  
More recently, explorative genome-wide (Puente et al 2011, Schuh et al 
2012) and exome-wide (Ljungström et al 2016, Quesada et al 2012) 
sequencing efforts have identified a number of additional, low frequency, 
recurrently acquired mutations in the coding regions of genes. Mutations 
in genes including TP53 (Zenz et al 2008, Zenz, Eichhorst, et al 2010, Zenz, 
Mohr, Edelmann, et al 2009), SF3B1 (Quesada et al 2012, D Rossi, 
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Bruscaggin, et al 2011, Wang et al 2011) and NOTCH1 (Fabbri et al 2011, 
Rossi et al 2012, 2011b) have been associated with resistance to 
treatment, advanced disease, poor prognosis and transformation to 
Richters syndrome. To date, the majority of studies have focussed primarily 
on somatic changes within the coding sequence of a gene, although a 
recent study, using a combination of WGS and WES, identified recurrent 
non-coding mutations in CLL (Puente et al 2015), and started to define the 
significance and impact of these mutations. In that study, the authors 
defined a region of localised hypermutation, or kataegis, affecting a 
promoter site 300kb upstream of the PAX5 gene.  Furthermore, both WGS 
and WES approaches have revealed the clinical significance of sub-clonal 
evolution in CLL as a marker for poor prognosis (Landau et al 2013).  
Furthermore, global analyses of WGS and WES data revealed the presence 
of specific mutation signatures in leukaemia and cancers (Alexandrov et al 
2013, Nik-Zainal et al 2012, 2016). These signatures can be indicative of the 
mechanisms underlying the mutagenesis of the disease, for example ultra-
violet light exposure in malignant melanomas or tobacco smoke in lung 
adenocarcinomas. For CLL, three mutational signatures have been 
proposed, associated with (1) the ageing process, (2) the activity of the 
APOBEC cytidine-deaminase enzyme family, and (3) polymerase η involved 
in the somatic hypermutation mechanism (Alexandrov et al, 2013). 
Studies such as this illustrate the potential of whole genome sequencing to 
reveal important driver mutations outside of the coding regions. However, 
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the nature and biological significance of these non-coding regions in CLL 
remains largely unknown. 
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4.2 Aims and Objectives 
The aim of this work is to provide a comprehensive analysis of the 
mutational landscape of the CLL genome, with reference to both 
somatically acquired mutations and structural variants.  
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4.3 Clinical and Biological Characteristics of the 
Patients 
Informed consent from 42 CLL patients diagnosed and treated at the John 
Radcliffe Hospital, Oxford, was obtained in line with both the Declaration 
of Helsinki and the Oxford IRB ethics approval 09/H0606/5. Tumour and 
germline DNA was extracted from peripheral blood and saliva samples, 
respectively, in accordance with section 2.1. The cohort comprised 14 
mutated and 25 unmutated IgHV cases, with a further three cases being 
classified as unmutated due to the presence of the IgHV3-21 sub-type, 
despite >98% homology to the germline sequence. The median age was 69 
(range 49-94). Sixty-two per cent (26/42) were male, giving a male to 
female ratio of 1.6:1. Twenty-one cases were classified as being resistant to 
chemotherapy, defined as either the patient having relapsed within 24 
months of initial treatment, or due to the presence of a disruption on 
chromosome 17 (either deletion of the 17p-arm or a mutation involving 
TP53). Eighteen cases were treated prior to sequencing (Table 4.1). 
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Table 4.1 Clinical and biological details of the patient cohort 
Age n=42 
<69 years 19 
≥69 years 23 
Sex   
Male 26 
Female 16 
IgHV status   
Mutated 14 
Unmutated 25 
IgHV3-21 3 
Chemo-resistance   
Positive due to relapse 
<24 months 10 
Positive due to 17p 
disruption 11 
Negative 21 
Treatment status   
Prior treatment 18 
No prior treatment 24 
 
4.4 Results 
4.4.1 Somatic Mutations Identified by WGS 
Whole-genome sequencing was performed on tumour DNA extracted from 
peripheral blood samples taken from 42 CLL cases, alongside matched 
germline DNA from saliva samples, according to section 2.5.9. Tumour 
samples were sequenced to a mean depth of 39x (range 35-54x) and 
germline to a mean depth of 36x (range 28-54x). The removal of variants 
with either a low quality score, sequencing read depth below 10x or that 
were present in the matched germline sample, ensured that only high 
confidence, somatically acquired mutations were used for downstream 
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analysis. In total, 96,305 somatic mutations were identified across the 42 
genomes, ranging from 153 to 4567 per sample (median = 2132) (Figure 
4.1, Appendix C), corresponding to a mean mutation rate of 0.69 ±0.27 per 
megabase (range 0.05-1.52). A total of 7,944 genes harboured at least one 
mutation. Of these, 553 missense, 38 nonsense and 76 splice site 
mutations occurred in protein-coding regions, including one resulting in the 
loss of an initiator codon and one stop-loss event. Of the 6,055 insertions 
and deletions detected across the genomes, 54 affected protein-coding 
regions. One case, CLL134, appeared to harbour only 153 somatic 
mutations in total with no coding mutations at all (Figure 4.1). This is 
potentially due to the presence of tumour DNA in the germline sample, 
leading to removal of the majority of variants at the sequence data filtering 
stage.  
Excluding mutations at the immunoglobulin loci on chromosomes 2, 14 and 
22, patients with unmutated IgHV status exhibited significantly lower 
counts of both coding (P=0.0058) and total mutations (P<0.0001) (Figure 
4.2). Conversely, there was no difference in either total (P=0.7312) or 
coding (P=0.1590) mutation rates between the chemo-sensitive and 
chemo-refractory groups. There was also no significant difference when 
comparing the number of mutations affecting the known CLL driver genes 
between the subgroups (Figure 4.2). 
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Figure 4.1 Distribution of mutations within gene boundaries across 42 CLL genomes. 
Each column represents a single patient and shows the composition of mutation types identified within each. Patients are arranged according to total mutational 
load. The Y-axis is plotted on a log10 scale and shows total number of mutations for each patient. 
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Figure 4.2 Total and coding mutation rates in IgHV mutated and 
unmutated CLL. 
Dot plots comparing the (a) total, (b) coding and (c) driver mutation counts between IgHV 
mutated and unmutated cases. Each data point represents an individual patient. 
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4.4.2 Validation of Coding Mutations 
To validate the presence of the somatically acquired mutations detected in 
the WGS data, a TSCA deep sequencing panel (Illumina, San Diego, CA, 
USA) was used. The panel was defined using the online DesignStudio 
pipeline (https://designstudio.illumina.com Illumina, San Diego, CA, USA) 
and was designed to target some, or all, of the coding region of 28 
commonly mutated genes in CLL (Table 4.2). For the 40 cases for which 
tumour DNA was available, dual-barcoded sequencing libraries were 
prepared as described in section 2.5.8. The libraries were subjected to 
2x151bp paired-end sequencing on a MiSeq instrument (Illumina, San 
Diego, CA, USA), to a mean depth of 2429x. 
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Table 4.2 Details of genomic regions targeted by the CLL TSCA sequencing 
panel. 
Gene Location Chromosomal         Coordinates (hg19) Targeted Exons 
ATM 11q22.3 108,093,559 - 108,239,826 All 63 exons 
BCOR Xp11.4 39,910,499 - 39,956,719 5, 10, 13 
BIRC3 11q22.2 102,188,181 - 102,210,135 2-4, 9 & 10 
BRAF 7q34 140,433,813 - 140,624,564 14 
CDKN2A 9p21.3 21,967,751 - 21,975,132 All three exons 
CHD2 15q26.1 93,443,551 - 93,571,237 20 
DDX3X Xp11.4 41,192,651 - 41,209,524 2, 10-12 
EGR2 10q21.3 64,571,756 - 64,576,126 4 
FBXW7 4q31.3 153,242,410 - 153,456,185 5, 9-11 
HIST1H1E 6p22.2 26,156,559 - 26,157,343 1 
IRF4 6p25.3 391,739 - 411,443 2 & 3 
ITPKB 1q42.12 226,819,391 - 226,926,876 2 & 8 
KLHL6 3q27.1 183,205,319 - 183,273,499 1 & 5 
KRAS 12p12.1 25,358,180 - 25,403,854 2 & 3 
MED12 Xq13.1 70,338,406 - 70,362,304 All 45 exons 
MYD88 3p22.2 38,179,969 - 38,184,512 5 
NOTCH1 9q34.3 139,388,896 - 139,440,238 34 
NRAS 1p13.2 115,247,085 - 115,259,515 2 & 3 
POT1 7q31.33 124,462,440 - 124,570,037 6-9 
PTEN 10q23.31 89,623,195 - 89,728,532 All nine exons 
RIPK1 6p25.2 3,076,998 - 3,115,421 8 & 10 
SAMHD1 20q11.23 35,520,227 - 35,580,246 All 16 exons 
SF3B1 2q33.1 198,256,698 - 198,299,771 14-16, 18 
TGIF1 18p11.31 3,451,591 - 3,458,406 All three exons 
TP53 17p13.1 7,571,720 - 7,590,868 All 11 exons 
XPO1 2p15 61,705,069 - 61,765,418 16 
ZFPM2 8q23.1 106,331,147 - 106,816,767 All eight exons 
ZMYM3 Xq13.1 70,459,474 - 70,474,038 2, 6, 8, 15, 21, 34, 34 
The majority of genes contained mutational hotspots that are well defined in the 
literature. In these cases, only those regions were targeted. In contrast, for genes where 
mutations are distributed throughout the coding sequence, in ATM for example, all exons 
were targeted. All co-ordinates refer to hg19 genome build. 
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4.4.2.1 Correlation with WGS Data 
Of the 40 samples sequenced with the TSCA panel, 30 harboured a 
combined total of 57 mutations identified by the WGS data (Appendix D), 
and which were expected to be covered by the targeted sequencing panel. 
These mutations, located in 16 genes, comprised 48 non-synonymous 
substitutions and nine frameshift deletions, ranging in size from one to 
19bp. The MiSeq successfully identified all 57 mutations. Furthermore, 
there was a high correlation of variant allele frequencies between both the 
WGS and MiSeq data (r=0.812, P<0.001, Spearman’s rank correlation) 
(Figure 4.3).  
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Figure 4.3 Correlation of variant allele frequencies between WGS and 
targeted deep sequencing.  
Each data point represents an individual mutation. X-axis shows the VAF according to the 
WGS data. Y-axis shows the VAF according to the MiSeq targeted sequencing validation 
runs. Red data points indicate indels. Blue data points represent SNVs. Abbreviations: VAF, 
variant allele frequency. 
 
4.4.2.2 Additional Mutations 
In addition to the 57 known variants, four further mutations were 
identified in the MiSeq data (Table 4.3). These comprised three missense 
substitutions in TP53 (Arg158His, Ser241Phe and Arg282Trp) in two cases 
(CLL307 and CLL374), and a single missense substitution in MED12 
(Glu33Gln) in CLL186.  
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Table 4.3 Additional mutations identified during WGS validation. 
Sample Gene Variant Chr Coordinate (hg19) Mutation 
WGS MiSeq 
VAF RD VAF RD 
CLL186 MED12 G>C/C X 70,338,701 Glu33Gln 100 5 100 22 
CLL307 TP53 C>C/T 17 7,578,457 Arg158His 18 11 21 4187 
CLL307 TP53 G>G/A 17 7,577,094 Arg282Trp 12 17 30 344 
CLL374 TP53 G>G/A 17 7,577,559 Ser241Phe 82 11 79 2117 
All co-ordinates refer to hg19 genome build. Abbreviations: Chr, chromosome; WGS, whole genome 
sequencing; VAF, variant allele frequency; RD, sequencing read depth. 
 
Further investigation of the WGS data, in particular visualisation of the 
aligned reads using IGV (Robinson et al 2011) revealed that all four variants 
were present in the raw data, but were not listed in the variant call file. 
There was also no evidence of any variant reads in the respective germline 
sequencing data. This removes the possibility of the analysis pipeline 
identifying these mutations as germline, and thereby removing them from 
the analysis.  
4.4.3 Mutations in CLL WGS Data 
4.4.3.1 Recurrent Coding Mutations 
As expected, the most frequently mutated genes, in terms of non-
synonymous variants within the coding region, were SF3B1, TP53, ATM and 
NOTCH1, occurring in 31% (13/42), 21% (9/42), 14% (6/42) and 12% (5/42), 
respectively (Figure 4.4, Figure 4.5).  
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Figure 4.4 Recurrent coding mutations in CLL driver genes.  
Bar chart showing the occurrence of coding mutations in genes understood to act as 
drivers of pathogenesis in CLL. Y-axis shows absolute mutation count for each gene. 
 
Mutations in SF3B1 were divided across 13 individuals, and tended to 
affect males more than females (P=0.0835). The most common mutation in 
SF3B1 was the Lys700Glu substitution, identified in 31% (4/13) of mutated 
cases. The Glu622Asp substitution was seen in two patients, with one each 
of Tyr623Cys, Arg625Cys, Lys666Glu, Ile704Asn, Ile704Phe, Gly740Glu and 
Gly742Asp. All SF3B1 mutations occurred between the third and fifth HEAT 
domains.  
Missense mutations were the most frequently seen variant type in TP53, 
accounting for 80% (8/10) variants detected. All occurred within the DNA 
binding domain, and were recorded previously in the COSMIC database 
(http://cancer.sanger.ac.uk/cosmic). Furthermore, two cases harboured 
indels within the TP53 coding region, one a 4bp deletion in exon 4, and the 
other a larger 19bp deletion in exon five.  
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Six cases contained a total of seven coding mutations in ATM, comprising 
five missense mutations, a 5bp deletion in exon 53 and a nonsense variant 
in exon 25, resulting in the loss of 60% of the coding sequence. Mutations 
in ATM co-occurred with del(11q) (4/6, P=0.008) and were associated with 
increased coding mutation rates (P=0.029).  
Mutations in NOTCH1 were confined to exon 34, with 83% (5/6) comprising 
the c.7541_7542delCT variant that results in the early termination of the 
PEST domain. The tumour suppressor gene FAT1 harboured protein coding 
mutations in 9% of samples (4/42), encompassing both chemo-sensitive 
and refractory patients (Messina et al 2014).  
Most FAT1 mutations occurred within exon two (75%, 3/4), and included a 
nonsense mutation at the Lys125 residue, resulting in the loss of >97% of 
the coding region. Other previously described candidate driver genes 
harboured low frequency mutations in the cohort, including three in 
MED12, two each in BIRC3, EGR2, IKZF3, MGA, MYD88, RPS15, SAMHD1, 
and one each in BCOR, BRAF, CHD2, DDX3X, FBXW7, NXF1, POT1 and XPO1 
(Clifford et al 2014, Fabbri et al 2011, Landau et al 2013, 2015, Ljungström 
et al 2016, Puente et al 2011, Schuh et al 2012, Wang et al 2011). 
 
 
 
 
 
Figure 4.5 Co-occurrence of mutations in CLL driver genes and clinical risk factors in 42 CLL genomes.   
Filled blocks indicate unmutated IgHV genes, chemo-refractoriness, prior treatment, the presence of a coding gene mutation or copy number aberration 
characteristic. Columns represent individual patients. The patients are arranged initially according to IgHV mutational status, then chemo-refractoriness. 
Abbreviations; CR, chemo-refractoriness; PT, prior treatment. 
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4.4.3.2 Mutations within Gene Boundaries 
Mutations in non-coding regions of genes have been identified in a number 
of cancer types, including CLL (Kasar et al 2015), and have been linked to 
increased cancer susceptibility. To determine the genes most affected by 
somatic mutations, the mutation rate per bp was calculated for all genes. 
This included variants located in 5’ UTRs, exons, introns and 3’ UTRs of all 
genes with ≥ 2 mutations. The mutation rates were normalised for the 
length of the canonical transcript. A total of 4,075 genes were recurrently 
mutated.  
Of the genes in the 99th percentile, a number have been previously 
identified with mutations in CLL; including IGLL5 (Kasar et al 2015), BTG2 
(Landau et al 2013), RPS15 (Ljungström et al 2016, Messina et al 2014, 
Quesada et al 2012) and TP53 (Dufour et al 2013, Landau et al 2013, el 
Rouby et al 1993, Zenz, Eichhorst, et al 2010) (Figure 4.6).  
The immunoglobulin Lambda Like Polypeptide 5 (IGLL5) gene harboured 
107 mutations across 40% of cases (17/42), the majority of which were 
clustered in intron one (81%, 87/107) close to the boundary with exon one. 
Exon one harboured 6.5% (7/107) and 12% extended into intron two 
(13/107) (Figure 4.7). Mutations in exon one comprised three variants in 
the 5’ UTR, with a further four missense mutations in the coding region, 
distributed across four patients. Patient CLL144 harboured two mutations 
in the 5’ untranslated region; CLL331 contained one 5’ UTR and one 
missense (Arg23His) mutation, CLL342 contained two missense (Ala44Pro 
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and Arg69Gly) mutations, whilst CLL156 contained a single missense 
mutation (Glu15Asp) that has been recorded previously in the COSMIC 
database (COSM1161415). 
 
Figure 4.6 Genes with greatest mutation frequencies per bp. 
Bar chart detailing the genes in the 99th percentile according to mutation rate per bp and 
their prevalence within the cohort. Mutation rates are calculated as the number of 
mutations, including coding and non-coding, divided by the length in bp of the canonical 
gene transcript. Red bars indicate intronic variants. Green bars indicate mutations in 
coding regions or UTRs. The X-axis represents the total number of mutations identified in 
each gene. Y-axis shows the gene IDs, the percentage and number of patients harbouring 
mutations, and the mutation rate per bp. Genes are arranged according to the percentage 
of cases affected. 
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Figure 4.7 Somatic mutations in IGLL5.  
Graphical representation of the IGLL5 gene showing the distribution of individual 
mutations in both IgHV mutated (green) and unmutated (red) CLL cases. 
 
Of the 107 IGLL5 mutations, 39% (42/107) have been recorded in the 
dbSNP database, including rs185781522 an Arg69Gly missense variant. This 
SNP is recorded in the ExAC database as being covered in <80% of 
individuals in the database, which may be indicative of a low-quality site 
and could, therefore, be a recurrent sequencing error. The presence of 
IGLL5 mutations was closely associated with mutated IgHV status 
(P<0.001), although there was no relationship with either del(11q) 
(P=0.271), gain(12) (P=1), del(13q) (P=0.339) or del(17p) (P=1). ENCODE 
data for the GM12878 cell-line showed all IGLL5 mutations were located in 
regions of low heterochromatin signal. The precise function of IGLL5 
remains largely unknown, other than it is a homolog of IGLL1, which is 
critical for the development of B-cells. Mutations in IGLL5 have been 
described previously in a cohort of low-risk CLL, in which mutated cases 
showed a trend towards reduced expression compared to wild-type cases 
(Kasar et al, 2015). Furthermore, mutations in the 5’ UTR and first exon 
were subclonal, whereas intronic mutations were clonal, suggesting that 
these two groups of mutation were acquired at different times in disease 
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development (Kasar et al, 2015). Analysis of RNA-Seq data, kindly provided 
by Dr Basile Stamatopoulos, showed no significant difference in IGLL5 
transcript level in this cohort when comparing either wild-type and coding 
mutations (P=0.439), wild-type and intronic mutations (P=0.417) or coding 
and intronic mutations (P=0.378) (Figure 4.8). 
 
 
Figure 4.8 IGLL5 expression levels in CLL.  
Dot plots showing the gene expression levels associated with wild type IGLL5 transcripts, 
transcripts with intronic mutations and transcripts with coding mutations. Error bars show 
standard error of the mean (± SEM.) 
 
Eleven intronic mutations across six patients in the tumour suppressor 
gene BTG2 (five mutated and one unmutated IgHV cases) were also 
identified. All mutations clustered in intron 1, in an active promoter region, 
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however, RNA-Seq data showed no significant difference in transcript 
levels between patients with mutated BTG2 and those without (P=0.1850).  
Two IgHV mutated cases harboured three intronic mutations in AICDA (two 
in CLL366 and one in CLL158), which encodes the activation-induced 
cytidine deaminase (AID) enzyme responsible for somatic hypermutation in 
B-cells. All three mutations were located in a strong promoter region in the 
first intron. RNA-Seq data for these samples was unavailable. 
4.4.4 Structural Variants 
4.4.4.1 Copy Number Aberrations 
Dr Sam Knight, of the Wellcome Trust Centre for Human Genetics, kindly 
provided copy-number aberration (CNA) analysis of the 42 CLL genomes. 
The analysis focussed initially on the most frequently reported CNAs in CLL, 
del(11q), gain(12), del(13q), del(17p), gain(2p) and del(8p). In this analysis, 
33 of the 42 CLL cases (78%) harboured at least one CNA, with a median 
count of one. The most frequent CNA was del(13q), occurring in 43% of 
cases (18/42), followed by del(11q) (9/42, 21%) and del(17p) (8/42, 19%) 
(Table 4.4, Figure 4.5, Figure 4.9). Trisomy 12 was identified in 19% of CLL 
cases (8/42) and was found to associate with the chemo-sensitive cases 
(P=0.009).   
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Table 4.4 Recurrent copy number aberrations in 42 CLL genomes 
Abnormality No. cases (%) 
Del(13q) 18/42 (43) 
Del(11q) 9/42 (21) 
Trisomy 12 8/42 (19) 
Del(17p) 8/42 (19) 
Gain(2p) (Chapiro et al 2010) 3/42 (7) 
Del(8p) (Brown et al 2012) 2/42 (5) 
 
In all 18 patients with del(13q), the minimally deleted region included 
DLEU2, mir3613 and both miR15a and miR16-1, with 89% (16/18) also 
covering the D13S319 locus and 50% (9/18) covering the RB1 locus. All 
eight 17p deletions encompassed the TP53 locus. Seven TP53 mutations 
were shared between five del(17p) cases, including two frameshift 
(Tyr103Argfs*19 and Arg158Serfs*6), causing early termination with the 
loss of 69% and 59% of the coding region respectively. In addition to TP53, 
the MDR on chromosome 17 covered mir4520a, mir4520b, mir195, mir497 
and mir324. The del(11q) MDR encompassed the ATM locus in all nine 
del(11q) cases, with four patients also harbouring ATM mutations, 
including one frameshift resulting in early termination (Ile2629Serfs*25). 
Partial or full gain of 2p (Chapiro et al 2010) was found in three of 42 cases 
(7%), ranging from 70Mb to 90.5Mb in length. The minimally amplified 
region contained the oncogenes REL, ALK and MYCN; however RNA-Seq 
data showed no increase in the expression levels of these targets between 
mutated and unmutated samples. Deletions of 8p were identified in three 
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patients; CLL364, CLL154 and CLL372, with an MDR of 18.6Mb stretching 
from 8p23.1 to 8p12. Patient CLL364 had concomitant del(11q) gain(12) 
and del(17p) events, CLL372 harboured both del(11q) and del(17p), whilst 
CLL154 harboured a 13q deletion. This concurs with previous studies that 
8p deletions often co-exist with other copy number changes (Brown et al 
2012, Forconi et al 2008). CLL364 was also the only case to display 
chromothripsis, defined as the presence of 10 or more copy number 
changes in a single chromosome.  
4.4.4.2 Translocations 
A total of 79 high confidence, somatic, inter-chromosomal translocations 
were identified across 30 patients (Figure 4.9, Table 4.5), with an average 
of 3.1 per case (range 1-13). With the exception of chromosome 22, all 
others were involved in at least one translocation. The most frequently 
affected region was the q-arm of chromosome 13, which accounted for 
15% (23/158) of the translocation partners, and was affected in 11 cases. 
Of note, in five of those 11 cases, the translocation breakpoint centred on 
13q14 and was concurrent with del(13q) at the same position.  
The next most frequently affected regions were 1p (5.7%), 3q (5.7%), 14q 
(4.4%) and 17p (4.4%). One of the seven cases with 17p translocations, only 
one (CLL350) was centred on 17p13.1, and there was no evidence of a 
concurrent del(17p) event in this patient.  
Seventeen of the 79 events (22%) are predicted to result in gene fusion 
proteins (tier one translocations), with a further 44% (35/79) involving a 
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single gene (tier two). The remaining 27 translocations involved only 
intergenic regions (tier three). The number of tier one and tier two events 
in refractory patients was significantly higher than in untreated cases 
(P<0.001), reflecting the increased genomic instability of this molecular 
subgroup.  
Table 4.5 Details of translocations detected in 42 CLL genomes. 
Sample 
ID Chr 
Coordinates 
(hg19) Gene Chr 
Coordinates 
(hg19) Gene Tier 
CLL372 7      8,663,231  NXPH1 5   37,709,720  WDR70 One 
CLL006 8     70,602,300  SLCO5A1 1   91,853,200  HFM1 One 
CLL345 9     33,130,549  B4GALT1 6   43,655,549  MRPS18A One 
CLL006 9   131,457,166  SET 2 116,376,668  DPP10 One 
CLL006 13     21,746,650  SKA3 11 108,585,748  DDX10 One 
CLL130 13     42,750,778  DGKH 2 214,996,194  SPAG16 One 
CW_L80 15 41,853,322  TYRO3 13 44,069,827  ENOX1 One 
CLL374 16 11,874,783  ZC3H7A 1 97,549,042  DPYD One 
CLL364 16 48,434,657  MIR5095 10 70,695,546  DDX50 One 
CLL331 17 20,625,713  NR_073509 15 42,581,488  GANC One 
CLL372 17 42,116,511  LSM12 3 185,532,743  LGF2BP2 One 
CLL252 18 9,386,313  TWSG1 17 27,269,460  PHF12 One 
CLL252 18 29,085,459  DSG2 17 27,124,612  FAM222B One 
CLL301 18 60,793,528  BCL2 14 86,373,086  IGH One 
CLL348 18 60,793,528  BCL2 14 86,373,086  IGH One 
CLL186 19 45,210,662  BCL3 14 24,996,194  IGH One 
CLL372 X 96,772,745  DIAPH2 15 63,807,663  USP3 One 
CLL130 1 117,690,373  VTCN1 10 52,548,106  Intergenic Two 
CW_L80 1 156,186,624  PMF1 / PMF1-BGLAP 20 26,190,323  Intergenic Two 
CLL301 2 11,929,913  LPIN1 4 162,053,779  Intergenic Two 
CLL130 2 214,929,829  SPAG16 1 89,072,486  Intergenic Two 
CLL374 3 12,526,084  TSEN2 19 30,862,678  Intergenic Two 
CLL307 3 31,620,715  STT3B 4 44,130,189  Intergenic Two 
CLL372 4 37,977,988  TBC1D1 18 52,407,341  Intergenic Two 
CLL332 4 66,413,946  EPHA5 2 42,051,404  Intergenic Two 
CLL006 4 103,872,694  SLC9B1 2 91,925,936  Intergenic Two 
CLL130 6 13,611,391  SIRT5 15 40,406,783  Intergenic Two 
CLL331 8 94,666,356  LINC00535 19 9,277,839  Intergenic Two 
CLL331 9 15,449,336  SNAPC3 5 52,041,533  Intergenic Two 
CLL364 9 18,951,669  SAXO1 4 24,713,600  Intergenic Two 
CLL364 9 27,511,928  MOB3B 12 64,573,814  Intergenic Two 
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CLL331 9 28,174,273  LINGO2 5 101,286,989  Intergenic Two 
CLL342 9 115,804,583  ZFP37 4 114,699,773  Intergenic Two 
CLL331 10 74,767,587  P4HA1 17 32,673,513  Intergenic Two 
CLL371 10 74,767,587  P4HA1 17 32,673,499  Intergenic Two 
CLL364 12 46,277,056  ARID2 4 34,711,038  Intergenic Two 
CLL130 13 41,823,533  MTRF1 1 89,313,108  Intergenic Two 
CLL160 13 49,585,503  FNDC3A 3 106,401,370  Intergenic Two 
CLL160 13 51,495,444  RNASEH2B 3 98,355,667  Intergenic Two 
CLL160 13 51,624,971  GUCY1B2 3 145,020,376  Intergenic Two 
CLL344 13 74,708,039  KLF12 9 118,726,343  Intergenic Two 
CLL129 13 74,742,546  Intergenic 5 159,707,167  CCNJL Two 
CLL374 13 99,957,834  
UBAC2 / 
MIR548AN / 
GPR183 
17 21,345,246  Intergenic Two 
CLL364 14 36,186,681  RALGAPA1 12      11,652,111  Intergenic Two 
CLL144 14 101,113,952  Intergenic 6 41,927,166  CCND3 Two 
CLL372 14  101,521,935  Intergenic 1  225,498,498  DNAH14 Two 
CLL145 15 90,328,126  ANPEP 13 105,798,330  Intergenic Two 
CLL006 17 21,303,192  KCNJ12 20  29,517,483  Intergenic Two 
CLL364 17 21,303,192  KCNJ12 20 29,517,483  Intergenic Two 
CLL374 19 4,453,370  UBXN6 3 74,751,470  Intergenic Two 
JB 
210308 19 11,421,943  TSPAN16 1 38,241,383  Intergenic Two 
CLL372 21 19,655,584  TMPRSS15 13 79,548,645  Intergenic Two 
CLL374 3 74,756,594  Intergenic 1 121,485,433  Intergenic Three 
CLL364 7 57,754,536  Intergenic 6 154,216,103  Intergenic Three 
CLL130 10 51,740,169  Intergenic 1 89,309,996  Intergenic Three 
CLL364 12 46,007,143  Intergenic 4 33,814,499  Intergenic Three 
CLL182 12 68,185,130  Intergenic 6 157,613,848  Intergenic Three 
CLL374 12 127,940,972  Intergenic 8 92,457,820  Intergenic Three 
CLL129 13 46,899,835  Intergenic 5 163,791,833  Intergenic Three 
CLL160 13 47,335,753  Intergenic 3 106,401,127  Intergenic Three 
CLL330 13 48,627,074  Intergenic 8 57,735,922  Intergenic Three 
CLL160 13 48,710,887  Intergenic 3 104,937,978  Intergenic Three 
CLL160 13 49,179,166  Intergenic 3 145,020,088  Intergenic Three 
CLL160 13 50,464,198  Intergenic 3 98,213,117  Intergenic Three 
CLL160 13 50,464,300  Intergenic 3 98,358,948  Intergenic Three 
CLL130 13 52,735,038  Intergenic 10 50,643,371  Intergenic Three 
CLL372 13 79,548,569  Intergenic 11 81,957,761  Intergenic Three 
CLL364 14 39,662,187  Intergenic 12 11,667,959  Intergenic Three 
CLL130 15 40,405,166  Intergenic 12 123,135,798  Intergenic Three 
CLL372 17 6,048,351  Intergenic 6 77,287,806  Intergenic Three 
CLL350 17 10,138,719  Intergenic 11 37,429,056  Intergenic Three 
CLL156 17 21,666,669  Intergenic 13 63,621,280  Intergenic Three 
CLL345 17 41,486,914  Intergenic 11 83,028,992  Intergenic Three 
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CLL077 19 27,738,439  Intergenic 1 121,485,249  Intergenic Three 
CLL374 19 27,872,204  Intergenic 3 42,747,598  Intergenic Three 
CLL351 19 36,066,634  Intergenic 5 71,146,742  Intergenic Three 
CW_L80 20 26,148,193  Intergenic 13 63,637,910  Intergenic Three 
CLL149 20 29,438,015  Intergenic 6 154,215,663  Intergenic Three 
CLL154 M 16,571  Intergenic 11 49,883,563  Intergenic Three 
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Figure 4.9 Structural rearrangements in CLL.  
Circos plot depicting the frequency and location of the CNAs and translocations detected 
in 42 CLL genomes. The two outermost tracks represent CNAs; CN loss (red) and CN gain 
(green), with each track scaled appropriately for each MDR (CN loss n=18, CN gain n=8). 
The centre plot shows translocations identified in the cohort. Red links indicate tier one 
events (gene:gene), green links represent tier two events (gene:intergenic) and grey 
indicate tier three (intergenic:intergenic). The widths of the bands are indicative of the 
number of each individual event detected in the cohort. 
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Two untreated cases (CLL301 and CLL348) harboured IGH/BCL2 (14;18) 
translocations, one each anchored in the 3’ and 5’ UTR of BCL2, 
respectively.  This was the only copy number or structural variant present 
in CLL301, however CLL348 also harboured trisomy 12. A single case with 
an IGH/BCL3 translocation (14;19) was also identified. Interestingly, a 
translocation between the first exon of the RNASEH2B gene on 
chromosome 13, and an intergenic region on chromosome 3 was found in 
CLL160. The protein encoded by RNASEH2B forms one subunit of RNase 
H2, which plays an important role in the maintenance of genome stability. 
Loss-of-function mutations in RNASEH2B are frequently seen in the 
inflammatory disease Aicardi-Goutieres syndrome (AGS) (Crow et al 2006). 
Interestingly, mutations in SAMHD1 are also present in both AGS (Rice et al 
2009) and CLL (Clifford et al 2014). 
  
4.4.5 Identification of Regions of Kataegis 
Localised regions with increased mutation rates, or kataegis, have been 
described previously in other types of cancer. The presence of kataegic 
regions was detected via the construction of rainfall plots as previously 
described (Nik-Zainal et al 2012). Each region was defined as containing a 
minimum of six substitutions, insertions or deletions whose 
intermutational distances are more than two standard deviations below 
the median intermutational distance for that sample (Lawrence et al 2013). 
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4.4.5.1 Kataegis within Individual Patients 
Seventy-four instances of kataegis were identified in 31 samples affecting 
14 chromosomes (Appendix E). The region size ranged from 219bp to 
4.3Mb, with a median of 93,854bp. The total number of mutations across 
all regions was 1,591, with SNVs comprising the majority (1553/1591, 97%), 
followed by small deletions (30/1591, 2%) and insertions (17/1591, 1%). 
The number of mutations within each region ranged from six to 99, with a 
median of 14.  
The spectrum of mutations contained within kataegis regions was 
significantly different to that found in the whole genome sequencing 
overall (Figure 4.10). The contribution of A>C, A>T and C>A transversions 
was significantly lower in the kataegic regions (P<0.001), whereas C>G 
transversions were enriched (P<0.001).  
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Figure 4.10 Comparison of mutation composition between whole genome 
sequencing data and kataegic regions.  
Each box-and-whisker plot displays the contribution of each substitution type to the 
overall mutation burden in both the whole genome (green) and kataegic (red) regions. 
Whiskers represent minimum and maximum values. 
 
Some chromosomal regions were recurrently affected, most notably, and 
as expected, those encoding the immunoglobulin light and heavy chains on 
chromosomes 2 (11/74, 15%), 14 (33/74, 45%) and 22 (13/74, 18%). These 
regions accounted for 88% (1,397/1,591) of all kataegic mutations (Figure 
4.11). 
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Figure 4.11 Individual kataegic regions in CLL.  
Each data point represents a single kataegis event in one patient. Chromosomes are 
arranged according to the number of kataegic regions present. Y-axis indicates the 
number of mutations within each region. 
 
Eighteen regions across 11 patients did not occur at sites of 
immunoglobulin rearrangement (Table 4.6), ranging in length from 219bp 
to 159kb. Thirteen of these regions were located within or across gene 
boundaries. Importantly, almost half of these (6/13 46%) affected non-
coding regions of genes known to carry coding mutations in CLL including 
KLHL6 (Puente et al 2011), MEGF9 (Quesada et al 2013), CDH12 (Landau et 
al 2013), CADPS2 (Landau et al 2013, Puente et al 2011), LRP1B (Landau et 
al 2013, Quesada et al 2013) and ATM (Schaffner et al 1999, Stankovic et al 
1999). 
  
 
 
143 
 
Table 4.6 Kataegis regions within individual CLL patients, excluding 
immunoglobulin gene loci. 
Sample Mutations in region Chr 
Region Start 
(hg19) 
Region End 
(hg19) 
Genes in 
Region 
CLL156 8 2 140,885,911 141,045,820 LRP1B 
CLL154 6 3 157,290,339 157,295,704 C3orf55 
CLL348 6 3 183,273,058 183,273,364 KLHL6 
CLL063 9 5 21,810,369 21,843,504 CDH12 
CLL301 12 7 122,433,699 122,517,296 CADPS2 
CLL301 6 7 122,622,586 122,638,447 TAS2R16 
CLL351 43 9 123,416,699 123,479,606 MEGF9 
CLL144 9 11 108,121,624 108,129,499 ATM 
CLL307 6 13 51,664,141 51,665,954 LINC00371 
CLL156 6 14 21,835,327 21,835,546 SUPT16H 
CLL252 6 18 9,284,149 9,374,417 ANKRD12, TWSG1 
CLL301 12 18 60,873,525 60,988,029 BCL2 
CLL348 10 18 60,906,440 60,988,117 BCL2 
CLL348 9 3 187,660,014 187,660,463 -  
CLL371 11 4 59,097,561 59,114,524 -  
CLL301 10 5 26,070,177 26,074,185 -  
CLL371 9 7 49,672,829 49,682,118 -  
CLL342 6 9 76,656,503 76,656,760 -  
All co-ordinates refer to hg19 genome build. 
One recurrent region of kataegis centred on the 5’ region of BCL2 on 
chromosome 18 occurred in two patients (Figure 4.12). These regions were 
81,677bp and 114,504bp in length and harboured 10 and 12 mutations 
respectively, starting 1.5kb upstream of the start codon and terminating 
within the second intron. Both cases affected by kataegis in BCL2 
harboured concurrent t(14;18) translocations in the same gene. The 
breakpoint in CLL301 was located much further upstream, in the 3’ UTR, 
whereas the CLL348 breakpoint was centred on the kataegic region in the 
5’ UTR. A further three mutations were identified in the same region in 
CLL154. Correlation of the position of these mutations against the ENCODE 
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database revealed overlapping regions of both mono- and tri-methylated 
histone 3 lysine 4 residues (H3K4me1 and H3K4me3, respectively), which 
are known markers of active gene enhancers and promoters, respectively. 
Analysis of the RNA-Seq data showed that cases with mutations in these 
regulatory regions displayed increased levels of BCL2 transcript expression, 
compared to both cases with intronic mutations and wild-type cases 
(Figure 4.12). BCL2 is over-expressed in CLL (Kitada et al 1998), but 
mutations in its coding region have not been described.  
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Figure 4.12 Regions of kataegis and gene expression levels in BCL2. 
(a) Location of somatic mutations in BCL2 in cases CLL154 (black), CLL301 (red) and CLL348 
(blue) overlaying H3K4me1 and H3K4me3 data for the K562 cell line from ENCODE. (b) Dot 
plot showing the expression levels of the BCL2 transcript comparing cases with no BCL2 
mutations (BCL2WT), cases with intronic mutations downstream of exon one (BCL2Imut) and 
cases with mutations in the promoter region (BCL2Pmut). Error bars show ± SEM.   
 
One case, CLL144, harbored a kataegic region within ATM, comprising nine 
mutations in a 7.8kb span between exon 10 and intron 15. Seventy-eight 
percent (7/9) of the mutations occurred in intronic regions, with two more 
in exon 10. The two coding mutations affected adjacent bases, resulting in 
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a single serine to valine residue substitution (Ser478Val), predicted as 
tolerated by SIFT. RNA-Seq data suggests a similar level of reduced ATM 
expression as those cases harboring del(11q), which itself was significantly 
lower than the wild-type cases (P=0.0005)  (Figure 4.13), as expected 
(Stankovic et al 1999). 
 
 
Figure 4.13 Kataegic ATM mutations in CLL144.  
a) Graphical representation of ATM showing the distribution of kataegic mutations in 
CLL144. Dark and light blue represent exonic and intronic regions of the ATM transcript, 
respectively. b) Dot plot comparing the ATM transcript expression levels of CLL cases with 
no 11q disruption (wild type), those with del(11q), mutations in ATM (ATMmut) and 
CLL144. Expression levels are shown as reads per million aligned reads. Error bars show ± 
SEM. 
 
Kataegis was also observed in the non-coding region of one gene affected 
 
 
147 
 
by coding mutations in other haematological malignancies: SUPT16H 
(Abaan et al 2013, Patel et al 2012), however this region also overlaps an 
AluY repeat, and so could be a result of low sequence quality. The 
remaining four genes affected by kataegis; ANKRD12, C3orf55, LINC00371 
and TAS2R16 have not been described in the context of either cancer or 
haematological disease and include a microRNA and an open reading 
frame. Overall, this means that eight of 14 (57%) of kataegis regions in 
genes were related to genes implicated in the pathogenesis of 
haematological disease.  
Sites of kataegis have been shown to co-localise with structural 
rearrangements (Nik-Zainal et al 2012, Walker et al 2015). As such, the 19 
kataegic regions were correlated with the CNA data. Of the 18 kataegis 
regions not at sites of somatic hypermutation, only three were found to be 
in close proximity to deletion events. The kataegis site in CLL307 was 
located 482bp downstream of a 13q deletion. CLL301 harboured a region 
located 19kb into a 141kb gain on chromosome 7. Sample CLL252 
contained a region sitting between two deletions on chromosome 18, 
21.8kb downstream of one and 765bp upstream of the other. In line with 
both the BCL2 data and previous observations (Nik-Zainal et al 2012, 
Walker et al 2015), this suggests that kataegis may also be a consequence 
of structural rearrangements. 
4.4.5.2 Kataegis across the Cohort 
By integrating the somatic variants from all 42 patients, an additional 66 
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regions with high mutation counts were identified. Regions in centromeric 
or telomeric areas, along with those in areas of segmental duplication were 
excluded. Seventeen contained genes affected by multiple mutations 
(Table 4.7).  
Table 4.7 Kataegis regions across the cohort 
No. of 
Patients 
Affected 
Mutations 
in region Chr Start (hg19) Stop (hg19) 
Genes in 
Region 
12 18 1 187,201,043 187,292,419 LINC01036 
14 16 2 79,902,807 79,995,799 CTNNA2 
6 19 3 60,528,213 60,588,662 FHIT 
11 15 3 174,110,612 174,189,396 NAALADL2 
12 24 3 187,418,868 187,490,720 BCL6 
12 16 4 62,913,619 62,987,350 LPHN3 
11 17 4 93,701,552 93,798,834 GRID2 
14 19 4 136,800,043 136,899,101 LINC00613 
12 18 4 158,200,175 158,289,441 GRIA2 
14 15 4 162,406,955 162,494,646 FSTL5 
10 15 4 162,502,368 162,596,645 FSTL5 
12 16 5 19,801,833 19,892,529 CDH18 
13 17 7 82,400,133 82,495,632 PCLO 
14 25 13 70,404,177 70,498,648 KLHL1 
14 18 18 64,102,223 64,199,022 CDH19 
All co-ordinates refer to hg19 genome build. Abbreviations; Chr, chromosome. 
 
A cluster of 20 mutations, in 24% of patients (10/42), were localised to a 
1kb region in the first intron of BCL6 (Figure 4.14a). No other BCL6 
mutations were detected in any other patients. All ten cases were of 
mutated IgHV status, and were predominantly treatment naïve (8/10, 
80%). All 20 mutations were heterozygous single base substitutions. There 
were no recurrent mutations. ENCODE data revealed these mutations lie in 
a region of strong tri-methylation of the H3K4 residue, suggestive of an 
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active promoter (Figure 4.14a). Translocations involving the BCL6 locus 
have been described in B-cell lymphomas; however there was no evidence 
of such a translocation in any of these samples. Mutations in the non-
coding region of BCL6, in IgHV mutated CLL, have been described 
previously in similar frequencies to that found in this cohort, although no 
link between BCL6 mutational status and the protein expression level has 
been identified (Capello et al 2000, L Pasqualucci et al 2000). Indeed, no 
significant difference in BCL6 expression was observed between those with 
intronic mutations and wild-type cases (P=0.2261) (Figure 4.14b). 
Other kataegic areas of interest include a 16 mutation region spanning 
93kb across exon three of the tumour suppressor gene CTNNA2 on 
chromosome 2, with mutations present in 33% of cases (14/42). The 16 
mutations were evenly distributed between FR and treatment naïve 
patients, the majority of which were intronic (15/16, 94%), with only one 
missense variant in exon three (His552Pro). There is no record of a variant 
at this residue in the COSMIC database. Analysis of the RNA-Seq data 
showed no expression of CTNNA2 in any sample, regardless of mutational 
status. 
Another kataegic region of interest was identified in Lysine-specific 
methyltransferase 2C (KMT2C) on chromosome 7. Sixteen patients (38%) 
contained a combined 23 mutations in this region, with an enrichment in 
treatment naïve cases (10 vs 4, P=0.050). RNA-Seq data was available for 
11 mutated and 21 unmutated cases, however no significant difference 
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was seen in transcript levels between the groups. 
 
Figure 4.14 BCL6 kataegic mutations and transcript expression levels.  
(a) Schematic representation of the first exon and intron of the BCL6 gene, showing the 
position of the 20 kataegic mutations. Green and red triangles represent mutations in 
untreated and refractory patients, respectively. Lower tracks display ENCODE ChIP-Seq 
data for the K562 cell line from ENCODE. High H3K4me3 signals are indicative of promoter 
regions. (b) Dot plot comparing BCL6 transcript expression levels between patients with 
and without BCL6 mutations. Error bars show ± SEM. 
 
4.4.6 Extraction of Mutational Signatures  
WGS and WES data facilitates the detection of distinct mutational profiles, 
or signatures, within many cancer types, including in CLL. Using methods 
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previously described (Alexandrov et al 2013, Brunet et al 2004) four 
distinct signatures were isolated from the tumour sequencing data, and 
two in the germline samples (Figure 4.15).  
 
4.4.6.1 CLL Tumour Mutational Signatures 
Tumour signature one (Tsig1) was primarily composed of substitutions 
involving cytosine residues, with C>T transitions and C>A transversions 
being the most common. Tsig1 was previously only identified in 2% of 
cancer cases, including breast and medulloblastoma (Alexandrov et al 
2013).  
Tsig2 had a relatively even contribution from all mutation types, with T>G 
transversions contributing the most. This signature was previously seen in 
nine different cancer types, including myeloma and B-cell lymphomas, but 
not in CLL, and has not been linked to any particular cause (Alexandrov et 
al 2013).  
Like Tsig1, Tsig3 is also characterised by the presence of C>T transitions. 
However, in contrast to those of Tsig1, these dominate in an NpCpG 
context. Interestingly, Tsig3 is identical to the signature previously ascribed 
to the increased deamination activity of 5-methyl-cytosine, resulting in C>T 
substitutions at NpCpG motifs.  
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Figure 4.15 Germline and tumour mutational signatures detected in CLL 
patients.  
Each signature is arranged according to the 96 possible substitution classifications, as 
defined by both the nucleotide substitution and the sequence context immediately 5’ and 
3’ to the mutated position. Each substitution type is represented on the x-axis in a 
different colour, whereas the y-axis displays the percentage contribution of each mutation 
type to that particular signature. 
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Tsig4 is characterised by T>G transversions at both CpTpT and TpTpT 
trinucleotides. Tsig4 is the non-canonical AID signature (ncAID) associated 
with the activity of polymerase η during AID induced somatic 
hypermutation of the IgHV locus in CLL (Alexandrov et al 2013, Kasar et al 
2015).  
A high level of inter-patient diversity in the distribution of mutation 
signatures was also observed. For example, seven out of 22 (33%) chemo-
sensitive cases only harboured three of the four signatures compared to 0 
out of 21 chemo-refractory cases (Figure 4.16). 
  
 
 
Figure 4.16 Contribution of different mutational signatures to the overall mutation burden in individual CLL patients.  
Each bar represents a single patient, while the vertical axis shows the percentage of mutations contributed by each signature. Patients are divided 
first by sensitivity to chemotherapy, then by immunoglobulin mutation status. 
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4.4.6.2 CLL Germline Mutation Signatures 
In contrast to the tumour samples, the matched germline samples 
harboured only two mutational signatures, Gsig1 and Gsig2 (Figure 4.15), 
present at similar levels in all 42 cases. Both signatures are closely matched 
in composition, being defined by a high incidence of C>T transitions in an 
NpCpG context, and, as expected, are related to the ageing signature found 
in the tumour genomes. Indeed, Gsig1 displays a strong correlation with 
the age of the patient (P=0.0015) reinforcing the idea that mutations in the 
germline genomes are acquired sporadically throughout the lifetime of the 
patient.  
 
4.4.6.3 Correlation with Clinical and Biological Characteristics 
Tsig1 showed no significant correlation with any clinical or biological 
characteristic.  Tsig2 was found to correlate with higher patient age at the 
time of diagnosis in this cohort (P<0.001). The mutation pattern 
corresponding to Tsig3 has been found in more than 60% of cancer types, 
and has been also shown to correlate with the age of the patient at 
diagnosis (Alexandrov et al 2013). In this cohort, not only did it correlate 
with age (P=0.02), it was also more prevalent in the chemo-refractory 
patients compared to the treatment naïve cases (P<0.001) despite there 
being no significant difference in the ages of the two subgroups (P=0.9469).   
The mutations ascribed to Tsig4 are a result of the underlying mechanism 
behind somatic hypermutation in B-cells, a relationship confirmed by the 
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fact that cases with a high Tsig4 signature also had hypermutated IgHV 
genes (P=0.0005) and an increased total mutation burden (P=0.0097) 
compared to those with low TSig4 (Figure 4.17). Interestingly, compared to 
chemo-refractory cases, chemo-sensitive patients showed a higher 
variability of Tsig4 mutational load, likely due to both the higher number of 
IgHV mutated patients in the untreated cohort (n=10) compared to the 
refractory (n=7) and the level of variance from the IgHV sequence, which is 
greater in the untreated cases (P<0.0001, F test).   
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Figure 4.17 Tsig4 correlates with mutated IgHV genes and higher somatic 
mutation burden in CLL.  
Dot plots describing the relationship between Tsig4 and (a) IgHV mutation status and (b) 
total mutation count. Each dot represents a single patient. Low mutation burden cases are 
those with a total mutation count lower than the median for the cohort (2,095). Error bars 
show ± SEM. 
 
4.4.6.4 Canonical-AID Induced Mutations 
The introduction of mutations by activation-induced cytidine deaminase 
(AID) is an ongoing process in CLL (Huemer et al 2014, Kasar et al 2015). In 
total, 3,524 canonical AID (cAID) mutations (C>T and G>A transitions in 
WRCY and RGYW motifs, respectively) were identified, accounting for 3.6% 
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of all mutations in the cohort. Forty-two per cent (1,476/3,524) of these 
occurred within the boundaries of a gene. As expected, there was a 
particular clustering of cAID mutations at the IgHV (n=178) locus, on 
chromosome 14 (Figure 4.18).  
 
Figure 4.18 Occurrence of cAID mutations across the CLL genome.  
Bar chart showing the enrichment of cAID mutations on chromosome 14 in both IgHV 
mutated and unmutated patients. Mutation counts are normalised to account for differing 
chromosome lengths. 
 
Although cAID mutations associated with mutated IgHV status (P=0.0328), 
they were nevertheless also present across the genome and in unmutated 
patients and even patients with IgHV with 100% homology to the germline 
(Figure 4.19). There was no significant difference in the occurrence of cAID 
mutations between refractory and treatment naïve cases (P=0.6292). 
Interestingly, IGLL5 contained 11 cAID mutations, accounting for 10% of all 
IGLL5 variants.  
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Figure 4.19 Distribution of cAID mutations between IgHV mutated and 
unmutated CLL patients.  
Dot plot showing the absolute count of cAID mutations in the IgHV mutated and 
unmutated subgroups. Red data points represent patients with 100% homology to the 
IgHV germline sequence. Error bars show ± SEM. 
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4.5 Discussion 
CLL is a disease that displays a high level of biological and clinical 
heterogeneity. The application of whole genome sequencing in cancer 
studies has enabled researchers to obtain reliable and accurate 
information on translocations and copy-number aberrations, as well as 
identifying mutations in non-coding regions of genes. It also facilitates the 
extraction of tumour-specific mutation signatures, which are frequently 
linked to particular causative agents. This study has sought to utilise whole-
genome sequencing to provide a wide-ranging description of the CLL 
genome. 
This study demonstrates the validity of whole-genome sequencing as an 
approach to characterise the mutational landscape of a cancer genome. 
The presence of coding mutations in the WGS data was confirmed by the 
targeted deep sequencing panel, which previous studies have shown is just 
as accurate and even more sensitive than Sanger sequencing (Fernandez-
Mercado et al 2013). Additionally, the variant allele frequencies correlate 
well between these two sequencing protocols. It is important to note, 
however, that even if the sequencing chemistry works well, accurate 
variant detection also depends upon using the most appropriate 
downstream analysis pipeline. For example, the targeted deep sequencing 
panel highlighted four missense mutations, one in MED12 and three in 
TP53, which were not initially identified by the WGS. Visual inspection of 
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the aligned WGS reads revealed that the mutations were present in the 
raw data but had not been picked up by the variant calling software.  
In concordance with other studies, these data show that CLL has a 
relatively low global mutation rate compared to other cancer types (Kasar 
et al 2015, Landau et al 2013, Lawrence et al 2013, Schuh et al 2012). 
Furthermore, whilst there is a significant difference in both the coding and 
non-coding mutation count between the IgHVmut and IgHVunmut subgroups, 
there was no difference in the occurrence of mutations in known CLL driver 
genes. This suggests that oncogenesis and disease progression in CLL are 
linked to the presence of mutations in a small number of key genes. 
Alternatively, it might be that patients with high absolute mutation burden 
are protected from disease progression by the immune system. It has been 
shown that checkpoint inhibition is more effective in cancers with high 
mutational load (Hugo et al 2016). 
Coding mutations in ATM are well characterised in CLL and, along with 
deletions of 11q, are known to confer shorter overall survival and 
increased risk of disease progression (Austen et al 2005, 2007, Nadeu, 
Delgado, Royo, Baumann, Stankovic, Pinyol, Jares, Navarro, Martin-Garcia, 
Bea, Salaverría, et al 2016, Skowronska et al 2012, Stankovic et al 1999). By 
using whole-genome sequencing, this study identified a region of kataegis, 
comprised of predominantly intronic mutations, in a single CLL patient, 
spanning introns 10 to 15 of the ATM gene. Although there was no 
evidence of an 11q deletion in this patient, the level of ATM transcript 
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expression was significantly reduced, and was comparable to that of the 
del(11q) subgroup. This evidence suggests that non-coding mutations may 
represent a new mechanism for ATM disruption in CLL.  
By using complex mathematical modelling, it has become possible to 
isolate a number of mutational patterns, or signatures, within the 
molecular landscape of cancer (Alexandrov et al 2013, Morganella et al 
2016, Nik-Zainal et al 2012, 2016). In this study, four such signatures were 
identified, each of which correlated well with those previously seen in CLL 
(Alexandrov et al 2013). In particular, Tsig3 correlates with both the age of 
the patient at diagnosis and chemo-refractoriness. A recent study also 
identified an on-going ageing signature in CLL that is associated with 
advanced disease and, interestingly, with sub-clonal mutations (Kasar et al 
2015). Sub-clonal mutations in CLL have been shown to expand over time, 
often due to external selection pressures such as chemotherapy, and as a 
result contribute towards disease progression (Landau et al 2013). This 
supports the findings of this study that the ageing signature is more 
prevalent in refractory patients than in treatment naïve patients. Future 
work, including sub-clonal analysis on sequential patient samples, could 
offer additional insights to this. 
An ncAID signature was also isolated from the tumour sequencing data, 
which is caused by the inefficient activity of DNA polymerase eta during 
mismatch repair following AID activity. The ncAID signature is correlated 
with both increased mutational burden and mutated IgHV status in this 
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cohort, although when comparing only IgHVmut patients, there is 
enrichment for this signature in the treatment naïve samples. Kasar et al 
(2015) found that mutations attributed to the ncAID signature tended to be 
clonal, hypothesising that they occur early in tumour development, 
perhaps even prior to tumour initiation. 
As part of the maturation process, healthy B-cells undergo SHM of the 
immunoglobulin (Ig) loci in the germinal centre. The activation-induced 
cytidine deaminase enzyme (AID) is responsible for inducing SHM. AID 
deaminates cytidine bases preferentially in a WRCY motif, converting them 
into uracils. If these changes are allowed to proceed to replication 
unrepaired, DNA polymerases insert an adenosine residue opposite the 
uracil, ultimately resulting in a C>T transition. These mutations are 
clustered at the Ig loci, although evidence shows a significant level of 
mutation (Kato et al 2012, Laura Pasqualucci et al 2008) and chromosomal 
disruption (Chiarle et al 2011, Hakim et al 2012, Robbiani et al 2008) in 
non-Ig genes. The present study reveals significant levels of AID activity in 
regions other than the Ig loci and shows that it also occurs in cases with 
100% homology to the germline at the IgHV locus. 
The majority of cancer sequencing studies have focussed on somatic 
mutations within the coding region of the genome. However, this only 
comprises 3% of the human genome. This study has shown that not only do 
the majority of somatically acquired mutations in CLL occur in non-coding 
regions, but that mutational hotspots occur in regulatory regions of genes. 
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Mutations in regulatory regions have been described in cancer, perhaps 
most notably in the promoter region of the TERT gene. These variants 
result in increased gene expression levels by introducing de novo ETS 
binding sites in a number of cancer types (Allory et al 2014, Brennan et al 
2013, Horn et al 2013, Huang et al 2013, Liu et al 2013, Rachakonda et al 
2013, Vinagre et al 2013, Wu et al 2014). Many other mutational hotspots, 
however, show no correlation between mutational status and transcript 
expression level (Fredriksson et al 2014). This finding is supported by these 
data in which, with the exception of BCL2 and ATM, there was no 
correlation between regulatory region mutations and increased or 
decreased gene expression when compared to wild-type cases. However, 
the fact that a number of these regions occur in genes frequently affected 
by coding mutations in CLL suggests that these may not be random events. 
There are a number of possible reasons for this lack of association. It may 
be that some mutations have a more subtle effect on gene function than 
can be seen at whole-transcriptome level. Alternatively it may be that 
these regions are simply more susceptible to mutations, perhaps due to 
inaccessibility of the DNA repair mechanisms and that these are events 
without functional consequences. On the other hand, it may be that the 
small sample size of this study is insufficient to generate a statistically 
significant value. It is also worth noting that much of the data generated by 
the ENCODE project is based on cell-line DNA, which may not be 
representative of genuine CLL DNA, potentially rendering the annotation of 
mutated regions as promoters or enhancers as incorrect, and thus making 
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direct comparisons difficult. Most likely, the lack of difference in gene 
expression between mutant and wild-type cases is due to the fact that in 
wild-type cases indirect mechanisms lead to changes in gene expression 
similar to the mutations identified. Future, large-scale sequencing efforts, 
such as that provided by the 100,000 genomes project, may provide a 
better insight into these non-coding variants and mechanistic studies need 
to be performed to understand the functional impact of these non-coding 
mutations. 
In summary, this work demonstrates that global mutation signatures are 
present in CLL patients, with contrasting levels according to both IgHV 
mutation status and chemo-refractoriness. Further work is required to fully 
define the functional significance of these findings; however this study 
serves to highlight the heterogeneous nature of CLL, particularly with 
regards to the number of non-coding mutations present and, importantly, 
demonstrates that, with the exception of low VAF mutations, whole-
genome sequencing provides SNV calls that are comparable to clinical 
grade targeted sequencing. 
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 DISCUSSION Chapter 5 
 
5.1 Introduction 
The advent of NGS has provided clinicians and researchers alike with a 
powerful new tool that promises to further our understanding of the 
molecular alterations underpinning the development and progression of 
cancer. Information regarding the mutational status of a number of key 
genes can be used to aid in diagnosis, predict a patient’s response to 
treatment, or give an indication as to the likelihood of remission or relapse. 
Furthermore, whole genome sequencing can provide information on novel 
therapeutic targets, opening up new options for patients and clinicians in 
the future. With the work presented in this thesis, I demonstrate firstly 
that targeted NGS is a reliable, more sensitive alternative to established 
mutation screening techniques and that it offers genuine clinical value 
when offered as a routine service in a diagnostic laboratory. Furthermore, 
targeted NGS can be used as a research tool to characterise a small section 
of the mutational landscape of a particular cohort of patients. Secondly, I 
show that whole-genome sequencing can provide a comprehensive 
analysis of the CLL genome, revealing the heterogeneous nature of the 
molecular landscape, including the presence of specific mutational 
signatures, structural alterations and localised regions of increased 
mutational frequency. 
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5.2 Targeted Next-Generation Sequencing as a 
Diagnostic Tool 
AML is the most common myeloid malignancy in Europe (Visser et al 2012). 
The molecular landscape of AML is somewhat complex, with both 
structural alterations and gene mutations providing important clinical 
information at the time of diagnosis. Indeed, at the time of writing, the 
WHO guidelines for classifying AML and related neoplasms are 
predominantly concerned with the presence of specific translocations 
(Grimwade 2012, Swerdlow et al 2008), despite the fact that 40% of cases 
possess a normal karyotype (Grimwade et al 2010). Recurrently mutated 
genes have been identified within the wider group of myeloid disorders 
(AML, MDS and MPN), a number of which provide important clinical 
information at the time of diagnosis. For example, mutations in NPM1 
increases the efficacy of treatment with either Bortezomib or arsenic 
trioxide in AML patients (M Huang et al 2013), leading to higher complete 
remission rates and longer overall survival, but only in the absence of 
concomitant mutations in the FLT3 gene (K Döhner et al 2005, Hollink et al 
2009, Schlenk et al 2008, Christian Thiede et al 2006), information that 
requires screening of both genes. The importance of these recent findings 
is reflected in the fact that the WHO classification for AML and related 
neoplasms includes cases with either NPM1 or CEBPα mutations as distinct 
groups (Swerdlow et al 2008). There is, therefore, a case to be made for a 
diagnostic test targeting several genes simultaneously, in order to provide 
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as clear a characterisation as possible of the mutational landscape of each 
individual patient. The work presented in chapter 3 demonstrates that a 
targeted sequencing assay can reliably detect mutations with clinical 
implications with a greater degree of sensitivity than is obtainable via 
existing methods, including Sanger sequencing.  
 
5.2.1 A Higher Degree of Sensitivity Offers Additional Clinical 
Insights 
As chapter three shows, this TSCA assay is able to detect mutations present 
in as few as 3% of the sequencing reads, this being an marked 
improvement on the 10-20% limit of detection offered by Sanger 
sequencing (Tsiatis et al 2010). As a result, targeted NGS is better suited to 
detecting sub-clonal mutations within a cancer cell population. A number 
of recent studies in CLL, for example, have shown that low level, sub-clonal 
mutations can have the same impact on disease progression as high 
frequency clonal mutations, predicting for shorter progression free survival 
(Landau et al 2013, Nadeu, Delgado, Royo, Baumann, Stankovic, Pinyol, 
Jares, Navarro, Martin-Garcia, Bea, Salaverria, et al 2016) and the 
development of chemo-refractoriness (Rossi et al 2014).  
 
Furthermore, the ongoing risk of relapse following initial treatment can be 
routinely assessed via the continuous monitoring of disease specific, low-
level mutations (Grimwade and Freeman 2014, Ivey et al 2016). This 
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minimal residual disease (MRD) monitoring currently employs modified 
quantitative real-time PCR assays to accurately quantify the level of 
mutation present in a post-treatment sample (Gorello et al 2006, Mancini 
et al 2015, Warren et al 2012) with sensitivity as low as 2.5% (Shivarov et al 
2014). Given that NGS generates a large number of clonal DNA molecules, 
making it possible to quantify the allelic ratio of a given variant, combined 
with the sensitivity and low background noise levels of the targeted panel 
described in chapter 3, it is possible that this is another clinical application. 
Indeed, in the time since I developed this panel, a number of studies have 
applied NGS to the question of MRD (Bibault et al 2015, Spencer et al 2013, 
Thol et al 2012), showing good concordance with existing methods (Bibault 
et al 2015).  
 
5.2.2 Alternative Target Enrichment Strategies 
The TruSeq Custom amplicon system used in chapter three is only one of a 
number of target enrichment strategies currently on the market, which 
differ in both enrichment method and sequencing performance. There are 
presently two main methods for target enrichment, those that employ 
hybridisation of DNA probes to isolate the region(s) of interest from a 
whole genome preparation, such as the SureSelectXT and Haloplex HS 
assays (both Agilent Technologies), and those that use PCR primers to 
amplify the chosen regions, including the TSCA assay (Illumina, San Diego, 
CA, USA), the Ion AmpliSeq assay (Thermo Fisher Scientific, Waltham, MA, 
USA) and the SeqCap EZ system (Roche Diagnostics Ltd., Basel, 
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Switzerland). Comparisons of the different methods, in the context of 
whole exome capture, show that hybridisation-based sequencing methods 
produce libraries with greater complexity than amplicon enrichment 
(Samorodnitsky, Jewell, et al 2015). Amplicon enrichment produces greater 
average sequencing coverage across the exome, along with greater 
standard deviation of coverage, suggesting that hybridisation techniques 
result in better sequencing uniformity (Samorodnitsky, Jewell, et al 2015). 
The level of G/C content in a given target region can also impact upon the 
efficiency of the enrichment method used as both high (<60%) and low 
(<40%) levels cause reduced amplification and, therefore, sequencing 
depth (Asan et al 2011, Clark et al 2011, Samorodnitsky, Datta, et al 2015). 
This is an important consideration when designing diagnostic panels in 
order to generate sufficient sequencing depth across clinically important 
genes with a high GC content, including CEBPa (Ahn et al 2016, Wouters et 
al 2009), which is one of the markers included in the WHO classification 
guidelines for AML cases (Swerdlow et al 2008). 
 
5.2.3 World Health Organisation 2016 Classification 
With the publication of the 2008 World Health Organisation guide for the 
classification of AML and related neoplasms, came the introduction of two 
provisional entries regarding the presence of specific mutations, namely 
those with mutated NPM1 and those with mutated CEBPa. In the time 
since these guidelines were published, studies have shed new light on the 
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diagnostic and prognostic information provided by existing and new 
molecular markers. To reflect this, the 2016 update to the WHO 
classification guidelines has refined and confirmed these groupings (Arber 
et al 2016). AML with mutated NPM1 has been upgraded from provisional 
to a full category. The finding that bi-allelic, but not mono-allelic, CEBPa 
mutations offer improved rates of OS, EFS and reduced risk of relapse (Ahn 
et al 2016, Wouters et al 2009), has resulted in a refinement of this 
category to only include bi-allelic mutated patients. A new provisional 
entity of AML with mutated RUNX1 has also been added to the system, 
since AML cases with mutated RUNX1 has been shown to have a worse 
prognosis (Gaidzik et al 2011, Mendler et al 2012, Schnittger et al 2011, 
Tang et al 2009). 
 
5.2.4 Implementation of Next-Generation Sequencing in a 
Diagnostic Setting 
In the years since the chemistries behind next-generation sequencing were 
first described (Bentley et al 2008, Margulies et al 2005), NGS has been 
used to characterise the molecular landscape of a number of diseases, 
including cancer. This has led to the discovery of new diagnostic and 
prognostic markers, and new therapeutic targets, with the ultimate goal 
being the provision of personalised, or precision, treatment on a case-by-
case basis. With the work described in chapter three, I demonstrated that a 
next-generation targeted sequencing panel provides the means to 
generate accurate and sensitive information regarding the mutational 
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status of multiple genes simultaneously, and that this same information is 
influencing the diagnosis, treatment and follow-up response decisions in a 
diagnostic laboratory.  
 
Targeted sequencing panels offer a number of advantages over a whole 
genome sequencing approach, particularly in the specific context of a 
diagnostic laboratory. The very nature of targeted sequencing means that 
the region(s) included in the panel can be very tightly regulated by the 
laboratory, with only those with a confirmed relationship between the 
presence of a mutation and pathology being included and reported on. 
Other advantages of targeted include the ability to multiplex samples 
together, a smaller DNA input requirement and a faster turnaround time 
than WGS. Targeted sequencing is also much cheaper than WGS, costing 
£300 for the myeloid panel described in chapter three, compared to £4,000 
for a single whole genome.  
 
It is also worth mentioning the question of ethics. As the targets of a 
sequencing panel are very tightly defined, the question of incidental 
findings is greatly reduced and, given the tightly controlled scope of the 
test, consent is usually easily obtained from the patient in clinic. In 
contrast, suppose a sample from a patient with AML is sent to a diagnostic 
laboratory for whole genome sequencing, with the goal of screening for 
mutations in NPM1. In this instance, it is possible, however unlikely, that a 
variant linked to an increased risk of developing another disease may be 
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identified. Alternatively, a heterozygous mutation in a recessive condition 
may be detected, which may impact upon the patient’s reproductive 
choices. Indeed, the European Society of Human Genetics (ESHG) has 
recommended the use of targeted sequencing panels over WGS in order to 
avoid these incidental findings (van El et al 2013). 
 
Of course, the absence of gene mutations can also offer important 
diagnostic information to a clinician. Of the 270 diagnostic cases screened 
with the myeloid sequencing panel in chapter three, 64 were either sent to 
the laboratory as an unexplained anaemia or as a suspected case of AML, 
MDS or MPD. In these instances, the panel is being used when a clinician is 
unsure of the condition, and wishes to obtain additional evidence before 
making any clinical decision.  
 
5.3 Characterisation of the CLL Genome 
Chronic lymphocytic leukaemia is characterised by a high level of both 
clinical and biological heterogeneity, with some patients requiring no 
treatment at all, while others develop resistance to chemotherapy and, 
therefore, disease progression. This heterogeneity may be explained by the 
diversity of mutations and structural variants present within the CLL 
genome. The work presented in chapter four sought to leverage the power 
of next-generation whole genome sequencing in an attempt to provide a 
comprehensive characterisation of a representative cohort of clinical CLL 
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patients. Furthermore, it sought to demonstrate the utility of WGS in a 
clinical setting. 
 
5.3.1 Appropriate Germline DNA Source Selection for 
Subtraction Analysis 
Cancer is the result of de-regulated clonal expansion of a single cell. This 
de-regulation is generally linked to one or more somatically acquired 
genetic alteration, including gene mutations and/or chromosomal 
alterations. In order to better understand the methods by which cancer 
develops, and to be able to predict the future disease course, including 
how a patient will respond to a particular therapy, it is important to be able 
to identify these mutations. Complicating the matter is the presence of 
germline mutations in the patient’s genome. These inherited changes are 
natural variations from the reference human genome and, as such, will 
appear as false positives in the cancer sample following DNA sequencing. 
One method of differentiating these from somatically acquired mutations 
is to sequence both germline and tumour DNA samples from a single 
patient, removing any mutations present in the germline DNA from those 
in the tumour DNA. Those that remain are considered somatically acquired. 
This approach is dependent on the germline DNA source containing no 
tumour cells, since this would cause the removal of tumour specific 
mutations during the subtraction analysis. Therefore the choice of germline 
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material is critical in obtaining an accurate picture of the tumour 
mutational landscape. 
 
In chapter four, WGS was used to isolate somatically acquired mutations in 
42 CLL genomes. The DNA used as a germline sample for each patient was 
extracted from buccal swabs, a method which has been used in a number 
of previous whole genome and exome studies in CLL (Kasar et al 2015, 
Ljungström et al 2016, Schuh et al 2012). However, buccal swabs and saliva 
samples are known to contain high levels of haematopoietic cells 
(Chaudhary et al 2015, Endler et al 1999, C Thiede et al 2000), raising the 
issue of tumour contamination in the germline DNA. Indeed, in the present 
study, one patient was shown to harbour only 153 somatic mutations, well 
below the median for this cohort, none of which affecting protein coding 
sites. It is possible that the germline DNA sample contained a high level of 
tumour cell contamination in this instance. 
 
It has also been shown that multiple buccal swabs from the same patient 
can vary in content. One study investigating DNMT3a mutations in AML 
analysed two swabs from one individual, one of which was found to 
contain the mutation with the other being wild-type (Ewalt et al 2011). 
Other recent whole genome studies in CLL isolated B-cells from T-cells 
based on specific cell surface markers using flow cytometry (Landau et al 
2013, Puente et al 2011). The T-cell population, being from a different cell 
lineage, are then used as a source of germline DNA for the CLL B-cells. 
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However, this approach also has limitations. It is based upon the 
assumption that the cancer initiating mutation arises once the cell lineage 
fate has been decided. A number of studies have demonstrated the 
presence of tumorigenic mutations in haematopoietic stem cell 
populations (Mian et al 2015, Shlush et al 2014), a fact that indicates 
mutations may be present in all haematopoietic cell lineages.   
 
5.3.2 Determination of the Function and Clinical Impact of 
Non-Coding Mutations in Cancer 
To date, the majority of cancer sequencing studies have focussed on 
somatic mutations within the coding region of the genome. However, this 
only comprises 3% of the human genome. The data presented in chapter 
four demonstrates that not only do the majority of somatically acquired 
mutations in CLL occur in non-coding regions, but that mutational hotspots 
occur in regions that regulate the expression of genes. The likely function 
of such regions can be determined using methods including DNase I 
hypersensitivity site sequencing (DNase-Seq) or chromatin 
immunoprecipitation sequencing (ChIP-Seq). The presence of DNase I sites 
are understood to be an indicator of open and accessible chromatin and, 
therefore, active genes. ChIP-Seq is used to identify chromatin 
modifications, specifically the methylation and acetylation status of key 
histones, which are hallmarks of promoter and enhancer regions (Hon et al 
2009). The genomic targets of such regions can be determined using a 
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chromosome conformation capture-on-chip  sequencing (4C-seq) approach 
(van de Werken et al 2012) to characterise the physical interactions 
between regulatory regions and genomic targets. Indeed, in one recent 
large-scale sequencing study in CLL, the authors identified a densely 
mutated region on chromosome 9p13 (Puente et al 2015). The presence of 
a DNase I hypersensitive site, along with nucleosomes containing both 
H3K4me1 and H3K27ac, indicated this was the site of an active enhancer. 
Using a combination of gene expression arrays and 4C-seq, they identified 
PAX5 as the target of the enhancer and found  that expression levels of 
PAX5  were altered in mutated patients (Puente et al 2015). Furthermore, 
the study showed that the introduction of the same mutations in B-cell cell 
lines resulted in the same reduction in PAX5 expression levels, further 
confirming the enhancer function of this region. The work presented in 
chapter four identified clusters of mutations in non-coding regions of 
genes, in particular within the first intron of BCL6. It would be interesting 
to further investigate the functional and clinical consequence of these 
mutations using 4C-Seq and RNA-Seq in a larger patient cohort.  
 
5.4 Future Work and Directions 
The work presented in this thesis demonstrates that both targeted and 
whole genome sequencing could be introduced into the diagnostic setting 
in order to aid with the clinical decision making process. However, the 
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findings here, and recent developments in the field of DNA sequencing, 
have raised further avenues for potential investigation. 
DNA sequencing using modified nanopores is able to generate sequencing 
reads of up to 50,000bp (Ip et al 2015) in comparison to the 300bp reads 
obtainable through current Illumina SBS methods. This increase in read 
length brings with it opportunities to detect genomic alterations larger 
than single nucleotide changes or short insertion/deletion events. 
It has been shown that CLL patients with hypermutated IgHV (<98% 
homology to the germline) have significantly increased OS rates compared 
to un-mutated patients (Damle et al 1999, Hamblin et al 1999) and, as 
such, screening for IgHV mutation status is an important part of the 
diagnostic work-up in new CLL patients. This screening is predominantly 
performed using a multiplex PCR followed by Sanger sequencing, an 
approach which, with its limited sensitivity, results in only the dominant 
IgHV clone being detected. Furthermore, the failure rate for this assay 
ranges from 8-18% (Austen et al 2005, Burger et al 2014, Kröber et al 
2002). Recent work using NGS methods have shown that 24% of CLL 
patients harbour at least 2 different IgHV rearrangements, the specific 
profile of which can improve risk stratification (Stamatopoulos et al 2016).  
It would be useful, therefore, to be able to integrate both IgHV mutation 
testing with screening for coding mutations in clinically relevant genes. The 
long read lengths, and PCR-free protocols afforded by nanopore 
sequencing make this an ideal approach for this.   
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APPENDICES 
Appendix A: List of non-synonymous variants with COSMIC ID or not reported in dbSNP 
Sample 
ID Diagnosis Gene 
Genome 
coordinates 
DNA 
change 
Protein 
change 
Variant call ratio 
[% 
(variant/total)] 
COSMIC ID dbSNP ID Polyphen2 
MDS16 RA (5q- syndrome) RUNX1 chr21:36259324 A>AG L29S 31.9 (23/72) COSM24756 rs111527738 Probably damaging  
MDS15 RA (5q- syndrome) SF3B1 chr2:198266834 T>TC K700E 11.4 (170/1496) COSM84677 N/A Probably damaging  
MDS07 RA (5q- syndrome) DNMT3A chr2:25457242 C>CA R882L 7.8 (92/1176) N/A N/A Probably damaging  
MDS08 RA (5q- syndrome) ASXL1 chr20:31022449 insG G646WfsX12 44.7 (174/389) COSM34210 N/A Truncated protein 
MDS08 RA (5q- syndrome) WT1 chr11:32413565 C>CT R462Q 49.0 (174/355) COSM21408 N/A Probably damaging  
MDS14 RA (5q- syndrome) TET2 chr4:106193748 C>CT R1404X 45.1 (309/685) COSM42037 N/A Truncated protein 
MDS12 RA (5q- syndrome) ASXL1 chr20:31022449 insG G646WfsX12 10.5 (37/351) COSM34210 N/A Truncated protein 
MDS12 RA (5q- syndrome) SF3B1 chr2:198266834 T>TC K700E 40.0 (620/1549) COSM84677 N/A Probably damaging  
MDS12 RA (5q- syndrome) TET2 chr4:106164896 insA fs (Y1255X) 5.3 (41/771) COSM110747 N/A Truncated protein 
MDS06 RA (5q- syndrome) TET2 chr4:106197552 C>CT P1962L 50.3 (303/602) COSM41894 N/A Probably damaging  
MDS11 RA (5q- syndrome) ASXL1 chr20:31022902 G>GA W796X 35.8 (144/402) COSM53207 N/A Truncated protein 
MDS10 RA (5q- syndrome) TP53 chr17:7578413 C>CG V173L 41.1 (109/265) COSM43559  N/A Probably damaging  
MDS29 RA (5q- syndrome) JAK2 Chr9:5073770 G>GT V617F 7 COSM12600 rs77375493 Probably damaging  
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MDS34 RA (5q- syndrome) JAK2 Chr9:5073770 G>GT V617F 28 COSM12600 rs77375493 Probably damaging  
MDS29 
Del(5q) RA with 
additional cytogenetic 
abnormalities 
DNMT3A chr2:25457176 G>GA P904L 44.0 (198/450) COSM52989 rs149095705 Probably damaging  
MDS28 
Del(5q) RA with 
additional cytogenetic 
abnormalities 
U2AF1 chr21:44514777 T>TC Q157R 38.3 (242/632) COSM144989 N/A Probably damaging  
MDS30 
Del(5q) RA with 
additional cytogenetic 
abnormalities 
CBL chr11:119149332 C>CT A447V 43.6 (99/227) N/A N/A Possibly damaging  
MDS26 
Del(5q) RA with 
additional cytogenetic 
abnormalities  
TP53 chr17:7577553 A>AG M243T 28.0 (327/1166) COSM43726 N/A Probably damaging  
MDS37 Advanced del(5q) MDS (RAEB) TP53 chr17:7577120 C>CT R273H 82.2 (620/754) COSM10660 rs28934576 
Possibly 
damaging  
MDS42 Advanced del(5q) MDS (CMML) ASXL1 chr20:31023821 G>GT E1102D 45.4 (366/806) COSM36205 rs139115934 
Possibly 
damaging  
MDS42 Advanced del(5q) MDS (CMML) CBL chr11:119149004 G>GT W408C 96.0 (267/278) COSM34072 N/A 
Probably 
damaging  
MDS36 Advanced del(5q) MDS (RAEB) ASXL1 chr20:31024704 G>GA G1397S 49.9 (875/1755) COSM133033 rs146464648 
Possibly 
damaging  
MDS33 Advanced del(5q) MDS (RAEB) TET2 chr4:106196850 insCATG E1728Dfs*13 17.0 (121/713) COSM211745 N/A 
Truncated 
protein 
MDS43 Advanced del(5q) MDS (RAEB) TET2 chr4:106164880 G>GT E1250X 27.3 (313/1145) N/A N/A 
Truncated 
protein 
MDS43 Advanced del(5q) MDS (RAEB) ASXL1 chr20:31022449 insG G646WfsX12 42.8 (470/1097) COSM34210 N/A 
Truncated 
protein 
MDS39 Advanced del(5q) MDS (RAEB) TP53 chr17:7578190 T>TC Y220C 38.7 (48/124) COSM99719 rs121912666 
Probably 
damaging  
MDS39 Advanced del(5q) MDS (RAEB) TP53 chr17:7578275 G>GA Q192X 49.3 (99/201) COSM117949 N/A 
Truncated 
protein 
MDS38 Advanced del(5q) MDS (RAEB) TP53 chr17:7577538 C>CA R248L 
44.1 
(1168/2648) COSM6549 rs11540652 
Probably 
damaging  
MDS38 Advanced del(5q) MDS (RAEB) TP53 chr17:7577568 C>CT C238Y 37.5 (998/2664) COSM11059 N/A 
Probably 
damaging  
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Appendix B: List of clinically relevant mutations in 270 diagnostic 
samples 
Sample Finding Gene Nucleotide Change Amino Acid Change 
AML1 Good Risk NPM1 c.859_860insTCTG p.Trp288CysfsTer12 
AML2 Targetable mutation IDH1 c.394C>T p.Arg132Cys 
AML3 Poor risk KIT c.1248_1256GACTTACGA>TCCACC p.Thr417_Asp419delins 
AML7 Targetable mutation IDH1 c.394C>A p.Arg132Ser 
AML8 Poor risk KIT c.2466T>G p.Asn822Lys 
AML9 MRD monitoring NPM1 c.863_864insTCGG, p.Trp288fs*12 
AML11 Targetable mutation IDH1 c.394C>T p.Arg132Cys 
AML13 Targetable mutation IDH2 c.419G>A p.Arg140Gln 
AML19 Poor risk CEBPA c.110_111delCG p.Arg37Glyfs*70 
AML20 Poor risk KIT c.2466T>G p.Asn822Lys 
AML21 Targetable mutation IDH2 c.515G>A p.Arg172Lys 
AML23 Targetable mutation IDH1 c.394C>T p.Arg132Cys 
AML25 Poor risk TET2 c.3781C>T p.Arg1261Cys 
AML27 Poor risk TET2 c.412C>T p.Gln138* 
AML30 Targetable mutation IDH2 c.419G>A p.Arg140Gln 
AML31 Poor risk ASXL1 c.1926_1927insG p.Gly646Trpfs*12 
AML37 Targetable mutation IDH1 c.395G>A p.Arg132His 
AML38 Poor risk KIT c.2447A>T p.Asp816Val 
AML40 Targetable mutation IDH2 c.515G>A p.Arg172Lys 
AML41 Targetable mutation IDH1 c.394C>T p.Arg132Cys 
AML43 Poor risk KIT c.2466T>G p.Asn822Lys 
AML44 Poor risk FLT3-ITD 
AML45 Good Risk NPM1 c.863_864insTCGG, p.Trp288fs*12 
AML46 Poor risk TET2 c.5152G>T p.Val1718Leu 
AML47 Good Risk CEBPA c.912_913insTTG p.Lys304_Q305insLeu 
AML48 MRD monitoring NPM1 c.859_860insTCTG p.Trp288Cysfs*12 
AML50 Poor risk TET2 c.2856_2872del p.Arg953Glufs*13 
AML52 Targetable mutation IDH2 c.515G>A p.Arg172Lys 
AML58 Targetable mutation IDH2 c.515G>A p.Arg172Lys 
AML60 Good Risk NPM1 c.863_864insTCGG, p.Trp288fs*12 
AML62 Poor risk CEBPA c.1042_1043dupAG p.Ser348Argfs*75 
AML64 Good Risk ASXL1 c.1926_1927insG p.Gly646Trpfs*12 
AML65 Good Risk IDH1 c.394C>A p.Arg132Ser 
MDS4 Targetable mutation IDH1 c.395G>T p.Ala132Leu 
MDS5 Confirmed diagnosis WT1 c.1108dupC p.Arg370Profs*15 
MDS6 Confirmed diagnosis Absence of mutations added weight to patient not having a myeloid 
disorder 
MDS11 Targetable mutation SF3B1 c.2098A>G p.Lys700Glu 
MDS15 Poor risk TP53 c.808T>A p.Phe270Ile 
MDS16 Poor risk RUNX1 c.335T>A p.Leu112Gln 
MDS17 Confirmed diagnosis TET2 c.4354C>T p.Arg1452* 
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MDS18 Targetable mutation IDH2 c.419G>A p.Arg140Gln 
MDS20 Poor risk RUNX1 c.601C>T p.Arg201* 
MDS21 Confirmed diagnosis U2AF1 c.101C>T p.Ser34Phe 
MDS27 Targetable mutation SF3B1 c.2098A>G p.Lys700Glu 
MDS29 Targetable mutation SF3B1 c.2098A>G p.Lys700Glu 
MDS30 Targetable mutation SF3B1 c.1874G>T p.Arg625Leu 
MDS32 Poor risk TP53 c.722C>T p.Ser241Phe 
MDS33 Poor risk TP53 c.526T>C p.Cys176Arg 
MDS36 Poor risk TP53 c.821T>A p.Val274Asp 
MDS37 Poor risk TP53 c.839G>T p.ArgR280Ile 
MDS38 Poor risk SF3B1 c.1984C>G p.His662Asp 
MDS40 Poor risk SF3B1 c.2098A>G p.Lys700Glu 
MDS41 Targetable mutation IDH2 c.419G>A p.Arg140Gln 
MDS45 Targetable mutation IDH1 c.394C>G p.Arg132Gly 
MDS46 Targetable mutation IDH1 c.395G>A p.Arg132His 
MDS47 Poor risk EZH2 c.1747C>T p.Arg583* 
MDS48 Poor risk TP53 c.568C>A p.Pro190Thr 
MDS54 Poor risk RUNX1 c.167T>C p.Leu56Ser 
MDS60 Poor risk ASXL1 c.1926_1927insG p.Gly646Trpfs*12 
MDS63 Poor risk TP53 c.838A>G p.Arg280Gly 
MDS64 Poor risk TP53 c.839G>C p.Arg280Thr 
MPN14 Confirmed diagnosis ASXL1 c.1926_1927insG p.Gly646Trpfs*12 
MPN17 Confirmed diagnosis RUNX1 c.602G>A p.Arg201Gln 
MPN32 Confirmed diagnosis KRAS c.35G>A p.Gly12Asp 
MPN33 Poor risk ASXL1 c.1926_1927insG p.Gly646Trpfs*12 
Other5 Poor risk ASXL1 c.1926_1927insG p.Gly646Trpfs*12 
Other15 Targetable mutation SF3B1 c.2098A>G p.Lys700Glu 
Other24 Poor risk TP53 c.341T>A p.Lys114* 
Other30 Poor risk ASXL1 c.2077C>T p.Arg693* 
Other58 Good Risk NPM1 c.863_864insTCGG, p.Trp288fs*12 
Other63 Targetable mutation IDH2 c.515G>A p.Arg172Lys 
Other68 Poor risk ASXL1 c.1926_1927insG p.Gly646Trpfs*12 
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Appendix C: List of somatically acquired coding-region 
mutations in 42 CLL genomes 
Sample 
ID Gene Variant Chr Coordinate 
Mutation 
Type 
Amino Acid 
Change 
Read 
Depth 
Variant 
Read 
Depth 
VAF 
CLL003 PLEKHG5 C>C/T 1 6,528,057 Missense Gly1026Arg 42 16 0.38 
CLL158 CASZ1 G>G/A 1 10,706,210 Missense Ser1224Phe 18 11 0.61 
CWL80 CASZ1 C>C/A 1 10,720,395 Missense Arg235Leu 32 12 0.38 
CLL372 PRAMEF4 C>C/A 1 12,942,917 Splice Site - 30 14 0.47 
CLL154 C1orf234 A>A/T 1 23,337,455 Missense Met102Lys 21 11 0.52 
CLL063 RHCE C>C/T 1 25,735,223 Missense Gly96Ser 39 19 0.49 
CLL129 ARID1A C>C/T 1 27,100,925 Nonsense Gln1403Ter 40 12 0.3 
CLL374 BAI2 C>C/T 1 32,198,683 Missense Val1172Ile 28 16 0.57 
CLL366 TMEM234 G>G/C 1 32,682,956 Splice Site - 33 16 0.48 
CLL346 KIAA0319L G>G/T 1 35,900,575 Missense Leu1024Ile 41 17 0.41 
CLL301 IPO13 C>C/T 1 44,433,258 Splice Site - 38 15 0.39 
CLL321 PTCH2 G>G/A 1 45,293,783 Missense Thr597Ile 32 15 0.47 
CLL160 ELAVL4 G>G/A 1 50,663,132 Missense Val273Ile 37 13 0.35 
CLL063 INADL C>C/T 1 62,614,029 Missense Ser1782Leu 30 13 0.43 
CLL348 RABGGTB A>A/T 1 76,255,692 Missense Tyr122Phe 42 20 0.48 
CLL145 LPAR3 G>G/A 1 85,331,529 Missense Pro92Leu 65 25 0.38 
CLL006 ARHGAP29 G>G/A 1 94,650,953 Missense Thr622Met 30 7 0.23 
CLL374 PALMD G>G/A 1 100,133,243 Missense Gly58Arg 41 15 0.37 
CLL348 AGL T>T/G 1 100,336,052 Missense Leu254Arg 38 19 0.5 
CLL372 TRMT13 C>C/G 1 100,606,068 Missense Gln167Glu 45 15 0.33 
CLL307 VCAM1 T>T/A 1 101,194,737 Missense Cys335Ser 38 20 0.53 
CLL158 OVGP1 C>C/G 1 111,962,252 Missense Ala334Pro 32 16 0.5 
CLL369 VANGL1 T>T/C 1 116,206,451 Missense Leu125Pro 50 32 0.64 
CLL145 GJA5 G>G/A 1 147,231,087 Missense Thr87Met 52 21 0.4 
CLL182 PI4KB G>G/C 1 151,288,917 Missense Thr26Ser 27 16 0.59 
CLL364 FLG2 T>T/G 1 152,329,415 Missense Ser283Arg 34 14 0.41 
CLL371 MSTO1 G>G/A 1 155,582,252 Missense Gly286Asp 38 10 0.26 
JB210308 MAEL C>C/T 1 166,958,656 Missense Arg23Trp 26 12 0.46 
CWL80 CCDC181 G>G/A 1 169,364,308 Missense Arg502Cys 42 24 0.57 
CLL330 TNFSF18 A>A/G 1 173,010,861 Splice Site - 38 14 0.37 
CLL321 TNFSF18 T>T/A 1 173,019,974 Missense Arg43Ser 39 17 0.44 
CLL003 SLC9C2 T>T/C 1 173,569,336 Missense Lys50Glu 39 21 0.54 
CLL346 SLC9C2 T>T/C 1 173,570,830 Missense Lys29Arg 31 15 0.48 
CLL307 LAMC2 G>G/A 1 183,204,825 Missense Gly806Ser 36 18 0.5 
CLL347 SWT1 A>A/G 1 185,175,878 Missense Tyr652Cys 36 20 0.56 
CLL342 ASPM G>G/A 1 197,053,473 Missense Thr3472Met 41 19 0.46 
CLL351 ZBTB41 C>C/T 1 197,150,209 Missense Asp529Asn 39 17 0.44 
JB210308 ZBTB41 T>T/C 1 197,160,918 Missense His411Arg 30 12 0.4 
CLL346 LHX9 C>C/T 1 197,890,624 Missense Leu190Phe 31 10 0.32 
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CWL80 KDM5B T>T/A 1 202,718,203 Missense His629Leu 42 14 0.33 
CLL331 KLHL12 A>A/G 1 202,880,288 Missense Val204Ala 34 15 0.44 
CLL332 TMCC2 A>A/G 1 205,238,228 Missense Thr300Ala 34 14 0.41 
CLL305 CAMK1G C>C/T 1 209,779,776 Missense Pro183Ser 19 6 0.32 
CLL331 LAMB3 A>A/C 1 209,788,737 Missense Leu1133Arg 34 11 0.32 
CLL112 ESRRG C>C/T 1 216,850,804 Missense Arg34Gln 44 13 0.3 
CLL342 KIF26B G>G/A 1 245,851,141 Missense Ser1619Asn 33 13 0.39 
CLL003 NLRP3 G>G/T 1 247,592,886 Splice Site - 49 26 0.53 
CLL003 TRIM58 C>C/G 1 248,028,028 Missense Gln180Glu 39 20 0.51 
CLL331 ZNF672 A>A/G 1 249,142,215 Missense Thr248Ala 37 18 0.49 
CLL112 SMC6 T>T/A 2 17,897,517 Missense Asp454Val 34 16 0.47 
CLL321 SMC6 T>T/G 2 17,919,587 Missense Lys82Thr 49 39 0.8 
CLL369 OTOF G>G/A 2 26,696,120 Missense Arg1205Cys 36 15 0.42 
CLL372 OTOF G>G/A 2 26,700,111 Missense Arg818Trp 26 13 0.5 
CLL186 PREB C>C/T 2 27,355,110 Missense Cys305Tyr 25 14 0.56 
CLL369 NDUFAF7 G>G/A 2 37,475,482 Missense Ala439Thr 39 13 0.33 
CLL364 PSME4 G>G/A 2 54,125,078 Nonsense Arg1179Ter 39 14 0.36 
CLL371 XPO1 T>T/C 2 61,719,471 Missense Glu571Gly 42 11 0.26 
CLL342 WDPCP C>C/T 2 63,631,276 Missense Val448Ile 30 14 0.47 
CLL130 VAX2 C>C/T 2 71,148,389 Missense Arg137Cys 24 11 0.46 
CLL077 EXOC6B G>G/C 2 72,802,673 Missense Ser265Cys 52 19 0.37 
CLL331 CCT7 G>G/A 2 73,466,870 Missense Val36Ile 39 15 0.38 
CLL364 LRRTM4 C>C/T 2 77,746,963 Missense Gly11Asp 31 11 0.35 
CLL369 CTNNA2 A>A/C 2 80,782,932 Missense His552Pro 30 10 0.33 
CLL347 ZNF514 T>T/A 2 95,815,443 Missense Ser263Cys 40 18 0.45 
CLL301 DUSP2 A>A/C 2 96,809,596 Missense Leu304Arg 31 16 0.52 
CLL149 KIAA1211L A>A/G 2 99,411,057 Missense Trp943Arg 37 17 0.46 
CLL372 MAP4K4 TA>TA/T 2 102,504,401 Splice Site - 33 13 0.39 
CLL372 IL1RL2 T>T/C 2 102,851,455 Missense Ser466Pro 46 11 0.24 
CLL348 CNTNAP5 C>C/A 2 125,284,856 Splice Site - 45 32 0.71 
CLL344 WDR33 G>G/A 2 128,477,186 Missense His805Tyr 34 17 0.5 
CLL305 LCT A>A/G 2 136,575,246 Missense Ser458Pro 31 12 0.39 
CWL80 NEB G>G/C 2 152,382,708 Missense Ile7338Met 39 15 0.38 
CLL366 PKP4 T>T/G 2 159,526,318 Missense Cys939Gly 50 11 0.22 
CLL171 FAP A>A/G 2 163,059,661 Splice Site - 63 24 0.38 
CLL348 SCN2A T>T/C 2 166,243,509 Missense Val1602Ala 36 7 0.19 
CWL80 SCN2A G>G/C 2 166,245,905 Missense Lys1863Asn 29 13 0.45 
CLL371 ABCB11 G>G/A 2 169,828,351 Splice Site - 44 16 0.36 
CLL144 KIAA1715 T>T/G 2 176,794,920 Missense Leu354Phe 36 17 0.47 
CLL330 TTN A>A/T 2 179,426,199 Missense Asp28220Glu 31 18 0.58 
CLL347 PMS1 G>G/T 2 190,719,352 Nonsense Glu452Ter 46 28 0.61 
CLL154 STAT4 A>A/C 2 191,929,687 Splice Site - 32 12 0.38 
CLL252 DNAH7 G>G/A 2 196,740,516 Nonsense Gln2057Ter 30 14 0.47 
CLL160 SF3B1 C>C/T 2 198,266,611 Missense Gly742Asp 45 15 0.33 
CLL305 SF3B1 C>C/T 2 198,266,713 Missense Gly740Glu 39 11 0.28 
CLL158 SF3B1 A>A/T 2 198,266,821 Missense Ile704Asn 31 13 0.42 
 
 
237 
 
CLL171 SF3B1 T>T/A 2 198,266,822 Missense Ile704Phe 40 17 0.43 
CLL003 SF3B1 T>T/C 2 198,266,834 Missense Lys700Glu 45 21 0.47 
CLL112 SF3B1 T>T/C 2 198,266,834 Missense Lys700Glu 42 19 0.45 
CLL145 SF3B1 T>T/C 2 198,266,834 Missense Lys700Glu 49 22 0.45 
CLL307 SF3B1 T>T/C 2 198,266,834 Missense Lys700Glu 30 19 0.63 
CLL130 SF3B1 T>T/C 2 198,267,361 Missense Lys666Glu 53 22 0.42 
CLL369 SF3B1 G>G/A 2 198,267,484 Missense Arg625Cys 42 19 0.45 
CLL156 SF3B1 T>T/C 2 198,267,489 Missense Tyr623Cys 42 13 0.31 
CLL129 SF3B1 C>C/G 2 198,267,491 Missense Glu622Asp 42 19 0.45 
CLL332 SF3B1 C>C/A 2 198,267,491 Missense Glu622Asp 33 10 0.3 
CLL347 AOX1 G>G/C 2 201,515,919 Missense Gly1024Arg 26 7 0.27 
CLL186 ABCA12 G>G/A 2 215,843,102 Missense Ala1689Val 27 15 0.56 
CLL330 FN1 G>G/A 2 216,286,817 Nonsense Arg515Ter 45 17 0.38 
CLL330 TNS1 G>G/A 2 218,712,872 Missense Arg665Cys 19 8 0.42 
CLL130 TNS1 A>A/G 2 218,750,770 Missense Ile221Thr 38 15 0.39 
CLL330 PAX3 G>G/A 2 223,161,923 Missense Pro32Leu 34 15 0.44 
CLL371 IRS1 G>G/A 2 227,662,157 Missense Ser433Phe 32 9 0.28 
CLL345 AGAP1 G>G/A 2 237,032,743 Missense Gly851Arg 19 13 0.68 
CLL186 HES6 C>C/T 2 239,147,581 Missense Ala188Thr 28 15 0.54 
CWL80 ZNF860 T>T/G 3 32,031,179 Missense Ile203Ser 42 11 0.26 
CLL346 ARPP21 
GGATAAAAAC
AAA>GGATAA
AAACAAA/G 
3 35,729,320 Indel Asp118_Lys121delinsdel 39 16 0.41 
CLL171 MYD88 C>C/G 3 38,182,032 Missense Ser219Cys 39 14 0.36 
CLL344 MYD88 T>T/C 3 38,182,641 Missense Leu273Pro 22 11 0.5 
CLL186 FAM198A G>G/C 3 43,074,354 Missense Gly200Ala 38 22 0.58 
CLL006 MAP4 T>T/C 3 47,898,936 Missense Ile1045Val 42 14 0.33 
CLL305 DNAH1 T>T/C 3 52,360,195 Missense Met149Thr 35 15 0.43 
CWL80 PTPRG G>G/A 3 62,189,079 Missense Arg537His 23 9 0.39 
CLL301 CADPS C>C/T 3 62,388,836 Missense Val1268Met 44 18 0.41 
CLL348 CADPS C>C/T 3 62,636,542 Missense Val395Met 48 11 0.23 
CLL144 MAGI1 T>T/G 3 65,422,862 Missense Asn444Thr 34 15 0.44 
CLL301 PDZRN3 G>G/A 3 73,432,532 Missense Ser1062Leu 38 20 0.53 
CLL364 PDZRN3 C>C/T 3 73,673,717 Missense Arg87His 39 14 0.36 
CLL149 ZNF717 T>T/G 3 75,790,493 Missense Ile71Leu 140 14 0.1 
CLL350 ROBO2 G>G/A 3 77,572,051 Missense Arg327Gln 44 8 0.18 
CLL305 ROBO1 G>G/A 3 78,663,819 Missense Arg1472Cys 41 11 0.27 
CLL371 LINC00971 A>A/T 3 84,744,510 Splice Site - 34 19 0.56 
CLL145 CADM2 G>G/T 3 85,932,593 Missense Gly124Cys 71 28 0.39 
CLL331 KIAA1407 G>G/A 3 113,737,706 Missense Arg328Trp 35 17 0.49 
CLL331 GTF2E1 C>C/G 3 120,500,126 Missense Arg377Gly 33 18 0.55 
CLL186 GOLGB1 TG>TG/T 3 121,414,228 Indel Thr1714LysfsTer16 32 10 0.31 
CLL154 IQCB1 G>G/A 3 121,491,506 Nonsense Arg489Ter 38 18 0.47 
CLL372 ALDH1L1 C>C/T 3 125,855,672 Missense Gly437Arg 47 24 0.51 
CLL369 KBTBD12 G>G/A 3 127,642,243 Missense Met113Ile 46 16 0.35 
CLL331 PLXND1 G>G/C 3 129,285,429 Missense Leu1378Val 31 13 0.42 
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CLL369 COL6A6 C>C/T 3 130,282,383 Missense Thr179Met 51 21 0.41 
CLL301 RYK A>A/G 3 133,910,706 Missense Cys337Arg 31 12 0.39 
CLL366 AMOTL2 G>G/A 3 134,078,211 Missense Ala673Val 31 17 0.55 
CLL301 SOX14 G>G/A 3 137,484,309 Missense Gly228Asp 26 11 0.42 
CLL130 PLS1 T>T/C 3 142,402,993 Missense Ile242Thr 39 16 0.41 
CLL307 PLSCR4 T>T/C 3 145,917,655 Missense Gln190Arg 37 18 0.49 
CLL186 TSC22D2 G>G/A 3 150,128,527 Missense Gly464Ser 34 12 0.35 
CLL321 SLC33A1 T>T/C 3 155,547,682 Missense Tyr426Cys 39 22 0.56 
CLL154 SLITRK3 T>T/G 3 164,908,641 Splice Site - 42 18 0.43 
CLL154 SLITRK3 G>G/T 3 164,908,642 Splice Site - 41 18 0.44 
CLL144 KLHL6 C>C/T 3 183,211,965 Missense Val418Met 28 12 0.43 
CLL348 KLHL6 A>A/T 3 183,273,179 Missense Val88Glu 31 15 0.48 
CLL348 KLHL6 A>A/G 3 183,273,242 Missense Met67Thr 33 12 0.36 
CLL348 KLHL6 G>G/C 3 183,273,246 Missense Arg66Gly 33 12 0.36 
CLL301 DGKG G>G/T 3 185,970,894 Missense Arg530Ser 33 11 0.33 
CLL006 C3orf43 C>C/A 3 196,242,031 Missense Arg17Ile 28 12 0.43 
CLL301 KIAA0226 A>A/G 3 197,401,948 Missense Tyr954His 31 12 0.39 
CLL145 TMEM129 C>C/T 4 1,722,396 Missense Ala57Thr 47 24 0.51 
CLL158 TMEM129 A>A/G 4 1,722,458 Missense Leu36Pro 39 19 0.49 
CLL144 WFS1 C>C/A 4 6,279,318 Missense Pro46Thr 37 13 0.35 
CLL364 WFS1 G>G/A 4 6,302,843 Missense Val441Met 40 15 0.38 
CLL348 PROM1 C>C/T 4 15,989,305 Missense Arg704His 39 15 0.38 
CLL129 KDR G>G/A 4 55,991,411 Missense Thr17Ile 34 10 0.29 
CWL80 CEP135 C>C/T 4 56,818,360 Missense Arg22Cys 39 8 0.21 
CLL171 AASDH G>G/A 4 57,204,917 Missense Pro983Leu 72 33 0.46 
CWL80 UGT2B11 G>G/C 4 70,080,232 Missense Ser70Cys 31 8 0.26 
CLL003 AMTN C>C/T 4 71,396,909 Missense Arg171Cys 34 10 0.29 
CLL347 ADAMTS3 A>A/T 4 73,184,400 Missense Asp458Glu 35 11 0.31 
CLL346 AFM G>G/GT 4 74,347,531 Indel Leu16PhefsTer3 37 20 0.54 
CLL307 RASSF6 A>A/T 4 74,442,412 Missense Leu285Gln 29 13 0.45 
CLL344 RASSF6 T>T/G 4 74,459,160 Splice Site - 31 9 0.29 
CLL144 CDS1 G>G/A 4 85,504,636 Missense Gly28Ser 38 18 0.47 
CLL374 ABCG2 C>C/T 4 89,015,811 Missense Ala580Thr 37 17 0.46 
CLL321 MMRN1 C>C/G 4 90,874,276 Missense Pro1132Ala 29 13 0.45 
CLL305 MTTP A>A/C 4 100,512,476 Missense Ile196Leu 35 11 0.31 
CLL369 ANK2 T>T/C 4 114,278,689 Missense Val2972Ala 53 29 0.55 
CLL372 QRFPR T>T/G 4 122,250,611 Missense Glu385Ala 40 19 0.48 
CLL003 ADAD1 T>T/A 4 123,304,983 Missense Cys131Ser 37 19 0.51 
CLL351 FAT4 C>C/A 4 126,336,381 Missense Thr2088Asn 40 15 0.38 
CLL154 FAT4 G>G/T 4 126,371,628 Missense Asp3153Tyr 40 14 0.35 
CLL348 INTU T>T/G 4 128,564,730 Nonsense Tyr67Ter 45 24 0.53 
CLL372 FREM3 C>C/T 4 144,620,949 Missense Val294Met 44 18 0.41 
CLL171 OTUD4 T>T/C 4 146,059,289 Missense Ile815Val 58 25 0.43 
CLL330 FBXW7 T>T/A 4 153,247,310 Missense Met498Leu 33 15 0.45 
CLL305 FGA C>C/T 4 155,509,966 Missense Gly115Ser 41 11 0.27 
CLL374 SPOCK3 C>C/A 4 167,833,859 Missense Arg132Met 40 22 0.55 
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CLL156 VEGFC G>G/T 4 177,632,668 Missense Pro230Gln 50 10 0.2 
CLL321 FAT1 C>C/T 4 187,534,362 Missense Ala3122Thr 37 17 0.46 
CLL346 FAT1 C>C/G 4 187,628,094 Missense Arg963Thr 38 16 0.42 
CLL364 FAT1 C>C/T 4 187,628,602 Missense Val794Ile 32 11 0.34 
CLL342 FAT1 T>T/A 4 187,630,609 Nonsense Lys125Ter 40 22 0.55 
CLL144 PLEKHG4B C>C/T 5 171,380 Missense Arg935Trp 26 14 0.54 
CLL331 KIAA0947 T>T/C 5 5,447,828 Splice Site - 64 24 0.38 
CLL252 40603 T>T/G 5 16,067,822 Missense Asn323His 32 8 0.25 
CLL171 CDH12 C>C/T 5 21,842,354 Missense Gly244Arg 37 18 0.49 
CLL252 CDH12 C>C/T 5 22,078,749 Missense Val13Ile 47 14 0.3 
CLL145 PRDM9 C>C/T 5 23,522,473 Missense Ala190Val 67 30 0.45 
CLL347 CDH10 T>T/A 5 24,537,560 Missense Asp152Val 38 14 0.37 
CLL171 C5orf22 G>G/T 5 31,552,890 Missense Asp404Tyr 61 20 0.33 
CLL145 PDZD2 C>C/T 5 32,052,757 Missense Thr569Met 42 20 0.48 
CLL374 PDZD2 G>G/C 5 32,090,702 Missense Gly2383Ala 39 17 0.44 
CLL144 SPEF2 A>A/C 5 35,793,438 Missense Met1578Leu 42 13 0.31 
CLL348 IL7R A>A/G 5 35,876,487 Missense Thr427Ala 32 8 0.25 
CLL374 UGT3A1 G>G/A 5 35,954,333 Missense Arg515Cys 39 15 0.38 
CLL345 DAB2 G>G/A 5 39,390,614 Missense Arg132Trp 40 20 0.5 
CLL369 PAPD4 C>C/G 5 78,919,184 Missense Arg113Gly 40 16 0.4 
CLL366 ACOT12 C>C/A 5 80,643,687 Nonsense Glu187Ter 35 8 0.23 
CLL372 ARRDC3 GTC>GTC/G 5 90,670,824 Indel Glu261AspfsTer20 48 19 0.4 
CLL330 ARRDC3 T>T/C 5 90,678,723 Missense Arg63Gly 38 20 0.53 
CLL129 KCNN2 C>C/A 5 113,698,547 Missense His25Gln 37 23 0.62 
CLL321 DMXL1 C>C/T 5 118,533,442 Splice Site - 26 9 0.35 
CLL301 SLC12A2 G>G/T 5 127,516,625 Missense Asp1051Tyr 38 16 0.42 
CLL364 FBN2 G>G/A 5 127,670,870 Missense Thr1322Ile 40 10 0.25 
CLL372 FBN2 G>G/A 5 127,872,095 Missense Pro113Ser 38 14 0.37 
CLL307 RAD50 A>A/G 5 131,977,898 Missense Asn1261Asp 43 27 0.63 
CLL003 SHROOM1 A>A/G 5 132,160,714 Missense Ser344Pro 48 23 0.48 
CLL371 WNT8A G>G/A 5 137,426,659 Nonsense Trp318Ter 31 14 0.45 
CLL160 PCDHB3 CT>CT/C 5 140,482,214 Indel Leu661ProfsTer79 23 11 0.48 
CLL369 PCDHB8 C>C/T 5 140,558,459 Missense Leu282Phe 72 20 0.28 
CLL149 RNF14 C>C/T 5 141,353,281 Missense Pro43Leu 31 14 0.45 
CLL347 SH3RF2 G>G/A 5 145,428,816 Splice Site - 33 8 0.24 
CLL144 PPP2R2B A>A/C 5 145,969,658 Missense Val398Gly 36 17 0.47 
CLL374 FBXO38 CT>CT/C 5 147,812,978 Splice Site - 43 16 0.37 
CLL348 ABLIM3 C>C/A 5 148,630,028 Missense Ser583Tyr 34 13 0.38 
JB210308 KIF4B T>T/C 5 154,394,237 Missense Val273Ala 39 13 0.33 
CLL348 GABRA1 A>A/G 5 161,324,181 Missense Tyr375Cys 36 12 0.33 
CLL348 FGF18 C>C/A 5 170,883,805 Missense Ala207Asp 27 15 0.56 
CLL344 SH3PXD2B T>T/A 5 171,766,452 Missense Thr553Ser 31 14 0.45 
CLL186 SH3PXD2B G>G/A 5 171,774,312 Missense Pro346Leu 34 21 0.62 
CLL342 MGAT1 G>G/A 5 180,219,755 Nonsense Gln73Ter 31 8 0.26 
CLL144 PXDC1 C>C/T 6 3,738,356 Missense Asp95Asn 35 16 0.46 
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CLL372 DSP C>C/T 6 7,581,486 Missense Ala1688Val 34 20 0.59 
CLL301 CD83 C>C/T 6 14,118,264 Missense Pro41Ser 48 20 0.42 
CLL149 HIST1H2AG C>C/T 6 27,101,100 Missense Leu84Phe 26 10 0.38 
CLL301 HIST1H2BM C>C/G 6 27,782,831 Missense Pro4Ala 40 17 0.43 
CLL366 OR2B6 G>G/T 6 27,925,466 Missense Val150Phe 30 13 0.43 
CLL144 ZNF311 T>T/G 6 28,963,397 Missense His461Pro 50 24 0.48 
CWL80 PRRC2A C>C/T 6 31,603,374 Nonsense Arg1797Ter 37 19 0.51 
CLL182 ZBTB22 C>C/T 6 33,283,955 Missense Val247Ile 33 13 0.39 
CLL348 KIF6 A>A/G 6 39,607,414 Missense Leu124Pro 36 19 0.53 
CLL351 DAAM2 C>C/T 6 39,846,218 Missense Arg467Trp 38 14 0.37 
CLL347 PTK7 G>G/T 6 43,112,282 Missense Arg790Leu 34 12 0.35 
CLL305 NFKBIE TGTAA>TGTAA/T 6 44,232,738 Indel Tyr254SerfsTer13 29 10 0.34 
CLL112 TNFRSF21 G>G/A 6 47,200,590 Missense Arg627Trp 31 17 0.55 
CLL305 TFAP2D C>C/T 6 50,740,501 Missense Ala428Val 36 10 0.28 
CLL144 PKHD1 C>C/A 6 51,512,894 Missense Gly3778Val 43 19 0.44 
CLL144 PKHD1 A>A/T 6 51,524,477 Missense Phe3483Ile 48 18 0.38 
CLL112 HMGCLL1 G>G/T 6 55,378,954 Missense Ala175Glu 53 27 0.51 
CLL301 COL21A1 A>A/T 6 55,988,882 Nonsense Leu579Ter 31 11 0.35 
CLL350 RIMS1 C>C/G 6 72,889,572 Missense Gln256Glu 34 11 0.32 
CLL144 KHDC1 A>A/C 6 74,019,377 Missense Tyr21Asp 39 9 0.23 
CLL129 KHDC3L C>C/T 6 74,073,459 Missense Ala177Val 35 17 0.49 
CLL364 EPHA7 A>A/C 6 93,967,229 Missense Met708Arg 38 11 0.29 
CLL347 PNISR CCT>CCT/C 6 99,848,839 Indel Arg665GlufsTer10 37 18 0.49 
CLL331 USP45 T>T/A 6 99,914,598 Missense Ile353Phe 39 21 0.54 
CLL344 AK9 T>T/A 6 109,837,076 Missense Tyr1350Phe 31 10 0.32 
CLL346 TRMT11 A>A/T 6 126,333,974 Missense Lys328Met 37 16 0.43 
CLL331 THEMIS G>G/C 6 128,134,980 Nonsense Ser269Ter 45 19 0.42 
CLL374 SGK1 G>G/C 6 134,495,183 Missense Pro158Arg 33 15 0.45 
CLL321 MAP7 G>G/A 6 136,667,042 Missense Leu761Phe 38 19 0.5 
CLL372 PDE10A C>C/A 6 165,832,148 Missense Val325Phe 16 9 0.56 
CLL112 KIF25 G>G/T 6 168,443,240 Splice Site - 33 11 0.33 
CLL171 IQCE C>C/T 7 2,627,479 Missense Arg338Trp 48 16 0.33 
CLL182 CYTH3 A>A/G 7 6,210,177 Missense Leu271Pro 29 13 0.45 
CLL171 ISPD G>G/T 7 16,298,032 Missense Pro368Thr 69 29 0.42 
CWL80 DNAH11 T>T/C 7 21,856,121 Missense Ile3464Thr 40 15 0.38 
CLL364 EVX1 G>G/A 7 27,284,672 Missense Gly145Ser 27 9 0.33 
CLL372 BMPER G>G/A 7 34,125,473 Missense Arg505His 49 18 0.37 
CLL348 AOAH T>T/C 7 36,634,006 Missense Thr293Ala 37 22 0.59 
CLL369 DBNL A>A/C 7 44,099,154 Missense Glu324Ala 31 11 0.35 
CLL158 PKD1L1 C>C/T 7 47,933,601 Missense Arg776Gln 27 15 0.56 
CLL347 SUN3 T>T/C 7 48,026,979 Missense Tyr341Cys 39 14 0.36 
JB210308 DDC C>C/T 7 50,571,751 Missense Ala241Thr 39 10 0.26 
CLL144 COBL T>T/G 7 51,096,337 Missense Lys819Thr 33 15 0.45 
CLL006 EGFR TG>TG/T 7 55,227,941 Indel Cys470SerfsTer6 42 20 0.48 
CLL347 CRCP A>A/G 7 65,599,285 Missense Lys55Glu 28 11 0.39 
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CLL112 MAGI2 G>G/T 7 77,885,444 Missense Asp621Glu 30 11 0.37 
CLL330 SEMA3C G>G/A 7 80,418,712 Missense Arg422Cys 40 21 0.53 
CLL006 PCLO A>A/T 7 82,582,369 Missense Ser2634Thr 46 13 0.28 
CLL063 SEMA3A A>A/G 7 83,606,456 Missense Leu570Ser 49 20 0.41 
CLL186 ASB4 G>G/A 7 95,157,380 Missense Arg248Gln 37 8 0.22 
CLL372 ZSCAN25 C>C/T 7 99,219,105 Missense Pro166Leu 44 23 0.52 
CLL006 PILRB G>G/T 7 99,956,959 Splice Site - 42 16 0.38 
CLL330 MUC3A C>C/G 7 100,552,712 Nonsense Ser1098Ter 53 18 0.34 
CLL348 MUC17 C>C/G 7 100,680,615 Missense Thr1973Ser 21 7 0.33 
CLL369 PSMC2 G>G/A 7 103,008,377 Missense Gly393Asp 32 15 0.47 
CWL80 RELN G>G/A 7 103,155,701 Missense Arg2684Cys 44 14 0.32 
CLL158 PNPLA8 T>T/TA 7 108,155,909 Indel Tyr10IlefsTer6 47 20 0.43 
CLL145 POT1 C>C/A 7 124,503,668 Missense Gln94His 53 13 0.25 
CLL347 BRAF T>T/C 7 140,453,193 Missense Asn581Ser 38 9 0.24 
CLL364 CLEC5A T>T/C 7 141,646,016 Missense Tyr26Cys 48 13 0.27 
CLL321 MGAM C>C/T 7 141,759,267 Splice Site - 29 14 0.48 
CLL252 MGAM G>G/A 7 141,759,672 Missense Gly1322Asp 44 14 0.32 
CLL003 KMT2C 
ATTGCCAACCT
GCACG>ATTGC
CAACCTGCACG
/A 
7 151,962,154 Indel Arg380_Gln384delinsdel 88 6 0.07 
CLL344 LOC100996700 G>G/C 7 153,932,892 Missense Trp9Ser 38 15 0.39 
CLL346 FBXO25 C>C/G 8 382,894 Missense Arg83Gly 56 29 0.52 
CLL345 GATA4 T>T/G 8 11,566,282 Missense Phe154Cys 20 8 0.4 
CLL129 FAM86B1 G>G/A 8 12,044,011 Nonsense Arg164Ter 44 6 0.14 
CLL063 MICU3 T>T/TA 8 16,942,809 Indel Glu256ArgfsTer14 51 20 0.39 
CLL006 CNOT7 G>G/A 8 17,088,342 Missense His249Tyr 45 15 0.33 
CLL003 MTUS1 C>C/A 8 17,507,447 Nonsense Glu1137Ter 47 18 0.38 
CLL331 MTUS1 T>T/A 8 17,611,963 Nonsense Lys452Ter 32 16 0.5 
CLL344 CLU G>G/C 8 27,466,610 Splice Site - 39 16 0.41 
CLL186 TEX15 G>G/T 8 30,704,711 Missense Thr608Asn 39 19 0.49 
CLL145 NRG1 C>C/A 8 32,453,520 Missense Pro92Gln 67 21 0.31 
CLL145 NRG1 G>G/T 8 32,453,522 Missense Gly93Trp 66 21 0.32 
CLL346 KCNU1 T>T/C 8 36,768,622 Missense Ser836Pro 25 7 0.28 
CLL006 LINC00293 C>C/T 8 47,757,708 Splice Site - 38 16 0.42 
CLL063 OPRK1 G>G/A 8 54,147,555 Missense Pro125Leu 41 16 0.39 
CLL347 RGS20 C>C/T 8 54,852,163 Missense Arg180Trp 30 9 0.3 
CLL371 CHD7 A>A/T 8 61,765,885 Nonsense Lys2201Ter 28 15 0.54 
CLL182 TRPA1 C>C/T 8 72,964,955 Missense Val564Ile 28 14 0.5 
CLL330 IL7 C>C/T 8 79,710,366 Missense Glu30Lys 42 18 0.43 
CLL307 MMP16 C>C/A 8 89,198,807 Missense Cys101Phe 21 10 0.48 
JB210308 VPS13B C>C/T 8 100,829,849 Nonsense Gln2752Ter 41 19 0.46 
CLL063 CSMD3 A>A/G 8 113,303,792 Missense Val2974Ala 40 21 0.53 
CLL144 COL14A1 G>G/A 8 121,209,122 Missense Val177Ile 32 15 0.47 
CLL344 ATAD2 A>A/G 8 124,358,860 Splice Site - 39 16 0.41 
CLL171 ASAP1 T>T/C 8 131,140,307 Missense Glu416Gly 46 13 0.28 
CLL321 KHDRBS3 C>C/A 8 136,594,147 Missense Pro213Gln 26 6 0.23 
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CLL129 FAM135B G>G/A 8 139,164,244 Missense Ala825Val 39 23 0.59 
CLL144 DENND3 
ACAGGTAACA
GCAT>ACAGGT
AACAGCAT/A 
8 142,202,432 Indel Gly1049TrpfsTer3 29 13 0.45 
CLL186 LY6D T>T/G 8 143,866,816 Missense Ser70Arg 22 9 0.41 
CLL144 GLIS3 G>G/A 9 3,937,028 Splice Site - 31 16 0.52 
CLL330 PTPRD T>T/C 9 8,486,190 Missense Lys876Arg 37 21 0.57 
CLL332 TYRP1 C>C/T 9 12,695,565 Missense Arg146Trp 40 16 0.4 
CLL129 FREM1 C>C/A 9 14,769,744 Missense Gly1728Trp 48 14 0.29 
CLL372 ADAMTSL1 C>C/T 9 18,721,614 Missense Arg653Trp 37 19 0.51 
CLL344 RPS6 C>C/T 9 19,376,365 Missense Glu226Lys 24 8 0.33 
CLL346 MLLT3 C>C/A 9 20,413,939 Missense Ser302Ile 47 24 0.51 
CLL003 IL11RA C>C/T 9 34,655,300 Missense Ala29Val 32 18 0.56 
CLL301 FAM214B G>G/T 9 35,107,995 Missense Pro93Thr 40 15 0.38 
CLL346 LOC100996689 C>C/T 9 66,454,921 Missense Gly275Arg 84 6 0.07 
CLL347 TMEM2 G>G/A 9 74,315,561 Missense Thr1125Met 44 20 0.45 
CLL063 GCNT1 C>C/T 9 79,118,139 Missense Pro281Leu 40 16 0.4 
CLL371 PRUNE2 C>C/T 9 79,244,178 Missense Val3027Ile 35 15 0.43 
CLL077 TLE4 C>C/CA 9 82,323,058 Indel Ser323ValfsTer9 50 11 0.22 
CLL154 WNK2 C>C/T 9 96,070,874 Splice Site - 28 13 0.46 
CLL342 FSD1L G>G/A 9 108,296,776 Missense Ser343Asn 30 12 0.4 
CLL182 ZNF462 C>C/T 9 109,691,847 Missense Pro1885Leu 32 9 0.28 
CLL351 SVEP1 C>C/T 9 113,173,761 Missense Arg2077His 42 19 0.45 
CLL330 LPAR1 C>C/T 9 113,703,772 Missense Arg241Gln 40 21 0.53 
CLL321 CDK5RAP2 G>G/A 9 123,182,182 Missense Ser1354Leu 39 19 0.49 
CLL156 TTLL11 G>G/A 9 124,801,635 Missense Arg249Trp 40 17 0.43 
CLL351 ZBTB6 T>T/C 9 125,673,189 Missense Asp388Gly 34 11 0.32 
CLL345 STRBP 
CATTTTCTAAC
AGTAAAA>CAT
TTTCTAACAGT
AAAA/C 
9 125,923,342 Splice Site - 36 11 0.31 
CLL374 TTC16 C>C/T 9 130,485,392 Splice Site - 24 7 0.29 
CLL003 SPTAN1 G>G/C 9 131,340,459 Missense Ala386Pro 43 13 0.3 
CLL112 POMT1 C>C/A 9 134,382,812 Missense Ala113Asp 39 21 0.54 
CLL301 SETX T>T/G 9 135,140,240 Missense Thr2474Pro 35 16 0.46 
CLL369 DDX31 C>C/T 9 135,536,620 Missense Val248Ile 39 25 0.64 
CLL342 REXO4 G>G/A 9 136,279,924 Missense Pro145Ser 42 17 0.4 
CLL130 NOTCH1 CAG>CAG/C 9 139,390,648 Indel Pro2514ArgfsTer4 40 16 0.4 
CLL186 NOTCH1 CAG>CAG/C 9 139,390,648 Indel Pro2514ArgfsTer4 36 12 0.33 
CLL331 NOTCH1 CAG>CAG/C 9 139,390,648 Indel Pro2514ArgfsTer4 36 13 0.36 
JB210308 NOTCH1 CAG>CAG/C 9 139,390,648 Indel Pro2514ArgfsTer4 22 13 0.59 
CLL158 NOTCH1 G>G/T 9 139,390,678 Missense Pro2505Thr 30 9 0.3 
CLL369 FBXW5 C>C/T 9 139,835,384 Missense Arg566His 32 11 0.34 
CLL003 EXD3 C>C/T 9 140,245,984 Splice Site - 54 19 0.35 
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CLL321 WDR37 C>C/T 10 1,132,303 Splice Site - 26 13 0.5 
CLL252 MSRB2 G>G/T 10 23,408,297 Missense Gly121Cys 32 12 0.38 
CLL171 KIAA1217 C>C/T 10 24,822,021 Missense Pro1090Leu 37 18 0.49 
CLL077 GPR158 C>C/T 10 25,888,057 Nonsense Arg1168Ter 47 18 0.38 
CLL346 PTCHD3 A>A/AT 10 27,687,469 Indel Asn686LysfsTer6 41 13 0.32 
CLL129 ANKRD30A C>C/T 10 37,508,487 Missense His1227Tyr 42 18 0.43 
CLL371 C10orf71 AC>AC/A 10 50,532,583 Indel His666ThrfsTer3 33 15 0.45 
CLL372 CHAT C>C/T 10 50,833,607 Missense Arg281Trp 36 15 0.42 
CLL351 ANK3 G>G/T 10 61,898,734 Missense Ala909Glu 46 26 0.57 
CLL186 EGR2 G>G/T 10 64,573,248 Missense His384Asn 34 14 0.41 
CLL330 EGR2 C>C/T 10 64,573,332 Missense Glu356Lys 30 8 0.27 
CLL130 TACR2 C>C/T 10 71,175,920 Missense Val54Ile 31 17 0.55 
CLL301 UNC5B C>C/T 10 73,044,512 Missense Arg114Trp 32 11 0.34 
CLL348 UNC5B G>G/T 10 73,053,326 Missense Trp646Leu 28 11 0.39 
CLL307 CDH23 C>C/T 10 73,461,867 Missense Thr829Ile 32 9 0.28 
CLL145 USP54 C>C/T 10 75,302,775 Splice Site - 58 16 0.28 
CLL332 CAMK2G G>G/A 10 75,579,350 Missense Arg403Trp 44 20 0.45 
CLL130 KAT6B T>T/C 10 76,790,464 Missense Met1961Thr 35 17 0.49 
CLL130 KCNMA1 A>A/T 10 78,649,280 Nonsense Tyr1130Ter 32 14 0.44 
CLL171 SORBS1 G>G/C 10 97,174,349 Missense Pro238Ala 53 18 0.34 
CLL351 MRPL43 A>A/G 10 102,747,068 Splice Site - 29 13 0.45 
CLL129 HPS6 C>C/T 10 103,826,400 Missense Ala390Val 30 14 0.47 
CLL145 PPRC1 A>A/T 10 103,892,826 Initiator Met1 45 14 0.31 
CLL112 PPRC1 CAT>CAT/C 10 103,901,047 Indel His928ArgfsTer87 52 20 0.38 
CLL145 SLK A>A/G 10 105,727,659 Splice Site - 34 11 0.32 
CLL351 BBIP1 CATT>CATT/C 10 112,660,259 Indel Asn98del 57 27 0.47 
CLL351 ENO4 T>T/C 10 118,630,628 Splice Site - 51 30 0.59 
CLL003 SLC18A2 T>T/C 10 119,026,492 Splice Site - 54 14 0.26 
CLL369 TACC2 C>C/T 10 123,844,891 Missense Ser959Leu 34 11 0.32 
CLL350 TACC2 G>G/A 10 123,997,536 Missense Glu2778Lys 32 12 0.38 
CLL063 DMBT1 A>A/T 10 124,380,792 Missense Asp1706Val 46 20 0.43 
CLL369 IKZF5 C>C/T 10 124,754,167 Missense Arg130His 44 26 0.59 
CLL145 TALDO1 T>T/A 11 763,742 Splice Site - 45 20 0.44 
CLL332 SLC25A22 G>G/C 11 792,960 Missense Leu108Val 31 11 0.35 
CLL369 MUC2 C>C/G 11 1,092,941 Missense Thr1586Ser 111 7 0.06 
CLL321 MUC5B A>A/G 11 1,265,854 Missense Thr2582Ala 18 8 0.44 
CLL321 DNHD1 A>A/C 11 6,532,648 Missense Ile461Leu 40 19 0.48 
CLL305 PDE3B C>C/A 11 14,854,278 Missense Thr702Asn 39 12 0.31 
CLL369 PIK3C2A T>T/C 11 17,190,732 Missense Tyr186Cys 36 11 0.31 
CLL347 OTOG C>C/A 11 17,590,706 Missense Gln562Lys 32 16 0.5 
CLL129 IGSF22 C>C/A 11 18,733,731 Missense Val766Leu 35 19 0.54 
CLL348 ANO5 C>C/G 11 22,283,687 Missense Thr548Arg 37 11 0.3 
CLL366 BBOX1 A>A/G 11 27,114,885 Missense Met169Val 32 11 0.34 
CLL158 CAPRIN1 AAC>AAC/A 11 34,104,528 Indel Gln304ValfsTer5 40 21 0.53 
CLL158 CAPRIN1 TAC>TAC/T 11 34,118,133 Indel Tyr605Ter 33 18 0.55 
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CLL171 F2 G>G/A 11 46,748,114 Missense Arg314His 33 13 0.39 
CLL371 MYBPC3 A>A/C 11 47,359,005 Missense Tyr847Asp 28 13 0.46 
CWL80 OR4C15 T>T/A 11 55,322,485 Missense Tyr235Asn 29 13 0.45 
CLL331 OR5M8 A>A/T 11 56,258,348 Missense Phe167Ile 35 14 0.4 
CLL305 TNKS1BP1 C>C/T 11 57,080,906 Missense Arg419His 39 11 0.28 
CLL331 FAM111B C>C/T 11 58,892,585 Missense Arg339Cys 45 22 0.49 
CLL351 SLC15A3 A>A/C 11 60,706,987 Missense Leu467Arg 43 14 0.33 
CLL372 FADS2 G>G/A 11 61,630,541 Missense Arg327Lys 35 12 0.34 
CLL345 NXF1 A>A/C 11 62,568,594 Missense Leu293Arg 36 10 0.28 
CLL077 PLA2G16 C>C/T 11 63,342,473 Missense Ala145Thr 50 18 0.36 
CLL366 PLCB3 CAGGT>CAGGT/C 11 64,032,697 Splice Site - 31 9 0.29 
CLL345 KCNK4 C>C/T 11 64,064,648 Missense Ala124Val 26 9 0.35 
CLL186 PACS1 A>A/G 11 66,001,717 Splice Site - 36 12 0.33 
CLL301 PPP6R3 
TCTATCAAATA
TTTTCCAC>TCT
ATCAAATATTT
TCCAC/T 
11 68,326,055 Indel Leu252_His257delinsdel 46 22 0.48 
CLL369 TENM4 G>G/A 11 78,574,151 Missense His371Tyr 31 19 0.61 
CLL332 PCF11 CAG>CAG/C 11 82,877,338 Indel Gln467ArgfsTer10 38 10 0.26 
CLL301 FAT3 G>G/C 11 92,086,092 Missense Val272Leu 35 20 0.57 
CLL171 FAT3 A>A/G 11 92,087,743 Missense Glu822Gly 57 17 0.3 
CLL171 FAT3 C>C/T 11 92,534,127 Missense Leu2650Phe 59 19 0.32 
CLL350 FAT3 T>T/A 11 92,616,197 Missense Val4192Glu 30 7 0.23 
CLL372 MAML2 T>T/C 11 95,825,240 Missense Gln652Arg 16 14 0.88 
CLL369 BIRC3 AG>AG/A 11 102,201,871 Indel Asn409IlefsTer4 14 4 0.29 
CLL330 BIRC3 T>T/A 11 102,207,782 Nonsense Cys588Ter 17 14 0.82 
CLL144 ATM T>T/G 11 108,121,624 Missense Ser478Ala 48 17 0.35 
CLL144 ATM C>C/T 11 108,121,625 Missense Ser478Leu 48 17 0.35 
CLL003 ATM G>G/A 11 108,153,522 Nonsense Trp1221Ter 32 26 0.81 
CLL063 ATM T>T/A 11 108,199,953 Missense Ile2432Asn 31 8 0.26 
CLL321 ATM C>C/T 11 108,201,099 Missense Ser2489Phe 15 14 0.93 
CLL372 ATM CTTATA>CTTATA/C 11 108,203,577 Indel Ile2629SerfsTer25 29 20 0.69 
CLL369 ATM A>A/C 11 108,236,116 Missense Lys3018Gln 23 22 0.96 
CLL144 HMBS C>C/T 11 118,959,849 Splice Site - 48 21 0.44 
CLL346 CBL G>G/C 11 119,142,445 Missense Arg148Ser 42 20 0.48 
CLL171 USP2 G>G/A 11 119,227,604 Missense Arg587Cys 28 12 0.43 
CLL129 USP2 C>C/T 11 119,228,894 Missense Asp436Asn 33 11 0.33 
CLL344 ARHGEF12 C>C/T 11 120,322,406 Nonsense Gln677Ter 30 18 0.6 
CLL301 TECTA C>C/A 11 121,039,469 Missense Pro1945His 39 13 0.33 
CLL351 CLMP T>T/C 11 122,968,651 Missense Tyr13Cys 39 21 0.54 
CLL182 OR10G4 G>G/A 11 123,886,964 Missense Arg228His 44 18 0.41 
CLL158 ADAMTS8 C>C/T 11 130,275,559 Missense Arg855Gln 35 16 0.46 
CLL305 DYRK4 C>C/T 12 4,722,678 Missense Ala441Val 53 17 0.32 
CLL063 KCNA5 C>C/T 12 5,154,337 Missense Arg342Cys 46 25 0.54 
CLL154 CD163L1 C>C/T 12 7,528,532 Missense Arg817His 45 19 0.42 
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CLL331 SLC2A14 A>A/T 12 7,984,356 Missense Ile62Lys 49 16 0.33 
CLL332 CLEC4A A>A/G 12 8,288,207 Missense Asn109Asp 35 17 0.49 
CLL369 RERGL C>C/T 12 18,234,195 Missense Arg183His 47 21 0.45 
CLL351 CAPZA3 C>C/T 12 18,891,446 Nonsense Arg82Ter 35 13 0.37 
CLL374 PDE3A C>C/G 12 20,783,046 Missense Pro582Arg 36 15 0.42 
CLL182 ABCC9 T>T/G 12 21,998,547 Missense Lys1029Thr 36 17 0.47 
CLL112 ABCD2 T>T/TA 12 40,012,873 Indel His182LeufsTer4 35 12 0.34 
CLL374 LRRK2 T>T/G 12 40,619,384 Missense Ile60Ser 34 14 0.41 
CLL344 MUC19 G>G/A 12 40,875,962 Missense Ala3054Thr 60 20 0.33 
CLL342 MUC19 C>C/G 12 40,964,307 Missense Leu8142Val 41 16 0.39 
CWL80 DIP2B A>A/G 12 51,092,990 Splice Site - 41 24 0.59 
CLL186 TFCP2 T>T/C 12 51,503,023 Missense Lys200Glu 44 12 0.27 
CLL154 NR4A1 T>T/A 12 52,451,019 Missense Leu459His 30 15 0.5 
CLL374 OR10A7 C>C/A 12 55,615,572 Missense Ala255Asp 29 14 0.48 
CLL307 RDH16 C>C/T 12 57,350,967 Missense Ala94Thr 28 10 0.36 
CLL149 XPOT A>A/C 12 64,827,339 Missense Gln803Pro 33 16 0.48 
CWL80 TBC1D30 G>G/A 12 65,225,933 Missense Gly148Asp 41 21 0.51 
CLL330 WIF1 T>T/C 12 65,448,930 Missense Gln329Arg 43 14 0.33 
CLL186 TMBIM4 T>T/C 12 66,531,789 Missense Asn223Ser 48 11 0.23 
CLL156 NAV3 G>G/GT 12 78,443,882 Splice Site - 52 20 0.38 
CLL129 SYT1 C>C/T 12 79,679,738 Missense Thr113Met 30 10 0.33 
CLL149 OTOGL T>T/C 12 80,764,475 Splice Site - 23 13 0.57 
CLL346 DAO C>C/A 12 109,278,851 Nonsense Tyr23Ter 31 18 0.58 
CLL301 BCL7A 
AAATGGTAAG
CGGAGGCGCC
CGC>AAATGGT
AAGCGGAGGC
GCCCGC/A 
12 122,460,085 Splice Site - 25 10 0.4 
CLL369 KNTC1 G>G/C 12 123,055,647 Missense Ala665Pro 25 10 0.4 
CLL374 SETD8 A>A/T 12 123,892,045 Missense Asp285Val 35 8 0.23 
CLL369 SFSWAP C>C/T 12 132,284,029 Missense Ser1003Phe 30 4 0.13 
CLL063 CDK8 C>C/A 13 26,975,653 Missense His387Gln 39 39 1 
CLL129 WASF3 G>G/A 13 27,250,750 Missense Arg202His 47 22 0.47 
CLL321 MTUS2 G>G/A 13 29,599,452 Missense Arg216Gln 30 17 0.57 
CLL342 DCLK1 C>C/T 13 36,367,609 Missense Gly651Asp 36 15 0.42 
CLL330 FAM124A G>G/T 13 51,855,235 Missense Arg531Leu 30 14 0.47 
CLL182 SLITRK6 G>G/T 13 86,369,172 Missense Thr491Lys 38 19 0.5 
CLL371 GPC5 G>G/C 13 92,408,651 Missense Trp419Cys 35 12 0.34 
CLL372 UGGT2 T>T/C 13 96,642,325 Missense Glu278Gly 38 17 0.45 
CLL371 UBAC2 G>G/A 13 100,020,087 Missense Arg285Gln 37 11 0.3 
CLL171 FGF14 G>G/A 13 102,527,580 Missense Pro92Leu 52 22 0.42 
JB210308 MYO16 G>G/A 13 109,779,874 Missense Ala1343Thr 28 14 0.5 
CLL130 ARHGEF7 TG>TG/T 13 111,944,508 Indel Asp748MetfsTer6 46 20 0.43 
CLL003 RPGRIP1 G>G/A 14 21,793,478 Missense Arg768Gln 42 18 0.43 
CLL186 OR4E2 C>C/A 14 22,133,426 Missense Leu44Ile 38 21 0.55 
CLL366 NFKBIA C>C/T 14 35,871,267 Splice Site - 38 19 0.5 
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CLL145 MDGA2 G>G/A 14 47,426,751 Missense Arg639Trp 47 24 0.51 
CLL372 NIN G>G/A 14 51,237,255 Nonsense Arg429Ter 36 22 0.61 
CLL171 KIAA0586 T>T/C 14 58,975,267 Splice Site - 53 22 0.42 
JB210308 SNAPC1 G>G/A 14 62,235,426 Missense Val168Met 39 15 0.38 
CLL374 WDR89 A>A/AT 14 64,065,524 Indel Asp379GlufsTer4 38 21 0.55 
CLL112 DCAF4 G>G/T 14 73,408,456 Missense Ala119Ser 35 14 0.4 
CLL372 HEATR4 C>C/T 14 73,973,175 Missense Cys661Tyr 36 15 0.42 
CLL331 IRF2BPL A>A/G 14 77,492,878 Missense Phe420Leu 31 15 0.48 
CLL154 CYP46A1 G>G/A 14 100,166,408 Missense Arg138Gln 33 14 0.42 
CLL182 TECPR2 C>C/A 14 102,901,154 Missense Thr667Asn 32 9 0.28 
CLL171 NC_000014 G>G/C 14 106,691,909 Missense Leu39Val 32 8 0.25 
CLL171 NC_000014 T>T/C 14 107,259,467 Missense Tyr71Cys 45 13 0.29 
CLL171 NC_000014 G>G/A 14 107,259,533 Missense Thr49Ile 43 11 0.26 
CLL372 GOLGA6L2 T>T/A 15 23,689,147 Missense Asp123Val 31 12 0.39 
CLL186 OCA2 A>A/T 15 28,090,097 Splice Site - 44 8 0.18 
CLL077 OCA2 C>C/T 15 28,096,543 Missense Gly775Ser 35 10 0.29 
CLL003 HERC2 A>A/G 15 28,437,181 Missense Ser2793Pro 47 13 0.28 
CLL330 THBS1 T>T/A 15 39,880,810 Missense Cys519Ser 44 20 0.45 
CLL321 PAK6 G>G/T 15 40,564,522 Missense Ser319Ile 40 23 0.58 
CLL171 TYRO3 G>G/A 15 41,864,736 Missense Ala617Thr 60 12 0.2 
CLL330 MGA TC>TC/T 15 41,962,023 Indel Ser311Ter 38 11 0.29 
CLL305 MGA G>G/GT 15 42,041,328 Indel Leu1842PhefsTer9 30 11 0.37 
CLL077 SLC12A1 A>A/G 15 48,533,713 Missense Asp406Gly 49 16 0.33 
CLL144 MYO5A A>A/G 15 52,725,448 Missense Val21Ala 40 16 0.4 
CLL171 FAM214A G>G/A 15 52,901,667 Missense Arg482Trp 40 18 0.45 
CWL80 FAM63B A>A/G 15 59,146,751 Missense Glu603Gly 36 13 0.36 
CLL348 VPS13C C>C/T 15 62,276,096 Missense Glu613Lys 40 19 0.48 
CLL348 CA12 A>A/G 15 63,667,882 Splice Site - 27 7 0.26 
CLL371 SLC51B A>A/T 15 65,343,854 Splice Site - 33 18 0.55 
CWL80 LARP6 G>G/A 15 71,125,137 Missense Arg244Trp 36 20 0.56 
CLL145 THSD4 G>G/A 15 71,507,745 Splice Site - 44 20 0.45 
CLL366 SEMA7A T>T/C 15 74,709,001 Missense Lys239Arg 28 9 0.32 
CLL347 PEAK1 G>G/C 15 77,451,003 Missense Pro1058Arg 34 12 0.35 
CLL345 ACSBG1 G>G/A 15 78,472,067 Missense Arg437Cys 34 18 0.53 
CLL307 TM6SF1 TG>TG/T 15 83,793,468 Indel Asp217IlefsTer2 31 19 0.61 
CLL305 BNC1 G>G/A 15 83,926,459 Missense Pro907Leu 33 12 0.36 
JB210308 TICRR G>G/C 15 90,127,629 Missense Trp349Cys 31 11 0.35 
CLL321 ZNF774 A>A/G 15 90,904,481 Missense His473Arg 45 21 0.47 
CLL144 IQGAP1 G>G/A 15 91,009,229 Splice Site - 35 10 0.29 
CLL371 CHD2 CA>CA/C 15 93,492,221 Indel Gln473HisfsTer5 46 16 0.35 
CLL346 SYNM C>C/T 15 99,671,702 Missense Arg1046Cys 27 12 0.44 
CLL332 RGS11 C>C/T 16 321,425 Missense Arg241Gln 30 12 0.4 
CLL171 RAB40C G>G/A 16 667,243 Missense Gly60Ser 34 15 0.44 
CLL160 CACNA1H G>G/A 16 1,259,077 Missense Ala1137Thr 27 13 0.48 
CLL112 TPSAB1 G>G/A 16 1,291,159 Missense Gly23Ser 35 12 0.34 
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CLL371 MAPK8IP3 G>G/A 16 1,816,361 Missense Val923Ile 27 13 0.48 
CLL186 PKD1 G>G/A 16 2,147,400 Missense Ala3442Val 25 11 0.44 
CLL345 CREBBP G>G/A 16 3,786,819 Splice Site - 34 22 0.65 
CLL182 CREBBP TGTGCTGGA>TGTGCTGGA/T 16 3,820,837 Indel Leu869HisfsTer98 26 8 0.31 
CLL347 MAZ AAGGCC>AAGGCC/A 16 29,818,962 Indel Lys286IlefsTer43 36 23 0.64 
CLL149 CCNYL3 TGTCTGCCA>TGTCTGCCA/T 16 34,290,520 Indel Ser390CysfsTer8 42 13 0.31 
CLL144 CHD9 A>A/G 16 53,337,916 Missense Asn2000Asp 32 9 0.28 
CLL130 IRX3 G>G/T 16 54,319,908 Missense Arg19Ser 36 16 0.44 
CLL158 CPNE2 A>A/G 16 57,168,709 Missense Asn380Ser 18 11 0.61 
CLL158 FAM192A T>T/C 16 57,188,212 Missense Glu252Gly 35 19 0.54 
CLL348 PRSS54 C>C/T 16 58,314,181 Missense Glu379Lys 27 6 0.22 
CLL154 TMED6 TTC>TTC/T 16 69,381,731 Indel Lys150GlyfsTer7 47 12 0.26 
CLL252 PKD1L3 T>T/C 16 71,963,589 Splice Site - 53 23 0.43 
CLL301 CNTNAP4 C>C/T 16 76,555,115 Missense Ala742Val 29 12 0.41 
CLL112 ADAMTS18 G>G/A 16 77,465,425 Nonsense Arg88Ter 46 15 0.33 
CLL160 PKD1L2 G>G/A 16 81,208,401 Missense Ala901Val 45 12 0.27 
CLL305 WFDC1 A>A/G 16 84,346,574 Missense Glu51Gly 29 9 0.31 
CLL006 GSE1 G>G/A 16 85,690,134 Missense Arg392Gln 54 27 0.5 
CLL156 ZC3H18 G>G/T 16 88,689,753 Splice Site - 35 10 0.29 
CLL252 ANKRD11 CG>CG/C 16 89,346,157 Indel Ala2265ProfsTer72 37 11 0.3 
CLL154 ANKRD11 TTC>TTC/T 16 89,349,133 Indel Arg1272LysfsTer10 41 15 0.37 
CLL158 PRPF8 G>G/A 17 1,577,866 Missense Arg1057Trp 33 16 0.48 
CLL158 ANKFY1 T>T/C 17 4,120,285 Missense Arg193Gly 34 15 0.44 
CLL371 EIF5A G>G/A 17 7,214,714 Missense Gly136Arg 27 10 0.37 
CLL305 GPS2 
CCCTAGAAAG
GGAGAAGGGC
TTCA>CCCTAG
AAAGGGAGAA
GGGCTTCA/C 
17 7,217,306 Splice Site - 26 9 0.35 
CLL331 GPS2 AC>AC/A 17 7,217,608 Splice Site - 19 17 0.89 
CLL156 TNK1 G>G/A 17 7,291,719 Splice Site - 47 14 0.3 
CLL345 LOC100996282 G>G/A 17 7,335,668 Missense Glu258Lys 32 13 0.41 
CLL346 POLR2A C>C/T 17 7,411,625 Missense Ala1099Val 21 7 0.33 
CLL145 TP53 C>C/T 17 7,577,120 Missense Arg273His 49 24 0.49 
CLL364 TP53 C>C/T 17 7,577,538 Missense Arg248Gln 16 9 0.56 
CLL332 TP53 T>T/C 17 7,578,190 Missense Tyr220Cys 32 26 0.81 
CLL252 TP53 A>A/C 17 7,578,204 Missense Ser215Arg 16 10 0.63 
CLL331 TP53 
TGTAGATGGCC
ATGGCGCGG>
TGTAGATGGCC
ATGGCGCGG/T 
17 7,578,440 Indel Arg158SerfsTer6 13 8 0.62 
CLL345 TP53 T>T/G 17 7,578,536 Missense Lys132Gln 29 13 0.45 
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CLL307 TP53 TGGTA>TGGTA/T 17 7,579,376 Indel Tyr103ArgfsTer19 27 8 0.3 
CLL307 TP53 G>G/A 17 7,579,382 Missense Thr102Ile 23 7 0.3 
CLL307 TP53 T>T/A 17 7,579,383 Missense Thr102Ser 23 7 0.3 
CWL80 TP53 G>G/A 17 7,579,717 Missense Pro27Ser 20 7 0.35 
CLL342 ARHGEF15 C>C/T 17 8,218,891 Missense Arg474Trp 22 13 0.59 
CWL80 MYH10 AT>AT/A 17 8,415,785 Indel Met979CysfsTer12 45 12 0.27 
CLL145 DHRS7C G>G/A 17 9,676,195 Nonsense Arg207Ter 45 28 0.62 
CLL158 DNAH9 A>A/G 17 11,696,850 Missense Lys2698Glu 30 13 0.43 
CLL366 ZNF286A G>G/A 17 15,619,550 Missense Arg171Lys 43 8 0.19 
CLL154 NCOR1 C>C/CT 17 15,974,831 Indel Arg1349AlafsTer5 31 13 0.42 
CLL366 NCOR1 C>C/G 17 16,012,099 Splice Site - 34 11 0.32 
CLL321 SUZ12 A>A/G 17 30,310,126 Splice Site - 31 17 0.55 
CLL344 C17orf75 C>C/G 17 30,669,083 Missense Glu26Gln 31 13 0.42 
CLL112 ASIC2 G>G/T 17 31,618,678 Nonsense Tyr152Ter 24 13 0.54 
CLL364 SLFN12L A>A/C 17 33,801,971 Missense Cys580Gly 31 14 0.45 
CLL366 IKZF3 A>A/C 17 37,947,776 Missense Leu162Arg 31 10 0.32 
JB210308 IKZF3 A>A/C 17 37,947,776 Missense Leu162Arg 35 15 0.43 
CLL321 CASC3 ATGG>ATGG/A 17 38,319,088 Indel Gly241del 50 15 0.3 
CLL003 KRTAP4-1 C>C/T 17 39,340,769 Splice Site - 28 10 0.36 
CLL144 KRT36 C>C/T 17 39,644,900 Missense Arg179Gln 43 19 0.44 
CLL252 KRT14 C>C/T 17 39,742,686 Missense Arg134His 39 12 0.31 
CLL077 GHDC A>A/G 17 40,345,464 Missense Trp46Arg 38 17 0.45 
CLL171 PSME3 G>G/C 17 40,986,400 Splice Site - 43 14 0.33 
CLL369 CRHR1 C>C/T 17 43,911,985 Splice Site - 27 10 0.37 
CLL158 KAT7 C>C/G 17 47,875,696 Missense Ala119Gly 40 17 0.43 
JB210308 CA10 T>T/C 17 49,726,575 Missense Asn201Ser 50 21 0.42 
CLL369 STXBP4 A>A/C 17 53,077,117 Missense Ser138Arg 39 16 0.41 
CLL347 VMP1 G>G/A 17 57,915,711 Missense Ala344Thr 31 13 0.42 
CLL321 PPM1D A>A/T 17 58,740,824 Nonsense Lys577Ter 33 15 0.45 
CLL342 CACNG4 G>G/T 17 65,026,889 Missense Glu251Asp 30 12 0.4 
CLL301 CASKIN2 G>G/A 17 73,498,766 Missense Arg797Trp 20 8 0.4 
CLL321 GALK1 C>C/G 17 73,759,505 Missense Gly124Ala 36 13 0.36 
CLL301 FBF1 A>A/T 17 73,922,843 Missense Asp183Glu 22 7 0.32 
CLL342 SRSF2 G>G/A 17 74,732,365 Missense Arg182Trp 24 10 0.42 
CLL342 ACTG1 G>G/C 17 79,479,359 Missense Leu8Val 38 17 0.45 
CLL332 L3MBTL4 C>C/T 18 6,213,153 Missense Val326Ile 44 14 0.32 
CLL154 SOGA2 C>C/T 18 8,784,510 Missense Thr467Met 28 15 0.54 
CLL331 ZNF521 C>C/T 18 22,804,982 Missense Arg967Gln 38 17 0.45 
CLL307 CCDC178 C>C/A 18 30,926,174 Splice Site - 53 11 0.21 
CLL156 TCEB3B C>C/T 18 44,561,056 Missense Gly194Arg 52 19 0.37 
CWL80 ALPK2 A>A/C 18 56,204,267 Missense Phe1051Cys 37 15 0.41 
CLL332 ALPK2 G>G/A 18 56,205,296 Missense Ser708Leu 42 12 0.29 
CLL301 BCL2 G>G/T 18 60,985,508 Missense Ala131Asp 39 13 0.33 
CLL063 CDH19 T>T/C 18 64,239,244 Splice Site - 44 23 0.52 
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CLL063 DSEL A>A/G 18 65,180,227 Missense Ile550Thr 34 15 0.44 
CLL351 TMX3 C>C/T 18 66,381,102 Missense Val28Ile 27 14 0.52 
CLL003 NFATC1 T>T/C 18 77,211,128 Splice Site - 57 21 0.37 
CWL80 NFATC1 C>C/T 18 77,227,543 Nonsense Arg672Ter 27 11 0.41 
CLL144 PARD6G G>G/A 18 77,917,848 Missense Pro313Ser 28 9 0.32 
CLL252 RPS15 C>C/T 19 1,440,439 Missense Ser139Phe 34 11 0.32 
CLL330 RPS15 G>G/T 19 1,440,458 Missense Lys145Asn 24 10 0.42 
CLL332 BTBD2 G>G/C 19 1,990,039 Missense Arg318Gly 40 15 0.38 
CLL112 AMH G>G/C 19 2,249,739 Missense Glu136Asp 31 14 0.45 
CLL006 TMPRSS9 C>C/T 19 2,424,182 Missense Arg848Cys 48 20 0.42 
CWL80 DUS3L G>G/A 19 5,786,847 Missense Arg467Cys 29 13 0.45 
CLL369 C3 TG>TG/T 19 6,718,177 Splice Site - 24 12 0.5 
CLL144 FBN3 C>C/T 19 8,203,180 Missense Arg349Gln 37 18 0.49 
CLL145 ZNF491 T>T/G 19 11,909,544 Splice Site - 54 22 0.41 
CLL144 ZNF763 G>G/A 19 12,089,142 Missense Glu138Lys 31 10 0.32 
CLL332 CCDC105 C>C/T 19 15,132,337 Splice Site - 37 13 0.35 
CLL345 NOTCH3 C>C/T 19 15,272,228 Missense Gly2071Arg 33 14 0.42 
CLL156 NOTCH3 C>C/A 19 15,288,804 Missense Arg1312Leu 28 15 0.54 
CLL371 CPAMD8 G>G/A 19 17,010,309 Nonsense Arg1656Ter 24 9 0.38 
CLL301 ZNF676 G>G/A 19 22,363,009 Missense Arg504Cys 41 20 0.49 
CLL364 ZNF91 G>G/A 19 23,543,172 Missense Thr870Met 43 10 0.23 
JB210308 ZNF536 C>C/T 19 31,025,799 Missense Ala739Val 38 19 0.5 
CLL158 CATSPERG C>C/T 19 38,861,163 Splice Site - 28 18 0.64 
CLL346 NFKBIB CCT>CCT/C 19 39,398,225 Indel Pro299ArgfsTer16 30 9 0.3 
CLL003 FCGBP G>G/T 19 40,362,885 Missense Thr5062Asn 38 16 0.42 
CWL80 C19orf47 G>G/A 19 40,832,340 Missense Arg202Trp 36 20 0.56 
CLL145 PRX C>C/G 19 40,901,309 Missense Gly984Arg 41 20 0.49 
CLL307 CYP2A7 C>C/T 19 41,383,114 Missense Arg381Gln 18 12 0.67 
CLL344 DEDD2 T>T/G 19 42,721,780 Splice Site - 30 14 0.47 
CLL321 ZNF180 C>C/A 19 44,980,955 Missense Gln581His 44 20 0.45 
CLL171 RSPH6A T>T/C 19 46,313,967 Missense Asp261Gly 55 25 0.45 
CLL301 SPHK2 C>C/T 19 49,129,346 Missense Arg80Cys 34 12 0.35 
CLL351 MED25 G>G/T 19 50,334,121 Missense Ala360Ser 29 14 0.48 
CLL321 SHANK1 G>G/A 19 51,189,591 Missense Ala827Val 34 12 0.35 
CLL342 ACPT T>T/A 19 51,297,217 Missense Met284Lys 35 11 0.31 
JB210308 CACNG8 G>G/A 19 54,483,121 Missense Arg123Gln 32 13 0.41 
CLL347 RPS9 T>T/G 19 54,705,110 Missense Phe20Val 32 10 0.31 
CLL330 ZNF580 C>C/A 19 56,154,265 Missense Arg131Ser 30 16 0.53 
CLL301 NLRP8 C>C/T 19 56,466,176 Missense Thr251Met 40 21 0.53 
CLL369 SOX12 G>G/A 20 306,792 Missense Gly75Asp 38 20 0.53 
CLL348 ANKEF1 A>A/C 20 10,033,863 Missense Lys658Asn 36 19 0.53 
CLL348 ANKEF1 TA>TA/T 20 10,033,865 Indel Gly661AlafsTer7 35 18 0.51 
JB210308 KIF16B T>T/C 20 16,348,288 Missense Ile1228Val 40 15 0.38 
CLL154 BFSP1 C>C/G 20 17,511,658 Missense Arg106Pro 26 17 0.65 
CLL156 RRBP1 T>T/C 20 17,601,357 Splice Site - 21 10 0.48 
CLL347 RIN2 C>C/T 20 19,937,365 Missense Arg138Trp 27 11 0.41 
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CLL345 APMAP G>G/A 20 24,950,241 Missense Arg257Trp 41 18 0.44 
CLL307 BPIFB6 A>A/G 20 31,630,645 Missense Thr405Ala 35 10 0.29 
CLL331 NCOA6 T>T/C 20 33,345,116 Missense Met479Val 36 16 0.44 
CLL186 TRPC4AP G>G/T 20 33,632,322 Missense Ala284Asp 32 14 0.44 
CLL130 NFS1 C>C/T 20 34,263,103 Missense Arg271His 35 19 0.54 
JB210308 RBM39 T>T/A 20 34,313,042 Missense Asp151Val 27 10 0.37 
CLL077 SAMHD1 A>A/T 20 35,526,336 Missense Phe545Leu 47 41 0.87 
CWL80 SAMHD1 C>C/A 20 35,532,562 Missense Asp501Tyr 39 13 0.33 
CLL063 IFT52 A>A/G 20 42,265,888 Missense Asn372Ser 31 13 0.42 
JB210308 NCOA3 A>A/G 20 46,276,057 Missense Asn1165Asp 35 16 0.46 
CLL372 ARFGEF2 A>A/G 20 47,633,921 Missense His1484Arg 47 22 0.47 
CLL305 KCNB1 C>C/T 20 47,991,256 Missense Glu281Lys 33 12 0.36 
CLL144 ADNP C>C/A 20 49,509,294 Missense Val653Phe 40 18 0.45 
CLL063 CDH4 G>G/A 20 60,427,955 Splice Site - 42 19 0.45 
CLL371 POTED A>A/T 21 14,995,146 Missense Asp359Val 16 7 0.44 
CLL331 BTG3 C>C/T 21 18,966,481 Nonsense Trp274Ter 45 21 0.47 
JB210308 TIAM1 C>C/G 21 32,575,227 Missense Glu830Asp 36 20 0.56 
CLL145 CHAF1B C>C/T 21 37,781,769 Splice Site - 35 17 0.49 
CLL112 TTC3 G>G/A 21 38,510,951 Missense Met532Ile 43 21 0.49 
CLL330 MX2 C>C/T 21 42,752,021 Missense Arg174Trp 33 14 0.42 
CLL006 U2AF1 C>C/T 21 44,514,662 Missense Arg165Gln 42 18 0.43 
CLL006 SIK1 C>C/T 21 44,839,738 Splice Site - 39 14 0.36 
CLL129 HSF2BP C>C/T 21 45,050,224 Missense Ala185Thr 40 19 0.48 
CLL364 PDXK C>C/T 21 45,168,940 Missense Thr148Met 35 14 0.4 
CLL301 POTEH C>C/G 22 16,287,300 Missense Val196Leu 24 7 0.29 
CLL077 BCL2L13 C>C/T 22 18,210,041 Missense Pro400Leu 40 20 0.5 
CLL347 LOC642643 A>A/G 22 18,737,516 Missense Asp338Gly 64 8 0.13 
CLL369 MED15 C>C/T 22 20,939,218 Missense Ala627Val 36 17 0.47 
CLL171 NC_000022 A>A/C 22 23,029,598 Missense Tyr67Ser 47 14 0.3 
CLL171 NC_000022 G>G/A 22 23,040,689 Missense Ser46Asn 48 16 0.33 
CLL171 NC_000022 A>A/T 22 23,040,704 Missense Tyr51Phe 39 11 0.28 
CLL171 NC_000022 G>G/A 22 23,040,737 Missense Gly62Asp 41 11 0.27 
CLL156 IGLL5 G>G/C 22 23,230,278 Missense Glu15Asp 41 28 0.68 
CLL331 IGLL5 G>G/A 22 23,230,301 Missense Arg23His 32 13 0.41 
CLL342 IGLL5 G>G/C 22 23,230,363 Missense Ala44Pro 21 19 0.9 
CLL342 IGLL5 A>A/G 22 23,230,438 Missense Arg69Gly 15 14 0.93 
CLL374 GGT1 G>G/A 22 25,019,872 Missense Asp337Asn 21 5 0.24 
CLL350 CRYBB3 G>G/A 22 25,601,239 Missense Arg127His 25 13 0.52 
CLL171 OSBP2 G>G/T 22 31,266,577 Missense Gly339Cys 50 26 0.52 
CLL252 SLC5A4 T>T/C 22 32,651,232 Missense Ile29Val 39 13 0.33 
CLL003 BPIFC C>C/T 22 32,831,696 Missense Glu307Lys 59 24 0.41 
CLL063 FAM227A C>C/T 22 38,982,176 Missense Arg556Lys 59 29 0.49 
CLL144 MCAT C>C/T 22 43,529,078 Missense Asp382Asn 40 13 0.33 
CLL332 PNPLA3 G>G/A 22 44,333,090 Missense Arg306His 37 11 0.3 
CLL366 LDOC1L C>C/T 22 44,893,030 Missense Arg136His 30 9 0.3 
CLL156 MAPK8IP2 C>C/T 22 51,049,170 Missense Arg813Cys 37 13 0.35 
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CLL149 GPR143 G>G/A X 9,733,850 Missense Ser3Phe 30 13 0.43 
CLL301 BEND2 T>T/G X 18,189,190 Missense Ser706Arg 32 13 0.41 
CLL063 DMD G>G/T X 31,986,508 Missense Leu2188Met 38 17 0.45 
JB210308 FAM47C G>G/T X 37,029,141 Missense Lys886Asn 40 13 0.33 
CLL347 RPGR T>T/C X 38,144,939 Missense Lys1105Glu 26 12 0.46 
CLL331 TSPAN7 G>G/A X 38,533,526 Missense Gly133Ser 22 22 1 
CLL077 BCOR C>C/T X 39,913,134 Splice Site - 21 20 0.95 
CLL112 DDX3X A>A/T X 41,203,361 Missense Ile282Phe 26 15 0.58 
CLL006 MED12 G>G/C X 70,339,253 Missense Gly44Arg 20 18 0.9 
CLL364 MED12 G>G/C X 70,339,253 Missense Gly44Arg 30 14 0.47 
CLL371 TAF1 
AGATGTAAGCT
>AGATGTAAGC
T/A 
X 70,643,086 Splice Site - 14 11 0.79 
CLL063 POF1B G>G/T X 84,600,896 Nonsense Cys231Ter 42 16 0.38 
CLL006 KLHL4 C>C/G X 86,873,001 Missense Thr265Ser 16 15 0.94 
CLL171 KLHL4 G>G/T X 86,877,226 Missense Val314Leu 52 24 0.46 
CLL366 RNF128 G>G/A X 106,034,395 Missense Ala362Thr 27 14 0.52 
CLL364 COL4A5 G>G/T X 107,823,942 Missense Gly289Cys 30 10 0.33 
CLL145 HTR2C G>G/A X 114,141,205 Missense Val202Met 23 21 0.91 
CLL372 SLC6A14 C>C/T X 115,590,000 Missense Ala603Val 48 10 0.21 
CLL369 NKAP 
TCCCTTTGGTC
TTTCTGTAAAC
>TCCCTTTGGT
CTTTCTGTAAA
C/T 
X 119,059,197 Indel Val405_Gly411delinsdel 31 14 0.45 
CLL345 AIFM1 T>T/A X 129,272,652 Nonsense Lys295Ter 42 22 0.52 
CLL321 LINC00893 A>A/T X 148,611,046 Splice Site - 42 19 0.45 
CLL112 GABRA3 C>C/A X 151,424,470 Nonsense Glu111Ter 21 15 0.71 
CLL006 NLGN4Y G>G/A Y 16,942,161 Missense Ala455Thr 16 13 0.81 
Abbreviations: Chr, chromosome; VAF, variant allele frequency. Chromosomal coordinates 
refer to hg19 human genome build. 
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Appendix D: List of sequencing validation mutations 
Sample ID Gene Chr Coordinate (hg19) 
Amino Acid 
Change 
Whole Genome 
Sequencing 
Targeted 
Sequencing 
RD VR VAF RD VR VAF 
CLL371 XPO1 2     61,719,471  Glu571Gly 42 11 0.26 5000 1807 0.36 
CLL160 SF3B1 2   198,266,611  Gly742Asp 45 15 0.33 4647 1570 0.34 
CLL305 SF3B1 2   198,266,713  Gly740Glu 39 11 0.28 3801 1281 0.34 
CLL158 SF3B1 2   198,266,821  Ile704Asn 31 13 0.42 2468 1220 0.49 
CLL145 SF3B1 2   198,266,834  Lys700Glu 49 22 0.45 3341 1480 0.44 
CLL307 SF3B1 2   198,266,834  Lys700Glu 30 19 0.63 256 164 0.64 
CLL130 SF3B1 2   198,267,361  Lys666Glu 53 22 0.42 3504 1466 0.42 
CLL316 SF3B1 2   198,267,371  His662Gln 29 6 0.21 1197 214 0.18 
CLL369 SF3B1 2   198,267,484  Arg625Cys 42 19 0.45 1570 747 0.48 
CLL156 SF3B1 2   198,267,489  Tyr623Cys 42 13 0.31 2430 1078 0.44 
CLL332 SF3B1 2   198,267,491  Glu622Asp 33 10 0.30 3028 1140 0.38 
CLL129 SF3B1 2   198,267,491  Glu622Asp 42 19 0.45 300 129 0.43 
CLL344 MYD88 3     38,182,641  Leu273Pro 22 11 0.50 2445 1113 0.46 
CLL144 KLHL6 3   183,211,965  Val418Met 28 12 0.43 3437 2169 0.63 
CLL348 KLHL6 3   183,273,174  Leu90Phe 30 13 0.43 4682 3380 0.72 
CLL348 KLHL6 3   183,273,179  Val88Glu 31 15 0.48 4682 1094 0.23 
CLL348 KLHL6 3   183,273,242  Met67Thr 33 12 0.36 578 253 0.44 
CLL348 KLHL6 3   183,273,246  Arg66Gly 33 12 0.36 1200 555 0.46 
CLL330 FBXW7 4   153,247,310  Met498Leu 33 15 0.45 3231 1348 0.42 
CLL006 IRF4 6          394,954  Asp117Val 40 4 0.10 1726 196 0.11 
CLL145 POT1 7   124,503,668  Gln94His 53 13 0.25 1882 745 0.40 
CLL372 BRAF 7   140,453,150  Phe595Leu 45 8 0.18 2942 277 0.09 
CLL347 BRAF 7   140,453,193  Asn581Ser 38 9 0.24 116 24 0.21 
CLL186 NOTCH1 9   139,390,648  Pro2514ArgfsX4 36 12 0.33 5000 1533 0.31 
CLL331 NOTCH1 9   139,390,648  Pro2514ArgfsX4 36 13 0.36 100 45 0.45 
CLL130 NOTCH1 9   139,390,648  Pro2514ArgfsX4 40 16 0.40 5000 1880 0.38 
JB 210308 NOTCH1 9   139,390,648  Pro2514ArgfsX4 22 13 0.59 3748 1845 0.49 
CLL317 NOTCH1 9   139,390,648  Pro2514ArgfsX4 37 21 0.57 217 121 0.56 
CLL158 NOTCH1 9   139,390,678  Pro2505Thr 30 9 0.30 87 44 0.51 
CLL186 EGR2 10     64,573,248  His384Asn 34 14 0.41 1992 906 0.45 
CLL330 EGR2 10     64,573,332  Glu356Lys 30 8 0.27 5000 1584 0.32 
CLL369 BIRC3 11   102,201,871  Asn409IlefsTer4 14 4 0.29 1116 569 0.51 
CLL330 BIRC3 11   102,207,782  Cys588Ter 17 14 0.82 2189 1841 0.84 
CLL144 ATM 11   108,121,624  Ser478Ala 48 17 0.35 4127 1889 0.46 
CLL144 ATM 11   108,121,625  Ser478Leu 48 17 0.35 4116 1874 0.46 
CLL112 ATM 11   108,199,953  Ile2432Asn 31 8 0.26 2285 883 0.39 
CLL321 ATM 11   108,201,099  Ser2489Phe 15 14 0.93 1769 1743 0.99 
CLL372 ATM 11   108,203,577  Ile2629SerfsTer25 29 20 0.69 2193 1872 0.85 
CLL182 ATM 11   108,224,493  Gly2891Asp 18 4 0.22 2302 305 0.13 
CLL369 ATM 11   108,236,116  Lys3018Gln 23 22 0.96 1069 987 0.92 
CLL307 TP53 17       7,577,018  c.919+1G>A 25 6 0.24 1136 285 0.25 
CLL145 TP53 17       7,577,120  Arg273His 49 24 0.49 1967 981 0.50 
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CLL364 TP53 17       7,577,538  Arg248Gln 16 9 0.56 1701 1091 0.64 
CLL332 TP53 17       7,578,190  Tyr220Cys 32 26 0.81 4999 3950 0.79 
CLL252 TP53 17       7,578,204  Ser215Arg 16 10 0.63 3189 1955 0.61 
CLL317 TP53 17       7,578,280  Pro190Leu 24 11 0.46 4990 2345 0.47 
CLL331 TP53 17       7,578,440  Arg158SerfsTer6 13 8 0.62 4344 4142 0.95 
CLL145 TP53 17       7,578,455  Ala159Pro 43 4 0.09 3992 379 0.09 
CLL345 TP53 17       7,578,536  Lys132Gln 29 13 0.45 2575 1186 0.46 
CLL307 TP53 17       7,579,376  Tyr103ArgfsTer19 27 8 0.30 311 38 0.12 
CLL307 TP53 17       7,579,382  Thr102Ile 23 7 0.30 298 38 0.13 
CLL307 TP53 17       7,579,383  Thr102Ser 23 7 0.30 298 38 0.13 
L80 TP53 17       7,579,717  Pro27Ser 20 7 0.35 111 25 0.23 
L80 SAMHD1 20     35,532,562  Asp501Tyr 39 13 0.33 2311 985 0.43 
CLL307 DDX3X X     41,204,790  Leu435Pro 18 18 1.00 96 96 1.00 
CLL364 MED12 X     70,339,253  Gly44Arg 30 14 0.47 4739 2217 0.47 
CLL006 MED12 X     70,339,253  Gly44Arg 20 18 0.90 610 598 0.98 
Abbreviations: Chr, chromosome; RD, total read depth; VR, number of reads containing the 
variant; VAF, variant allele frequency. Chromosomal coordinates refer to hg19 human 
genome build. 
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Appendix E: Full List of Kataegis Regions  
Sample 
ID Chr 
Region 
Start (hg19) 
Region End 
(hg19) 
Number of 
Mutations Size (bp) Muts/bp 
Genes in 
Region 
CLL144 2 89,159,052 89,185,267 51 26,215 0.001945 IGK 
CLL331 2 89,157,593 89,165,310 32 7,717 0.004147 IGK 
CLL342 2 89,140,694 89,161,003 32 20,309 0.001576 IGK 
CLL149 2 89,158,625 89,247,194 28 88,569 0.000316 IGK 
CLL301 2 89,159,105 89,400,894 28 241,789 0.000116 IGK 
CLL344 2 89,159,538 89,160,713 23 1,175 0.019574 IGK 
CLL346 2 89,158,227 89,185,578 23 27,351 0.000841 IGK 
CLL348 2 89,157,619 89,327,508 23 169,889 0.000135 IGK 
CLL145 2 89,066,584 89,160,438 13 93,854 0.000139 IGK 
CLL374 2 89,159,642 89,161,244 11 1,602 0.006866 IGK 
CLL156 2 140,885,911 141,045,820 8 159,909 0.00005 LRP1B 
CLL348 3 187,660,014 187,660,463 9 449 0.020045 - 
CLL154 3 157,290,339 157,295,704 6 5,365 0.001118 C3orf55 
CLL348 3 183,273,058 183,273,364 6 306 0.019608 KLHL6 
CLL371 4 59,097,561 59,114,524 11 16,963 0.000648 - 
CLL301 5 26,070,177 26,074,185 10 4,008 0.002495 - 
CLL063 5 21,810,369 21,843,504 9 33,135 0.000272 CDH12 
CLL301 7 122,433,699 122,517,296 12 83,597 0.000144 CADPS2 
CLL371 7 49,672,829 49,682,118 9 9,289 0.000969 - 
CLL301 7 122,622,586 122,638,447 6 15,861 0.000378 TAS2R16 
CLL351 9 123,416,699 123,479,606 43 62,907 0.000684 MEGF9 
CLL342 9 76,656,503 76,656,760 6 257 0.023346 - 
CLL144 11 108,121,624 108,129,499 9 7,875 0.001143 ATM 
CLL307 13 51,664,141 51,665,954 6 1,813 0.003309 LINC00371 
CLL144 14 106,152,090 107,259,530 99 1,107,440 0.000089 IGH 
CLL171 14 106,151,270 107,259,533 85 1,108,263 0.000077 IGH 
CLL145 14 106,211,966 106,330,421 57 118,455 0.000481 IGH 
CLL348 14 106,326,027 107,259,254 52 933,227 0.000056 IGH 
CLL301 14 106,323,279 107,179,197 51 855,918 0.00006 IGH 
CLL331 14 106,213,235 107,259,530 50 1,046,295 0.000048 IGH 
CLL156 14 106,325,382 107,178,939 46 853,557 0.000054 IGH 
CLL346 14 106,240,547 107,179,603 46 939,056 0.000049 IGH 
CLL063 14 106,211,717 107,170,126 34 958,409 0.000035 IGH 
CLL344 14 106,325,822 107,176,711 33 850,889 0.000039 IGH 
CLL371 14 106,210,618 106,726,347 33 515,729 0.000064 IGH 
CWL80 14 106,112,882 106,376,235 32 263,353 0.000122 IGH 
CLL342 14 106,213,606 107,179,703 31 966,097 0.000032 IGH 
CLL351 14 106,213,664 107,259,538 31 1,045,874 0.00003 IGH 
CLL154 14 106,329,401 107,269,172 29 939,771 0.000031 IGH 
CLL160 14 106,213,001 107,179,214 29 966,213 0.00003 IGH 
CLL149 14 106,325,402 107,179,022 23 853,620 0.000027 IGH 
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CLL372 14 106,325,813 106,800,347 21 474,534 0.000044 IGH 
CLL252 14 106,240,007 106,748,391 17 508,384 0.000033 IGH 
CLL158 14 106,176,677 106,327,757 15 151,080 0.000099 IGH 
CLL003 14 106,239,549 106,326,360 14 86,811 0.000161 IGH 
CLL145 14 106,725,391 107,179,022 12 453,631 0.000026 IGH 
CLL307 14 106,212,147 106,326,741 12 114,594 0.000105 IGH 
CLL369 14 106,326,563 106,384,422 11 57,859 0.00019 IGH 
CLL112 14 106,324,258 106,326,713 10 2,455 0.004073 IGH 
CLL130 14 106,237,375 106,392,658 9 155,283 0.000058 IGH 
CLL129 14 106,212,023 106,326,234 8 114,211 0.00007 IGH 
CLL182 14 106,323,732 107,049,039 8 725,307 0.000011 IGH 
CLL366 14 106,112,760 106,325,372 8 212,612 0.000038 IGH 
CLL186 14 106,239,597 106,329,751 7 90,154 0.000078 IGH 
CLL156 14 21,835,327 21,835,546 6 219 0.027397 SUPT16H 
CLL321 14 106,211,966 106,673,293 6 461,327 0.000013 IGH 
CLL344 14 104,922,215 106,112,736 6 1,190,521 0.000005 IGH 
CLL301 18 60,873,525 60,988,029 12 114,504 0.000105 BCL2 
CLL348 18 60,906,440 60,988,117 10 81,677 0.000122 BCL2 
CLL252 18 9,284,149 9,374,417 6 90,268 0.000066 ANKRD12, TWSG1 
CLL348 22 23,198,941 23,233,399 50 34,458 0.001451 IGL 
CLL156 22 23,040,749 23,247,495 21 206,746 0.000102 IGL 
CLL331 22 23,230,222 23,232,006 19 1,784 0.01065 IGL 
CLL171 22 23,040,689 23,247,586 17 206,897 0.000082 IGL 
CLL351 22 22,516,929 23,228,510 16 711,581 0.000022 IGL 
CLL371 22 23,236,283 23,247,607 15 11,324 0.001325 IGL 
CLL144 22 23,223,275 23,231,983 14 8,708 0.001608 IGL 
CLL342 22 23,153,963 23,247,619 14 93,656 0.000149 IGL 
CLL346 22 23,223,254 23,231,457 13 8,203 0.001585 IGL 
CLL344 22 23,223,277 23,231,043 9 7,766 0.001159 IGL 
CLL145 22 23,055,186 23,055,480 8 294 0.027211 IGL 
CLL063 22 23,241,895 23,247,626 6 5,731 0.001047 IGL 
CLL369 22 23,230,520 23,236,398 6 5,878 0.001021 IGL 
CLL301 23 98,765,633 98,769,284 10 3,651 0.002739 XRCC6P5 
  
 
 
257 
 
Appendix F: Publications arising from this work 
DELETED FROM ELECTRONIC VERSION 
Publications 
BURNS A, ALSOLAMI R, BECQ J, TIMBS A, BRUCE D, ROBBE P, VAVOULIS D, 
CABES M, DREAU H, TAYLOR J, KNIGHT SJ, MANSSON R, BENTLEY D, 
RIDOUT K, SCHUH A (2017) Whole genome sequencing reveals differences 
in the mutation spectrum of IgHV hypermutated and unmutated Chronic 
Lymphocytic Leukemia. Under Review. 
FERNANDEZ-MERCADO M, BURNS A, PELLAGATTI A, GIAGOUNIDIS A, 
GERMING U, AGIRRE X, PROSPER F, AUL C, KILLICK S, WAINSCOAT JS, 
SCHUH A AND BOULTWOOD J (2013) Targeted re-sequencing analysis of 25 
genes commonly mutated in myeloid disorders in del(5q) myelodysplastic 
syndromes. Haematologica 98(12): 1856–64 
 
Abstracts 
BURNS A, WELLER S, HUMPHRAY S, BECQ J, KINGSBURY Z, ALSOLAMI R, 
HAMBLIN A, CLIFFORD R, KNIGHT S, ROBBE P, CABES M, TIMBS A, MASON 
J, HATTON C, TAYLOR J, BENTLEY D, SCHUH A (2014) Whole Genome 
Sequencing, Targeted Deep Sequencing and Copy-Number Analysis 
Provides a Comprehensive Picture of the Mutational Landscape in 41 
Clinically Annotated CLL Cases; 56th American Society of Hematology 
Annual Meeting, San Francisco 
BURNS A, CLIFFORD R, DREAU H, HATTON C, HENDERSON S, TAYLOR J, 
SCHUH A (2012) Targeted gene profiling identifies differential genetic 
make-up depending on chronic lymphocytic leukaemia subtype; 54th 
American Society of Hematology Annual Meeting, Atlanta 
